



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International Patent Classification<sup>5</sup> : C12N 15/32, A01N 63/02 C12P 21/02, C12N 1/21 // (C12P 1/04, C12R 1:07) (C12N 1/21, C12R 1:19)</p>	A2	<p>(11) International Publication Number: <b>WO 92/20802</b></p> <p>(43) International Publication Date: 26 November 1992 (26.11.92)</p>								
<p>(21) International Application Number: PCT/US92/04316</p> <p>(22) International Filing Date: 22 May 1992 (22.05.92)</p> <p>(30) Priority data:</p> <table border="0"> <tr> <td>703,977</td> <td>22 May 1991 (22.05.91)</td> <td>US</td> </tr> <tr> <td>797,645</td> <td>25 November 1991 (25.11.91)</td> <td>US</td> </tr> <tr> <td>92304228.7</td> <td>12 May 1992 (12.05.92)</td> <td>EP</td> </tr> </table> <p>(34) Countries for which the regional or international application was filed: GB et al.</p> <p>(71) Applicant: MYCOGEN CORPORATION [US/US]; 5451 Oberlin Drive, San Diego, CA 92121 (US).</p> <p>(72) Inventors: PAYNE, Jewel, M. ; 7984 Hemphill Drive, San Diego, CA 92126 (US). KENNEDY, M., Keith ; 2 Landsdale Lane, Racine, WI 53402 (US). RANDALL, John, B. ; 1729 Centennial Lane, Racine, WI 53406 (US). MEIER, Henry ; 2827 Santa Fe Trail, Racine, WI 53404 (US). UICK, Heidi, J. ; 139 Greshell Lane, Racine, WI 53406 (US).</p>	703,977	22 May 1991 (22.05.91)	US	797,645	25 November 1991 (25.11.91)	US	92304228.7	12 May 1992 (12.05.92)	EP	<p>(74) Agents: SALIWANCHIK, David, R. et al.; Saliwanchik &amp; Saliwanchik, 2421 N.W. 41st Street, Suite A-1, Gainesville, FL 32606 (US).</p> <p>(81) Designated States: AT (European patent), AU, BE (European patent), BR, CA, CH (European patent), DE (European patent), DK (European patent), ES (European patent), FR (European patent), GB (European patent), GR (European patent), HU, IT (European patent), JP, KR, LU (European patent), MC (European patent), NL (European patent), RU, SE (European patent).</p> <p><b>Published</b> Without international search report and to be republished upon receipt of that report.</p>
703,977	22 May 1991 (22.05.91)	US								
797,645	25 November 1991 (25.11.91)	US								
92304228.7	12 May 1992 (12.05.92)	EP								
<p>(54) Title: NOVEL <i>BACILLUS THURINGIENSIS</i> ISOLATES ACTIVE AGAINST HYMENOPTERAN PESTS AND GENES ENCODING HYMENOPTERAN-ACTIVE TOXINS</p> <p>(57) Abstract</p> <p>Novel <i>Bacillus thuringiensis</i> isolates with hymenopteran activity are described. Also described are toxins having the advantageous hymenopteran activity. This invention further concerns genes or gene fragments which have been cloned from the novel <i>Bacillus thuringiensis</i> isolates which have formicidal activity. These genes or gene fragments can be used to transform suitable hosts for controlling ants.</p>										

Best Available Copy

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FI	Finland	MI	Mali
AU	Australia	FR	France	MN	Mongolia
BB	Barbados	GA	Gabon	MR	Mauritania
BE	Belgium	GB	United Kingdom	MW	Malawi
BF	Burkina Faso	GN	Guinea	NL	Netherlands
BG	Bulgaria	GR	Greece	NO	Norway
BJ	Benin	HU	Hungary	PL	Poland
BR	Brazil	IE	Ireland	RO	Romania
CA	Canada	IT	Italy	RU	Russian Federation
CF	Central African Republic	JP	Japan	SD	Sudan
CG	Congo	KP	Democratic People's Republic of Korea	SE	Sweden
CH	Switzerland	KR	Republic of Korea	SN	Senegal
CI	Côte d'Ivoire	LI	Liechtenstein	SU	Soviet Union
CM	Cameroon	LK	Sri Lanka	TD	Chad
CS	Czechoslovakia	LU	Luxembourg	TG	Togo
DE	Germany	MC	Monaco	US	United States of America
DK	Denmark	MG	Madagascar		
ES	Spain				

DESCRIPTION

NOVEL *BACILLUS THURINGIENSIS* ISOLATES ACTIVE AGAINST  
HYMENOPTERAN PESTS AND GENES ENCODING  
HYMENOPTERAN-ACTIVE TOXINS

5

Cross-Reference to a Related Application

This is a continuation-in-part of co-pending application Serial No. 07/703,977, filed on May 22, 1991. This is also a continuation-in-part of application Serial No. 07/797,645, filed on November 25, 1991.

10

Background of the Invention

The development of biological control agents as alternatives to chemical insecticides for the control of important pest species is a subject of increasing interest. Concerns for the environment and exposure of man to harmful substances in air, food and water have stimulated legislation and restrictions regarding the use of chemical pesticides, particularly for pests found in the urban environment. Control of insect pests in urban areas is highly desirable but exposure to chemical pesticides in the household and from lawns and gardens is of great concern to the public. If given a choice, most people would use a non-toxic biological control rather than a toxic chemical to control insects in the urban environment. The problem is that very few biological alternatives to chemical insecticides are available for purchase and use by the public.

15

20

25

*Bacillus thuringiensis* (*B.t.*) produces an insect toxin designated as  $\delta$ -endotoxin. It is synthesized by the *B.t.* sporulating cell. The toxin, upon being ingested in its crystalline form by susceptible insects, is transformed into biologically active moieties by the insect gut juice proteases. The primary target is insect cells of the gut epithelium, which are rapidly destroyed.

30

35

The reported activity spectrum of *B.t.* covers insect species within the order Lepidoptera, many of which are major pests in agriculture and forestry. The activity spectrum also includes the insect order Diptera, which includes mosquitos and black flies. See Couch, T.L. (1980) "Mosquito Pathogenicity of *Bacillus thuringiensis* var. *israelensis*," *Developments in Industrial Microbiology* 22:61-76; Beegle, C.C., (1978) "Use of Entomogenous Bacteria in Agroecosystems," *Developments in Industrial Microbiology* 20:97-104. Krieg, et al. (1983) *Z. ang. Ent.* 96:500-508, describe a *B.t.* isolate named *Bacillus thuringiensis* var. *tenebrionis*, which is reportedly active against two beetles in the order Coleoptera. These are the Colorado potato beetle, *Leptinotarsa decemlineata*, and *Agelastica alni*. In European Patent Application No. 0 202 739 there is disclosed a novel *B.t.* isolate active against Coleoptera. It is known as *B. thuringiensis* var. *san diego* (*B.t.s.d.*). U.S. Patent No. 4,966,765 discloses the coleopteran-active *Bacillus thuringiensis* isolate *B.t.* PS86B1.

Ants comprise a large group of insects (family Formicidae) from the taxonomic order, Hymenoptera. They are among the most common house pests. In many situations, ants are a

nuisance pest. Foraging ants create problems with hygiene in hospitals and the food industry. Ants also create problems in agriculture. Damage can be caused by direct feeding on plants. Harvester and fire ants are commonly associated with this type of damage (Holldobler, B., E.O. Wilson [1990] *The Ants*, Belknap Press, Cambridge, Mass. 732 pp.) Some ants cause indirect damage by nurturing and protecting sap feeding insects such as mealybugs and aphids. Ants, particularly in the genus *Solenopsis* are capable of producing extremely painful stings to humans. It has been estimated that approximately 10,000 stings occur each year (Häbermehl, G.G. [1981] *Venomous Animals and Their Toxins*, Springer-Verlag, NY, 195 pp.). The pharaoh ant (*Monomorium pharaonis*) is primarily an urban pest. However, this species can also be an agricultural pest and damage to corn has been noted (Ebeling, W. [1978] *Urban Entomology*, UC Press, Berkeley, Calif, 695 pp.).

Carpenter ants, *Camponotus* spp., are distributed throughout North America. Some of the more common and/or studied species include *C. modoc* in the Pacific northwest, *C. clarithorax* in southern California, and the black, red, and Florida carpenter ants, *C. pennsylvanicus*, *C. noveboracensis* and *C. abdominalis*, respectively, in the east (Ebeling, W. [1978] *Urban Entomology*, Univ. Calif.: Berkeley p. 209-213). Public concern over carpenter ants has been increasing due to the greater probability of structural infestations as suburban developments extend into the forest habitats of the ants.

Pestiferous species of carpenter ants may be considered nuisance pests because of their foraging activity inside homes. More significant damage occurs when carpenter ants extend their nests into sound wood. Nesting sites may be located in live and dead trees, sometimes resulting in damage to shade trees. Nests may also be established in walls and support beams of structures, or in voids within doors, walls, and furniture. Preference for moist or decaying wood has been reported, but nesting sites are not restricted to such areas. Carpenter ant populations develop relatively slowly with colonies of 300-2,000 workers being produced over a 2-year or longer period for various species. The presence of reproductives follows this slow development since their production has been reported only from well established colonies (Hansen, L.D., R.D. Akre [1985] *Biology of carpenter ants in Washington state* (Hymenoptera: Formicidae: *Camponotus*). *Melandria* 43. 62 p.; Pricer, J.L. [1908] *Biol. Bull.* 14:177-218). Despite the slow colony growth, large colonies with satellite colonies have been found. Worker movement occurs between the main colony and the satellites, which serve as areas for further brood development and colony expansion (Hansen and Akre [1985], *supra*).

Current methods for controlling structural infestations of carpenter ants include sanitation of potential and current nest sites, minimizing access to structures (eg. preventing the contact of tree branches with a structure), and the application of insecticides to repel (perimeter spray barriers) and/or eliminate carpenter ants. The use of boric acid dust in dry, wall voids is reported to be effective for up to 20 years (Hansen and Akre, *supra*).

Recommendations for the chemical control of established structural infestations in the home are often accompanied with warnings of possible hazards to the applicator as well as

children and pets. Alternative control methods such as effective biological control agents have not been found (Akre, R.D., L.D. Hansen, A.L. Antonelli [1989] Ext. Bull. Washington State Univ. Coop. Ext. Serv. 1989 rev. no. EB 0818, 6 pp.).

A need clearly exists for a safe, effective biological control agent for carpenter ants.

5        Pharaoh ants, *Monomorium pharaonis*, have been described as "... the most persistent and difficult of all our house-infesting ants to control or eradicate" (Smith, M.R. [1965] USDA-ARS Tech. Bull. No. 1326, 105 pp.). It is a tropical species which has extended its range to more temperate regions by establishing colonies in heated buildings. Pharaoh ants frequently infests buildings where food is prepared, and have been found to carry pathogenic organisms (Beatson, S.H. [1972] Lancet 1:425-427).

10        The difficulty in controlling pharaoh ants may be attributed to their inaccessible nesting sites, rapid population growth, and dispersion of colonies. Their small size allows establishment of colonies in any suitable location, including unusual places such as between books and in stored clothing. With multiple queen colonies, and the warm (30°C), humid (63-80% RH) conditions  
15        that favor pharaoh ants, large colonies can develop rapidly. Portions of these large colonies may disperse to form new colonies at any time, probably in response to overcrowding and unfavorable microenvironmental conditions. Unlike other ant species, pharaoh ants do not exhibit intercolony aggression. This permits the adoption of ants from other colonies and may further enhance the establishment of new colonies and reinfestations. Pharaoh ants also forage for food more than  
20        35 m from the nest without distinct trail following, and thus make nests difficult to find and eradicate.

      Control methods for pharaoh ants emphasize the use of insect growth regulators (IGR) or toxicants incorporated into baits. Properly implemented bait programs are effective, however it may take over a month to achieve control. Insecticide applications, while fast acting, usually  
25        do not eliminate colonies, and may be unacceptable in certain areas where toxic residues are a concern. In addition, insecticide applications are generally not compatible with bait programs.

A need exists for safe and effective biological control agents for pharaoh ants.

#### Brief Summary of the Invention

30        The subject invention concerns novel *Bacillus thuringiensis* (*B.t.*) isolates and genes therefrom which encode novel hymenopteran-active proteins. The novel *B.t.* isolates, known herein as *Bacillus thuringiensis* PS140E2 (*B.t.* PS140E2), *Bacillus thuringiensis* PS86Q3 (*B.t.* PS86Q3) and *Bacillus thuringiensis* PS211B2 (*B.t.* PS211B2) have been shown to be active against, for example, the pharaoh ant (*Monomorium pharaonis*). Toxins of the subject invention control,  
35        for example, fire ants, carpenter ants, argentine ants, and pharaoh ants.

      The subject invention also includes mutants of the above isolates which have substantially the same pesticidal properties as the parent isolate. Procedures for making mutants are well known in the microbiological art. Ultraviolet light and nitrosoguanidine are used extensively toward this end.

The subject invention also concerns novel toxins active against ants. A further aspect of the invention concerns genes coding for these formicidal toxins. The subject invention provides the person skilled in this art with a vast array of formicidal toxins, methods for using these toxins, and genes that code for the toxins. The genes or gene fragments of the invention encode *Bacillus thuringiensis*  $\delta$ -endotoxins which have formicidal activity. The genes or gene fragments can be transferred to suitable hosts via a recombinant DNA vector.

One aspect of the invention is the discovery of a generalized chemical formula common to a wide range of formicidal toxins. This formula can be used by those skilled in this art to obtain and identify a wide variety of toxins having the desired formicidal activity. The subject invention concerns other teachings which enable the skilled practitioner to identify and isolate ant-active toxins and the genes which code therefor. For example, characteristic features of ant-active toxin crystals are disclosed herein. Furthermore, characteristic levels of amino acid homology can be used to characterize the toxins of the subject invention. Yet another characterizing feature pertains to immunoreactivity with certain antibodies. Also, nucleotide probes specific for genes encoding toxins with formicidal activity are described. Thus, the identification of toxins of the subject invention can be accomplished by sequence-specific motifs, overall sequence similarity, immunoreactivity, and ability to hybridize with specific probes.

In addition to the teachings of the subject invention which broadly define *B.t.* toxins with advantageous formicidal activity, a further aspect of the subject invention is the provision of specific formicidal toxins and the nucleotide sequences which code for these toxins. One such toxin is the gene expression product of isolate PS86Q3.

#### Brief Description of the Drawings

Figure 1 is a photograph of a standard SDS polyacrylamide gel of *B.t.* PS140E2, and *B.t.* PS86Q3.

Figure 2 is a photograph of a standard SDS polyacrylamide gel showing alkali-soluble proteins of *B.t.* PS211B2 compared to a protein standard.

Figures 3-5 are transmission electron micrographs of ultrathin sections of the ant-active *B.t.* strains (Figure 3 is *B.t.* PS14E2; Figure 4 is *B.t.* PS86Q3; and Figure 5 is *B.t.* PS211B2). Cells were embedded in an epoxy resin and stained with uranyl acetate and lead citrate.

#### Brief Description of the Sequences

SEQ ID NO. 1 is the nucleotide sequence of gene 17a.  
SEQ ID NO. 2 is the amino acid sequence of protein 17a.  
SEQ ID NO. 3 is the nucleotide sequence of gene 17b.  
SEQ ID NO. 4 is the amino acid sequence of protein 17b.  
SEQ ID NO. 5 is the nucleotide sequence of gene 33F2.  
SEQ ID NO. 6 is the amino acid sequence of protein 33F2.  
SEQ ID NO. 7 is the nucleotide sequence of gene 86Q3(a).

SEQ ID NO. 8 is the amino acid sequence of protein 86Q3(a).

SEQ ID NO. 9 is the nucleotide sequence of gene 63B.

SEQ ID NO. 10 is the amino acid sequence of protein 63B.

5     SEQ ID NO. 11 is the amino acid sequence of a probe which can be used according to the subject invention.

SEQ ID NO. 12 is DNA coding for the amino acid sequence of SEQ ID NO. 11.

SEQ ID NO. 13 is DNA coding for the amino acid sequence of SEQ ID NO. 11.

SEQ ID NO. 14 is the amino acid sequence of a probe which can be used according to the subject invention.

10     SEQ ID NO. 15 is DNA coding for the amino acid sequence of SEQ ID NO. 14.

SEQ ID NO. 16 is DNA coding for the amino acid sequence of SEQ ID NO. 14.

SEQ ID NO. 17 is the N-terminal amino acid sequence of 17a.

SEQ ID NO. 18 is the N-terminal amino acid sequence of 17b.

SEQ ID NO. 19 is the N-terminal amino acid sequence of 86Q3(a).

15     SEQ ID NO. 20 is the N-terminal amino acid sequence of 63B.

SEQ ID NO. 21 is the N-terminal amino acid sequence of 33F2.

SEQ ID NO. 22 is an internal amino acid sequence for 63B.

SEQ ID NO. 23 is a synthetic oligonucleotide derived from 17.

SEQ ID NO. 24 is the forward oligonucleotide primer from 63B.

20     SEQ ID NO. 25 is the reverse oligonucleotide primer from 63B.

SEQ ID NO. 26 is oligonucleotide probe 33F2A.

SEQ ID NO. 27 is oligonucleotide probe 33F2B.

SEQ ID NO. 28 is a reverse primer used according to the subject invention.

25     SEQ ID NO. 29 is an oligonucleotide derived from the N-terminal amino acid sequence of 86Q3(a) (SEQ ID NO. 19).

SEQ ID NO. 30 is the amino acid sequence coded for by an oligonucleotide used according to the subject invention (SEQ ID NO. 31).

SEQ ID NO. 31 is an oligonucleotide which codes for the amino acid sequence of SEQ ID NO. 30.

30     SEQ ID NO. 32 is the amino acid sequence coded for by the oligonucleotide of SEQ ID NO. 33.

SEQ ID NO. 33 is a DNA sequence coding for the peptide of SEQ ID NO. 32.

SEQ ID NO. 34 is the reverse complement primer to SEQ ID NO. 38, used according to the subject invention.

35     SEQ ID NO. 35 is a forward primer according to the subject invention.

SEQ ID NO. 36 is an amino acid sequence according to the subject invention.

SEQ ID NO. 37 is a reverse primer according to the subject invention.

SEQ ID NO. 38 is the nematode (NEMI) variant of region 5 of H6fte and Whiteley.

Detailed Disclosure of the Invention

One aspect of the subject invention is the discovery of *Bacillus thuringiensis* isolates having activity against ants. The novel *Bacillus thuringiensis* isolates of the subject invention have the following characteristics in their biologically pure form:

5      Characteristics of *B.t.* PS140E2

Colony morphology—large colony, dull surface, typical *B.t.*

Vegetative cell morphology—typical *B.t.*

Culture methods—typical for *B.t.*

10      Inclusions—an elliptical coated inclusion outside the exosporium, and a long inclusion inside the exosporium

Approximate molecular weight of alkali/SDS-soluble polypeptides (kDa)—78, 70,  
35

Serotype—6, entomocidus.

15      Characteristics of *B.t.* PS86Q3

Colony morphology—large colony, dull surface, typical *B.t.*

Vegetative cell morphology—typical *B.t.*

Culture methods—typical for *B.t.*

20      Inclusions—long amorphous inclusion and a small inclusion, both of which remain with the spore after lysis

Approximate molecular weight of alkali/SDS-soluble polypeptides (kDa)—155, 135, 98,  
62, 58

Serotype—new serotype (not H-1 through H-27).

25      Characteristics of *B.t.* PS211B2

Colony morphology—large colony, dull surface, typical *B.t.*

Vegetative cell morphology—typical *B.t.*

Culture methods—typical for *B.t.*

Inclusions—large round amorphous inclusion with coat, and elliptical inclusion

30      Approximate molecular weight of alkali/SDS-soluble polypeptides (kDa)—175, 130, 100,  
83, 69, 43, 40, 36, 35, 34 and 27

Serotype—6, entomocidus.

35      A comparison of the characteristics of *B. thuringiensis* PS140E2 (*B.t.* PS140E2), *B. thuringiensis* PS86Q3 (*B.t.* PS86Q3), *B. thuringiensis* PS211B2 (*B.t.* PS211B2), *B. thuringiensis* var. san diego (*B.t.s.d.*), and *B. thuringiensis* var. *kurstaki* (HD-1) is shown in Table 1.



Table 1. Comparison of <i>B.t.</i> PS140E2, <i>B.t.</i> PS86Q3, <i>B.t.</i> PS211B2, <i>B.t.s.d.</i> , and <i>B.t.</i> HD-1					
	<i>B.t.</i> PS140E2	<i>B.t.</i> PS86Q3	<i>B.t.</i> PS211B2	<i>B.t.</i> HD-1	<i>B.t.s.d.</i>
Inclusions:	Ellipse and 2 small inclusions	1 long and 1 or 2 small inclusions	Large amorphous	Bipyramid	Flat square
Approximate molecular wt. of proteins by SDS-PAGE	78,000 70,000 35,000	155,000 135,000 98,000 62,000 58,000	175,000 130,000 100,000 83,000 69,000 43,000 40,000 36,000 35,000 34,000 27,000	130,000 68,000	72,000 64,000
Host range	Hymenoptera	Hymenoptera	Hymenoptera	Lepidopteran and Coleopteran	Coleoptera (Colorado Potato Beetle)

In addition to the ant-active *B.t.* isolates described herein, the subject invention concerns a vast array of *B.t.*  $\delta$ -endotoxins having formicidal activity. In addition to having formicidal activity, the toxins of the subject invention will have one or more of the following characteristics:

1. An amino acid sequence according to the generic formula disclosed herein.
2. A high degree of amino acid homology with specific toxins disclosed herein.
3. A DNA sequence encoding the toxin wherein said sequence hybridizes with probes or genes disclosed herein.
4. A nucleotide sequence which can be amplified using primers disclosed herein.
5. A crystal toxin presentation as described herein.
6. Immunoreactivity to an antibody raised to a toxin disclosed herein.

One aspect of the subject invention concerns the discovery of a generic chemical formula (hereinafter referred to as the Generic Formula) which can be used to identify toxins having activity against ants. This formula describes toxin proteins having molecular weights in excess of 130,000 kDa. The Generic Formula below covers those amino acids in the N-terminal region extending two amino acids past the invariant proline residue encountered at amino acid number 695 in the sequence of 86Q3(a). The organization of the toxins within this class is delineated by the following generic sequence motif that is the ultimate determinant of structure and function.

```

1  MOXLUEBYPx BXYUBLXxxx xxxxxxxxxx XXXXBXXXx EXXXKXXXXX
   XxxxxxxJXX XXBXXXXXXX XXLXXXXXXX XXLZBLZBxB PXXXXXXXXX
101 XBBBXXBXXX XXXXXXXXXX xLBXXBXXX BXXBBXXBX XXXXXXXUXX
    BXZLUXXXXX XXXOBXXXX* XXXXXXXXXX XXXXXXXXXX XX*XXXXXXXX
201 xxxxxxxXUZx XOXLXXBxx xxxxxxxxxE XXXXXxxxXL PYOXBOXXH
    LBLXJXXLxx xxxxxKXXB XXJXxBXXXK XXLXXXLXXX XLLOBXXXBXX
25 201 xxxxxxxXUZx XOXLXXBxx xxxxxxxxxE XXXXXxxxXL PYOXBOXXH
    LBLXJXXLxx xxxxxKXXB XXJXxBXXXK XXLXXXLXXX XLLOBXXXBXX
301 XLXXXxxxxJ xZXxxxxxy BJXBOXX*LE BXXXXPOBEX XXYXXxxxxx
    XLXXOKXLXZ XXXXXXXXXX BXXXXZXXX ZXXXXXXxx XXXBXXXXXX

```

401 XXXXBxxxxx xxxxXXXXXX LXXXXXXXXX XXX\*xxXXXX Xxxxxxxxxx  
XXXXXXXXXX XXXUX\*XXXX XXPLXXX\*XJ Xxxxxxxxxx XXXXXB\*XXX

5 501 XXZXXxxxxx xx\*x\*XXXX XXXXXXXXxx XXXXXXXXLXX LYXXXXXXXXJ  
XXXxXBx\*BB ZXXXXXExxx XXBZXXXXXX XXBXXXXBxx xxXXKxxxxx

601 XxxxxxxxxxE XLUZxUXBXL XXXUXBxBXB XXXXXXXXXYXL K\*KUPZXXXX  
XXBxBExxx xUXBXXXXXX XZXXXXXXXXZx XXXXXXXXYXBx ZXOxxxxxxx

10 701 xxLXxxxxxx xxxXUxxxxB BLEKLEBBPX X

Numbering is for convenience and approximate location only.

Symbols used:

A = ala      G = gly      M = met      S = ser  
C = cys      H = his      N = asn      T = thr  
15 D = asp      I = ile P = pro      V = val  
E = glu      K = lys      Q = gln      W = trp  
F = phe      L = leu      R = arg      Y = tyr

20 K = K or R  
E = E or D  
L = L or I

B = M, L, I, V, or F  
J = K, R, E, or D  
25 O = A or T  
U = N or Q  
Z = G or S

X = any naturally occurring amino acid, except C.  
\* = any naturally occurring amino acid.  
30 x = any naturally occurring amino acid, except C (or complete omission of any amino acids).

Where a stretch of wild-card amino acids are encountered (X(n) or x(n) where n>2), repetition of a given amino acid should be avoided. Similarly, P, C, E, D, K, or R utilization should be minimized.

Formicidal toxins according to the Generic Formula of the subject invention are specifically exemplified herein by the toxin encoded by the gene designated 86Q3(a). Since this toxin is merely exemplary of the toxins represented by the Generic Formula presented herein, it should be readily apparent that the subject invention further comprises equivalent toxins (and nucleotide sequences coding for equivalent toxins) having the same or similar biological activity of 86Q3(a). These equivalent toxins will have amino acid homology with 86Q3(a). This amino acid homology will typically be greater than 50%, preferably be greater than 75%, and most preferably be greater than 90%. The amino acid homology will be highest in certain critical

regions of the toxin which account for biological activity or are involved in the determination of three-dimensional configuration which ultimately is responsible for the biological activity. In this regard, certain amino acid substitutions are acceptable and can be expected if these substitutions are in regions which are not critical to activity or are conservative amino acid substitutions which do not affect the three-dimensional configuration of the molecule. For example, amino acids may be placed in the following classes: non-polar, uncharged polar, basic, and acidic. Conservative substitutions whereby an amino acid of one class is replaced with another amino acid of the same type fall within the scope of the subject invention so long as the substitution does not materially alter the biological activity of the compound. Table 2 provides a listing of examples of amino acids belonging to each class.

Table 2	
Class of Amino Acid	Examples of Amino Acids
Nonpolar	Ala, Val, Leu, Ile, Pro, Met, Phe, Trp
Uncharged Polar	Gly, Ser, Thr, Cys, Tyr, Asn, Gln
Acidic	Asp, Glu
Basic	Lys, Arg, His

In some instances, non-conservative substitutions can also be made. The critical factor is that these substitutions must not significantly detract from the biological activity of the toxin. The information presented in the generic formulae of the subject invention provides clear guidance to the person skilled in this art in making various amino acid substitutions.

Further guidance for characterizing the formicidal toxins of the subject invention is provided in Tables 4 and 5, which demonstrate the relatedness among toxins within the formicidal toxins. These tables show a numeric score for the best matching alignment between two proteins that reflects: (1) positive scores for exact matches, (2) positive or negative scores reflecting the likelihood (or not) of one amino acid substituting for another in a related protein, and (3) negative scores for the introduction of gaps. A protein sequence aligned to itself will have the highest possible score—i.e., all exact matches and no gaps. However, an unrelated protein or a randomly generated sequence will typically have a low positive score. Related sequences have scores between the random background score and the perfect match score.

The sequence comparisons were made using the local homology algorithm of Smith and Waterman ([1981] *Advances in Applied Mathematics* 2:482-489), implemented as the program "Bestfit" in the GCG Sequence Analysis Software Package Version 7 April 1991. The sequences were compared with default parameter values (comparison table: Swgappep.Cmp, Gap weight:3.0, Length weight:0.1) except that gap limits of 250 residues were applied to each sequence compared. The program output value compared is referred to as the Quality score.

Tables 4 and 5 show the pairwise alignments between the indicated amino acids of the ant-active proteins and representatives of dipteran (CryIV; ISRH3 of Sen, K. *et al.* [1988] *Agric. Biol. Chem.* 52:873-878), lepidopteran and dipteran (CryIIA; CryB1 of Widner and Whiteley [1989] *J. Bacteriol.* 171:965-974), and lepidopteran (CryIA(c); Adang *et al.* [1981] *Gene* 36:289-300) proteins.

Table 3 shows which amino acids were compared from the proteins of interest.

Table 3	
Protein	Amino acids compared
86Q3(a)	1-697
63B	1-692
33F2	1-618
17a	1-677
17b	1-678
CryIV	1-633
CryIIA	1-633
CryIA(c)	1-609

Table 4 shows the scores prior to adjustment for random sequence scores.

Table 4								
	86Q3(a)	63B	33F2	17b	17a	CryIVA	CryIIA	CryIA(c)
86Q3(a)	1046	389	310	342	340	236	237	238
63B		1038	274	339	338	235	228	232
33F2			927	323	322	251	232	251
17b				1017	1007	238	240	236
17a					1016	240	240	237
CryIVA						950	245	325
CryIIA							950	244
CryIA(c)								914

Note that ant-active protein 86Q3(a) is more closely related to 63B, 17a, 17b, and 33F2 than it is to the CryIVA, CryIIA, and CryIA(c) toxins.

Table 5 shows the same analysis after subtraction of the average score of 50 alignments of random shuffles of the column sequences with the row sequences.

Table 5								
	86Q3(a)	63B	33F2	17b	17a	CryIVA	CryIIA	CryIA(c)
86Q3(a)	841	184	118	136	135	41	40	50
63B		831	81	133	130	40	33	43
33F2			740	130	128	65	50	71
17b				811	798	42	44	47
17a					808	43	44	44
CryIVA						761	54	141
CryIIA							755	55
CryIA(c)								729

Note that in Table 5 the same relationships hold as in Table 4, i.e., 86Q3(a)'s highest score, aside from itself, is with 63B.

This degree of relatedness provides the basis for using common or similar sequence elements from the previously-described known genes to obtain related, but non-identical genes from an ant-active isolate.

Thus, certain toxins according to the subject invention can be defined as those which have formicidal activity and have an alignment value (according to the procedures of Table 5) greater

than 100 with 86Q3(a). As used herein, the term "alignment value" refers to the scores obtained using the methods described above which were used to create the scores reported in Table 5.

The toxins of the subject invention can also be characterized in terms of the shape and location of toxin inclusions.

5           Inclusion type

PS86Q3—Long amorphous inclusion and a small inclusion, both of which remain with the spore after lysis. See Figure 3.

PS140E2—An elliptical coated inclusion situated outside the exosporium, and a long inclusion inside the exosporium. See Figure 4.

10           PS211B2—Large round amorphous inclusion with coat, and an elliptical inclusion. See Figure 5.

15           The genes and toxins according to the subject invention include not only the full length sequences disclosed herein but also fragments of these sequences, or fusion proteins, which retain the characteristic formicidal activity of the sequences specifically exemplified herein.

20           It should be apparent to a person skilled in this art that genes coding for ant-active toxins can be identified and obtained through several means. The specific genes may be obtained from a culture depository as described below. These genes, or portions thereof, may be constructed synthetically, for example, by use of a gene machine. Variations of these genes may be readily constructed using standard techniques for making point mutations. Also, fragments of these genes can be made using commercially available exonucleases or endonucleases according to standard procedures. For example, enzymes such as *Bal31* or site-directed mutagenesis can be used to systematically cut off nucleotides from the ends of these genes. Also, genes which code for active fragments may be obtained using a variety of other restriction enzymes. Proteases may be used to directly obtain active fragments of these toxins.

25           Equivalent toxins and/or genes encoding these equivalent toxins can also be located from *B.t.* isolates and/or DNA libraries using the teachings provided herein. There are a number of methods for obtaining the ant-active toxins of the instant invention which occur in nature. For example, antibodies to the ant-active toxins disclosed and claimed herein can be used to identify and isolate other toxins from a mixture of proteins. Specifically, antibodies may be raised to the portions of the ant-active toxins which are most constant and most distinct from other *B.t.* toxins. These antibodies can then be used to specifically identify equivalent toxins with the characteristic formicidal activity by immunoprecipitation, enzyme linked immunoassay (ELISA), or Western blotting. Antibodies to the toxins disclosed herein, or to equivalent toxins, or fragments of these toxins, can readily be prepared using standard procedures in this art. The genes coding for these toxins can then be obtained from the microorganism.

35           A further method for identifying the toxins and genes of the subject invention is through the use of oligonucleotide probes. These probes are nucleotide sequences having a detectable label. As is well known in the art, if the probe molecule and nucleic acid sample hybridize by

forming a strong bond between the two molecules, it can be reasonably assumed that the probe and sample are essentially identical. The probe's detectable label provides a means for determining in a known manner whether hybridization has occurred. Such a probe analysis provides a rapid method for identifying formicidal endotoxin genes of the subject invention.

5           The nucleotide segments which are used as probes according to the invention can be synthesized by use of DNA synthesizers using standard procedures. In the use of the nucleotide segments as probes, the particular probe is labeled with any suitable label known to those skilled in the art, including radioactive and non-radioactive labels. Typical radioactive labels include <sup>32</sup>P, <sup>125</sup>I, <sup>35</sup>S, or the like. A probe labeled with a radioactive isotope can be constructed from a  
10           nucleotide sequence complementary to the DNA sample by a conventional nick translation reaction, using a DNase and DNA polymerase. The probe and sample can then be combined in a hybridization buffer solution and held at an appropriate temperature until annealing occurs. Thereafter, the membrane is washed free of extraneous materials, leaving the sample and bound probe molecules typically detected and quantified by autoradiography and/or liquid scintillation  
15           counting.

          Non-radioactive labels include, for example, ligands such as biotin or thyroxine, as well as enzymes such as hydrolases or peroxidases, or the various chemiluminescers such as luciferin, or fluorescent compounds like fluorescein and its derivatives. The probe may also be labeled at both ends with different types of labels for ease of separation, as, for example, by using an isotopic  
20           label at the end mentioned above and a biotin label at the other end.

          Duplex formation and stability depend on substantial complementarity between the two strands of a hybrid, and, as noted above, a certain degree of mismatch can be tolerated. Therefore, the probes of the subject invention include mutations (both single and multiple), deletions, insertions of the described sequences, and combinations thereof, wherein said mutations,  
25           insertions and deletions permit formation of stable hybrids with the target polynucleotide of interest. Mutations, insertions, and deletions can be produced in a given polynucleotide sequence in many ways, and these methods are known to an ordinarily skilled artisan. Other methods may become known in the future.

          The known methods include, but are not limited to:

- 30           (1)       synthesizing chemically or otherwise an artificial sequence which is a mutation, insertion or deletion of the known sequence;
- (2)       using a probe of the present invention to obtain via hybridization a new sequence or a mutation, insertion or deletion of the probe sequence; and
- (3)       mutating, inserting or deleting a test sequence *in vitro* or *in vivo*.

35           It is important to note that the mutational, insertional, and deletional variants generated from a given probe may be more or less efficient than the original probe. Notwithstanding such differences in efficiency, these variants are within the scope of the present invention.

          Thus, mutational, insertional, and deletional variants of the disclosed test sequences can be readily prepared by methods which are well known to those skilled in the art. These variants

can be used in the same manner as the instant probes so long as the variants have substantial sequence homology with the probes. As used herein, substantial sequence homology refers to homology which is sufficient to enable the variant to function in the same capacity as the original probe. Preferably, this homology is greater than 50%; more preferably, this homology is greater than 75%; and most preferably, this homology is greater than 90%. The degree of homology needed for the variant to function in its intended capacity will depend upon the intended use of the sequence. It is well within the skill of a person trained in this art to make mutational, insertional, and deletional mutations which are designed to improve the function of the sequence or otherwise provide a methodological advantage.

Specific nucleotide probes useful, according to the subject invention, in the rapid identification of ant-active genes are

(i) DNA coding for a peptide sequence whose single letter amino acid designation is "REWINGAN" (SEQ ID NO. 11) or variations thereof which embody point mutations according to the following: position 1, R or K; position 3, W or Y; position 4, I or L; position 7, A or N; position 8, N or Q; a specific example of such a probe is "AGA(A or G)T(G or A)(G or T)(A or T)T(A or T)AATGG(A or T)GC(G or T)(A or C)A" (SEQ ID NO. 12); another example of such a probe is "GA(A or G)TGG(A or T)TAAATGGT(A or G)(A or C)(G or C)AA" (SEQ ID NO. 13);

(ii) DNA coding for a peptide sequence whose single letter amino acid designation is "PTFDPDLY" (SEQ ID NO. 14) or variations thereof which embody point mutations according to the following: position 3, F or L; position 4, D or Y; position 5, P or T; position 6, D or H; position 7, L or H or D or N; a specific example of such a probe is "CC(A or T)AC(C or T)TTT(T or G)ATCCAGAT(C or G)(T or A)(T or C)TAT" (SEQ ID NO. 15); another example of such a probe is "CC(T or A)AC(T or A)TT(T or C)GAT(C or A)CA(G or C)AT(C or A)(T or A)TTAT" (SEQ ID NO. 16);

(iii) additional useful probes for detecting ant-active *B.t.* genes include "GCAATTTTAAATGAATTATA TCC" (SEQ ID NO. 23), "CAAYTACAAG CWCAACC" (SEQ ID NO. 24), "AATGAAGTWT ATCCWGTWAA T" (SEQ ID NO. 27), "GCAAGCGGCC GCTTATGGAA TAAATTCAAT TYKRTCWA" (SEQ ID NO. 28), "AGACTGGATC CATGGCWACW ATWAATGAAT TATAYCC" (SEQ ID NO. 29), "TAACGTGTAT WCGSTTTTAA TTTWGAYTC" (SEQ ID NO. 31), "TGGAATAAAT TCAATTYKRT CWA" (SEQ ID NO. 33), "AGGAACAAAYTCAAKWCGRT CTA" (SEQ ID NO. 34), and "TCTCCATCTT CTGARGWAAT" (SEQ ID NO. 37).

The potential variations in the probes listed is due, in part, to the redundancy of the genetic code. Because of the redundancy of the genetic code, i.e., more than one coding



nucleotide triplet (codon) can be used for most of the amino acids used to make proteins. Therefore different nucleotide sequences can code for a particular amino acid. Thus, the amino acid sequences of the *B.t.* toxins and peptides can be prepared by equivalent nucleotide sequences encoding the same amino acid sequence of the protein or peptide. Accordingly, the subject invention includes such equivalent nucleotide sequences. Also, inverse or complement sequences are an aspect of the subject invention and can be readily used by a person skilled in this art. In addition it has been shown that proteins of identified structure and function may be constructed by changing the amino acid sequence if such changes do not alter the protein secondary structure (Kaiser, E.T., Kezdy, F.J. [1984] *Science* 223:249-255). Thus, the subject invention includes mutants of the amino acid sequence depicted herein which do not alter the protein secondary structure, or if the structure is altered, the biological activity is substantially retained. Further, the invention also includes mutants of organisms hosting all or part of a toxin encoding a gene of the invention. Such microbial mutants can be made by techniques well known to persons skilled in the art. For example, UV irradiation can be used to prepare mutants of host organisms. Likewise, such mutants may include asporogenous host cells which also can be prepared by procedures well known in the art.

The toxin genes or gene fragments exemplified according to the subject invention can be obtained from *B. thuringiensis* (*B.t.*) isolates designated PS17, PS33F2, PS63B, and PS86Q3. Subcultures of the *E. coli* host harboring the toxin genes of the invention were deposited in the permanent collection of the Northern Research Laboratory, U.S. Department of Agriculture, Peoria, Illinois, USA. The accession numbers are as follows:

<u>Culture</u>	<u>Repository No.</u>	<u>Deposit Date</u>
<i>B.t.</i> PS140E2	NRRL B-18812	April 23, 1991
<i>B.t.</i> PS86Q3	NRRL B-18765	February 6, 1991
<i>B.t.</i> PS211B2	NRRL B-18921	November 15, 1991
<i>B.t.</i> PS17	NRRL B-18243	July 28, 1987
<i>B.t.</i> PS33F2	NRRL B-18244	July 28, 1987
<i>B.t.</i> PS63B	NRRL B-18246	July 28, 1987
<i>E. coli</i> NM522(pMYC2316)(33F2)	NRRL B-18785	March 15, 1991
<i>E. coli</i> NM522(pMYC2321)	NRRL B-18770	February 14, 1991
<i>E. coli</i> NM522(pMYC2317)	NRRL B-18816	April 24, 1991
<i>E. coli</i> NM522(pMYC1627)(17a)	NRRL B-18651	May 11, 1990
<i>E. coli</i> NM522(pMYC1628)(17b)	NRRL B-18652	May 11, 1990
<i>E. coli</i> NM522(pMYC1642)(63B)	NRRL B-18961	April 10, 1992
<i>E. coli</i> MR618(pMYC1647)(86Q3)	NRRL B-18970	April 29, 1992

The subject cultures have been deposited under conditions that assure that access to the cultures will be available during the pendency of this patent application to one determined by the Commissioner of Patents and Trademarks to be entitled thereto under 37 CFR 1.14 and 35 USC

122. The deposits are available as required by foreign patent laws in countries wherein counterparts of the subject application, or its progeny, are filed. However, it should be understood that the availability of a deposit does not constitute a license to practice the subject invention in derogation of patent rights granted by governmental action.

5 Further, the subject culture deposits will be stored and made available to the public in accord with the provisions of the Budapest Treaty for the Deposit of Microorganisms, i.e., they will be stored with all the care necessary to keep them viable and uncontaminated for a period of at least five years after the most recent request for the furnishing of a sample of the deposit, and in any case, for a period of at least 30 (thirty) years after the date of deposit or for the  
10 enforceable life of any patent which may issue disclosing the cultures. The depositor acknowledges the duty to replace the deposits should the depository be unable to furnish a sample when requested, due to the condition of the deposit(s). All restrictions on the availability to the public of the subject culture deposits will be irrevocably removed upon the granting of a patent disclosing them.

15 The *B.t.* isolates of the invention can be cultured using standard art media and fermentation techniques. Upon completion of the fermentation cycle, the bacteria can be harvested by first separating the *B.t.* spores and crystals from the fermentation broth by means well known in the art. The recovered *B.t.* spores and crystals can be formulated into a wettable powder, liquid concentrate, granules, or other formulations by the addition of surfactants,  
20 dispersants, inert carriers and other components to facilitate handling and application for particular target pests. These formulation and application procedures are all well known in the art.

Formulated products can be sprayed or applied as baits to control hymenopteran pests. When applied with a bait, the *B.t.* itself may be used, or another suitable host, as described herein,  
25 may be transformed with a *B.t.* gene and used to express toxins. A vegetable oil or other liquid substance can be added to a bait to make it more attractive to the pests. Various attractants, including pheromone compounds, are well known to those skilled in the art and can be used as a component of the bait. The bait and toxin or toxin-producing microbe can be used as part of a trap.

30 The *B.t.* cells of the invention can be treated prior to formulation to prolong the pesticidal activity when the cells are applied to the environment of a target pest. Such treatment can be by chemical or physical means, or by a combination of chemical and/or physical means, so long as the technique does not deleteriously affect the properties of the pesticide, nor diminish the cellular capability in protecting the pesticide. Examples of chemical reagents are halogenating agents, particularly halogens of atomic no. 17-80. More particularly, iodine can be used under  
35 mild conditions and for sufficient time to achieve the desired results. Other suitable techniques include treatment with aldehydes, such as formaldehyde and glutaraldehyde; anti-infectives, such as zephiran chloride; alcohols, such as isopropyl and ethanol; various histologic fixatives, such as Bouin's fixative and Helly's fixative (See: Humason, Gretchen L., *Animal Tissue Techniques*, W.H.

Freeman and Company, 1967); or a combination of physical (heat) and chemical agents that prolong the activity of the toxin produced in the cell when the cell is applied to the environment of the target pest(s). Examples of physical means are short wavelength radiation such as gamma-radiation and X-radiation, freezing, UV irradiation, lyophilization, and the like.

5 Genes encoding toxins having activity against the target susceptible pests can be isolated from the *B.t.* isolate of the invention by use of well known procedures.

The toxin genes of the subject invention can be introduced into a wide variety of microbial hosts. Expression of the toxin gene results, directly or indirectly, in the intracellular production and maintenance of the pesticide. With suitable hosts, e.g., *Pseudomonas*, the  
10 microbes can be applied to the situs of hymenopteran insects where they will proliferate and be ingested by the insects. The result is a control of the unwanted insects. Alternatively, the microbe hosting the toxin gene can be treated under conditions that prolong the activity of the toxin produced in the cell. The treated cell then can be applied to the environment of target pest(s). The resulting product retains the toxicity of the *B.t.* toxin.

15 Where the *B.t.* toxin gene is introduced via a suitable vector into a microbial host, and said host is applied to the environment in a living state, it is essential that certain host microbes be used. Microorganism hosts are selected which are known to occupy the "phytosphere" (phylloplane, phyllosphere, rhizosphere, and/or rhizoplane) of one or more crops of interest. These microorganisms are selected so as to be capable of successfully competing in the particular  
20 environment (crop and other insect habitats) with the wild-type microorganisms, provide for stable maintenance and expression of the gene expressing the polypeptide pesticide, and, desirably, provide for improved protection of the pesticide from environmental degradation and inactivation.

A large number of microorganisms are known to inhabit the phylloplane (the surface of the plant leaves) and/or the rhizosphere (the soil surrounding plant roots) of a wide variety of  
25 important crops. These microorganisms include bacteria, algae, and fungi. Of particular interest are microorganisms, such as bacteria, e.g., genera *Pseudomonas*, *Erwinia*, *Serratia*, *Klebsiella*, *Xanthomonas*, *Streptomyces*, *Rhizobium*, *Rhodopseudomonas*, *Methylophilus*, *Agrobacterium*, *Acetobacter*, *Lactobacillus*, *Arthrobacter*, *Azotobacter*, *Leuconostoc*, and *Alcaligenes*; fungi, particularly yeast, e.g., genera *Saccharomyces*, *Cryptococcus*, *Kluyveromyces*, *Sporobolomyces*,  
30 *Rhodotorula*, and *Aureobasidium*. Of particular interest are such phytosphere bacterial species as *Pseudomonas syringae*, *Pseudomonas fluorescens*, *Serratia marcescens*, *Acetobacter xylinum*, *Agrobacterium tumefaciens*, *Rhodopseudomonas spheroides*, *Xanthomonas campestris*, *Rhizobium melioli*, *Alcaligenes entrophus*, and *Azotobacter vinlandii*; and phytosphere yeast species such as *Rhodotorula rubra*, *R. glutinis*, *R. marina*, *R. aurantiaca*, *Cryptococcus albidus*, *C. diffluens*, *C. laurentii*, *Saccharomyces rosei*, *S. pretoriensis*, *S. cerevisiae*, *Sporobolomyces roseus*, *S. odor*,  
35 *Kluyveromyces veronae*, and *Aureobasidium pollulans*. Of particular interest are the pigmented microorganisms.

A wide variety of ways are available for introducing the *B.t.* gene expressing the toxin into the microorganism host under conditions which allow for stable maintenance and expression of

the gene. One can provide for DNA constructs which include the transcriptional and translational regulatory signals for expression of the toxin gene, the toxin gene under their regulatory control and a DNA sequence homologous with a sequence in the host organism, whereby integration will occur, and/or a replication system which is functional in the host, whereby integration or stable maintenance will occur.

The transcriptional initiation signals will include a promoter and a transcriptional initiation start site. In some instances, it may be desirable to provide for regulative expression of the toxin, where expression of the toxin will only occur after release into the environment. This can be achieved with operators or a region binding to an activator or enhancers, which are capable of induction upon a change in the physical or chemical environment of the microorganisms. For example, a temperature sensitive regulatory region may be employed, where the organisms may be grown up in the laboratory without expression of a toxin, but upon release into the environment, expression would begin. Other techniques may employ a specific nutrient medium in the laboratory, which inhibits the expression of the toxin, where the nutrient medium in the environment would allow for expression of the toxin. For translational initiation, a ribosomal binding site and an initiation codon will be present.

Various manipulations may be employed for enhancing the expression of the messenger, particularly by using an active promoter, as well as by employing sequences, which enhance the stability of the messenger RNA. The initiation and translational termination region will involve stop codon(s), a terminator region, and optionally, a polyadenylation signal.

In the direction of transcription, namely in the 5' to 3' direction of the coding or sense sequence, the construct will involve the transcriptional regulatory region, if any, and the promoter, where the regulatory region may be either 5' or 3' of the promoter, the ribosomal binding site, the initiation codon, the structural gene having an open reading frame in phase with the initiation codon, the stop codon(s), the polyadenylation signal sequence, if any, and the terminator region. This sequence as a double strand may be used by itself for transformation of a microorganism host, but will usually be included with a DNA sequence involving a marker, where the second DNA sequence may be joined to the toxin expression construct during introduction of the DNA into the host.

By a marker is intended a structural gene which provides for selection of those hosts which have been modified or transformed. The marker will normally provide for selective advantage, for example, providing for biocide resistance, e.g., resistance to antibiotics or heavy metals; complementation, so as to provide prototrophy to an auxotrophic host, or the like. Preferably, complementation is employed, so that the modified host may not only be selected, but may also be competitive in the field. One or more markers may be employed in the development of the constructs, as well as for modifying the host. The organisms may be further modified by providing for a competitive advantage against other wild-type microorganisms in the field. For example, genes expressing metal chelating agents, e.g., siderophores, may be introduced into the host along with the structural gene expressing the toxin. In this manner, the enhanced expression

of a siderophore may provide for a competitive advantage for the toxin-producing host, so that it may effectively compete with the wild-type microorganisms and stably occupy a niche in the environment.

5       Where no functional replication system is present, the construct will also include a sequence of at least 50 basepairs (bp), preferably at least about 100 bp, and usually not more than about 1000 bp of a sequence homologous with a sequence in the host. In this way, the probability of legitimate recombination is enhanced, so that the gene will be integrated into the host and stably maintained by the host. Desirably, the toxin gene will be in close proximity to the gene providing for complementation as well as the gene providing for the competitive advantage.  
10       Therefore, in the event that a toxin gene is lost, the resulting organism will be likely to also lose the complementing gene and/or the gene providing for the competitive advantage, so that it will be unable to compete in the environment with the gene retaining the intact construct.

      A large number of transcriptional regulatory regions are available from a wide variety of microorganism hosts, such as bacteria, bacteriophage, cyanobacteria, algae, fungi, and the like.  
15       Various transcriptional regulatory regions include the regions associated with the *trp* gene, *lac* gene, *gal* gene, the lambda left and right promoters, the *tac* promoter, the naturally-occurring promoters associated with the toxin gene, where functional in the host. See for example, U.S. Patent Nos. 4,332,898, 4,342,832 and 4,356,270. The termination region may be the termination region normally associated with the transcriptional initiation region or a different transcriptional  
20       initiation region, so long as the two regions are compatible and functional in the host.

      Where stable episomal maintenance or integration is desired, a plasmid will be employed which has a replication system which is functional in the host. The replication system may be derived from the chromosome, an episomal element normally present in the host or a different host, or a replication system from a virus which is stable in the host. A large number of plasmids  
25       are available, such as pBR322, pACYC184, RSF1010, pRO1614, and the like. See for example, Olson *et al.* (1982) *J. Bacteriol.* 150:6069; Bagdasarian *et al.* (1981) *Gene* 16:237; and U.S. Patent Nos. 4,356,270, 4,362,817, and 4,371,625.

      The *B.t.* gene can be introduced between the transcriptional and translational initiation region and the transcriptional and translational termination region, so as to be under the  
30       regulatory control of the initiation region. This construct will be included in a plasmid, which will include at least one replication system, but may include more than one, where one replication system is employed for cloning during the development of the plasmid and the second replication system is necessary for functioning in the ultimate host. In addition, one or more markers may be present, which have been described previously. Where integration is desired, the plasmid will  
35       desirably include a sequence homologous with the host genome.

      The transformants can be isolated in accordance with conventional ways, usually employing a selection technique, which allows for selection of the desired organism as against unmodified organisms or transferring organisms, when present. The transformants then can be tested for pesticidal activity.

Suitable host cells, where the pesticide-containing cells will be treated to prolong the activity of the toxin in the cell when the then treated cell is applied to the environment of target pest(s), may include either prokaryotes or eukaryotes, normally being limited to those cells which do not produce substances toxic to higher organisms, such as mammals. However, organisms which produce substances toxic to higher organisms could be used, where the toxin is unstable or the level of application sufficiently low as to avoid any possibility of toxicity to a mammalian host. As hosts, of particular interest will be the prokaryotes and the lower eukaryotes, such as fungi. Illustrative prokaryotes, both Gram-negative and -positive, include Enterobacteriaceae, such as *Escherichia*, *Erwinia*, *Shigella*, *Salmonella*, and *Proteus*; Bacillaceae; Rhizobiceae, such as *Rhizobium*; Spirillaceae, such as photobacterium, *Zymomonas*, *Serratia*, *Aeromonas*, *Vibrio*, *Desulfovibrio*, *Spirillum*; Lactobacillaceae; Pseudomonadaceae, such as *Pseudomonas* and *Acetobacter*; Azotobacteraceae and Nitrobacteraceae. Among eukaryotes are fungi, such as Phycomycetes and Ascomycetes, which includes yeast, such as *Saccharomyces* and *Schizosaccharomyces*; and Basidiomycetes yeast, such as *Rhodotorula*, *Aureobasidium*, *Sporobolomyces*, and the like.

Characteristics of particular interest in selecting a host cell for purposes of production include ease of introducing the *B.t.* gene into the host, availability of expression systems, efficiency of expression, stability of the pesticide in the host, and the presence of auxiliary genetic capabilities. Characteristics of interest for use as a pesticide microcapsule include protective qualities for the pesticide, such as thick cell walls, pigmentation, and intracellular packaging or formation of inclusion bodies; leaf affinity; lack of mammalian toxicity; attractiveness to pests for ingestion; ease of killing and fixing without damage to the toxin; and the like. Other considerations include ease of formulation and handling, economics, storage stability, and the like.

Host organisms of particular interest include yeast, such as *Rhodotorula* sp., *Aureobasidium* sp., *Saccharomyces* sp., and *Sporobolomyces* sp.; phylloplane organisms such as *Pseudomonas* sp., *Erwinia* sp. and *Flavobacterium* sp.; or such other organisms as *Escherichia*, *Lactobacillus* sp., *Bacillus* sp., *Streptomyces* sp., and the like. Specific organisms include *Pseudomonas aeruginosa*, *Pseudomonas fluorescens*, *Saccharomyces cerevisiae*, *Bacillus thuringiensis*, *Escherichia coli*, *Bacillus subtilis*, *Streptomyces lividans*, and the like.

The cell will usually be intact and be substantially in the proliferative form when treated, rather than in a spore form, although in some instances spores may be employed.

Treatment of the recombinant microbial cell can be done as disclosed *infra*. The treated cells generally will have enhanced structural stability which will enhance resistance to environmental conditions. Where the pesticide is in a proform, the method of inactivation should be selected so as not to inhibit processing of the proform to the mature form of the pesticide by the target pest pathogen. For example, formaldehyde will crosslink proteins and could inhibit processing of the proform of a polypeptide pesticide. The method of inactivation or killing retains at least a substantial portion of the bio-availability or bioactivity of the toxin.

The cellular host containing the *B.t.* insecticidal gene may be grown in any convenient nutrient medium, where the DNA construct provides a selective advantage, providing for a selective medium so that substantially all or all of the cells retain the *B.t.* gene. These cells may then be harvested in accordance with conventional ways. Alternatively, the cells can be treated prior to harvesting.

The *B.t.* cells may be formulated in a variety of ways. They may be employed as wettable powders, baits, granules or dusts, by mixing with various inert materials, such as inorganic minerals (phyllosilicates, carbonates, sulfates, phosphates, and the like) or botanical materials (powdered corncobs, rice hulls, walnut shells, and the like). The formulations may include spreader-sticker adjuvants, stabilizing agents, other pesticidal additives, or surfactants. Liquid formulations may be aqueous-based or non-aqueous and employed as foams, gels, suspensions, emulsifiable concentrates, or the like. The ingredients may include rheological agents, surfactants, emulsifiers, dispersants, or polymers.

The pesticidal concentration will vary widely depending upon the nature of the particular formulation, particularly whether it is a concentrate or to be used directly. The pesticide will be present in at least 1% by weight and may be 100% by weight. The dry formulations will have from about 1-95% by weight of the pesticide while the liquid formulations will generally be from about 1-60% by weight of the solids in the liquid phase. The formulations will generally have from about  $10^2$  to about  $10^4$  cells/mg. These formulations will be administered at about 50 mg (liquid or dry) to 1 kg or more per hectare.

The formulations can be applied to the environment of the hymenopteran pest(s), e.g., plants, soil or water, by spraying, dusting, sprinkling, baits or the like.

Following are examples which illustrate procedures, including the best mode, for practicing the invention. These examples should not be construed as limiting. All percentages are by weight and all solvent mixture proportions are by volume unless otherwise noted.

#### Example 1 – Culturing *B.t.* Isolates of the Invention

A subculture of a *B.t.* isolate can be used to inoculate the following medium, a peptone, glucose, salts medium.

Bacto Peptone	7.5 g/l
Glucose	1.0 g/l
$\text{KH}_2\text{PO}_4$	3.4 g/l
$\text{K}_2\text{HPO}_4$	4.35 g/l
Salts Solution	5.0 ml/l
$\text{CaCl}_2$ Solution	5.0 ml/l
Salts Solution (100 ml)	
$\text{MgSO}_4 \cdot 7\text{H}_2\text{O}$	2.46 g
$\text{MnSO}_4 \cdot \text{H}_2\text{O}$	0.04 g

22

ZnSO <sub>4</sub> ·7H <sub>2</sub> O	0.28 g
FeSO <sub>4</sub> ·7H <sub>2</sub> O	0.40 g
CaCl <sub>2</sub> Solution (100 ml)	
CaCl <sub>2</sub> ·2H <sub>2</sub> O	3.66 g
pH 7.2	

5

The salts solution and CaCl<sub>2</sub> solution are filter-sterilized and added to the autoclaved and cooked broth at the time of inoculation. Flasks are incubated at 30°C on a rotary shaker at 200 rpm for 64 hr.

10

#### Example 2 – Purification of Protein and Amino Acid Sequencing

The *B.t.* isolates PS86Q3, PS17, PS63B, and PS33F2 were cultured as described in Example 1. The parasporal inclusion bodies were partially purified by sodium bromide (28-38%) isopycnic gradient centrifugation (Pfannenstiel, M.A., E.J. Ross, V.C. Kramer, K.W. Nickerson [1984] *FEMS Microbiol. Lett.* 21:39). The proteins were bound to PVDF membranes (Millipore, Bedford, MA) by western blotting techniques (Towbin, H., T. Staehelin, K. Gordon [1979] *Proc. Natl. Acad. Sci. USA* 76:4350) and the N-terminal amino acid sequences were determined by the standard Edman reaction with an automated gas-phase sequenator (Hunkapiller, M.W., R.M. Hewick, W.L. Dreyer, and L.E. Hood [1983] *Meth. Enzymol.* 91:399). The sequences obtained were:

20

17a: A I L N E L Y P S V P Y N V (SEQ ID NO. 17)

17b: A I L N E L Y P S V P Y N V (SEQ ID NO. 18)

86Q3(a): M A T I N E L Y P N V P Y N V L (SEQ ID NO. 19)

63B: Q L Q A Q P L I P Y N V L A (SEQ ID NO. 20)

25

33F2: A T L N E V Y P V N (SEQ ID NO. 21)

In addition, internal amino acid sequence data were derived for 63B. The toxin protein was partially digested with *Staphylococcus aureus* V8 protease (Sigma Chem. Co., St. Louis, MO) essentially as described (Cleveland, D.W., S.G. Fischer, M.W. Kirschner, U.K. Laemmli [1977] *J. Biol. Chem.* 252:1102). The digested material was blotted onto PVDF membrane and a ca. 28 kDa limit peptide was selected for N-terminal sequencing as described above. The sequence obtained was:

30

63B(2) V Q R I L D E K L S F Q L I K (SEQ ID NO. 22)

From these sequence data oligonucleotide probes were designed by utilizing a codon frequency table assembled from available sequence data of other *B.t.* toxin genes. The probes were synthesized on an Applied Biosystems, Inc. DNA synthesis machine.

35

Protein purification and subsequent amino acid analysis of the N-terminal peptides listed above has led to the deduction of several oligonucleotide probes for the isolation of toxin genes from formicidal *B.t.* isolates. RFLP analysis of restricted total cellular DNA using radiolabeled oligonucleotide probes has elucidated different genes or gene fragments.



Example 3 – Cloning of Novel Toxin Genes and Transformation into *Escherichia coli*

Total cellular DNA was prepared by growing the cells *B.t.* PS17 to a low optical density ( $OD_{600} = 1.0$ ) and recovering the cells by centrifugation. The cells were protoplasted in TES buffer (30 mM Tris-Cl, 10 mM EDTA, 50 mM NaCl, pH = 8.0) containing 20 % sucrose and 50 mg/ml lysozyme. The protoplasts were lysed by addition of SDS to a final concentration of 4%. The cellular material was precipitated overnight at 4°C in 100 mM (final concentration) neutral potassium chloride. The supernate was extracted twice with phenol/chloroform (1:1). The DNA was precipitated with ethanol and purified by isopycnic banding on a cesium chloride-ethidium bromide gradient.

Total cellular DNA from PS17 was digested with *EcoRI* and separated by electrophoresis on a 0.8% (w/v) Agarose-TAE (50 mM Tris-HCl, 20 mM NaOAc, 2.5 mM EDTA, pH=8.0) buffered gel. A Southern blot of the gel was hybridized with a [ $^{32}$ P]-radiolabeled oligonucleotide probe derived from the N-terminal amino acid sequence of purified 130 kDa protein from PS17. The sequence of the oligonucleotide synthesized is (GCAATTTTAAATGAATTATATCC) (SEQ ID NO. 23). Results showed that the hybridizing *EcoRI* fragments of PS17 are 5.0 kb, 4.5 kb, 2.7 kb and 1.8 kb in size, presumptively identifying at least four new ant-active toxin genes, 17d, 17b, 17a and 17e, respectively.

A library was constructed from PS17 total cellular DNA partially digested with *Sau3A* and size fractionated by electrophoresis. The 9 to 23 kb region of the gel was excised and the DNA was electroeluted and then concentrated using an Elutip<sup>TM</sup> ion exchange column (Schleicher and Schuel, Keene NH). The isolated *Sau3A* fragments were ligated into LambdaGEM-11<sup>TM</sup> (PROMEGA). The packaged phage were plated on KW251 *E. coli* cells (PROMEGA) at a high titer and screened using the above radiolabeled synthetic oligonucleotide as a nucleic acid hybridization probe. Hybridizing plaques were purified and rescreened at a lower plaque density. Single isolated purified plaques that hybridized with the probe were used to infect KW251 *E. coli* cells in liquid culture for preparation of phage for DNA isolation. DNA was isolated by standard procedures.

Recovered recombinant phage DNA was digested with *EcoRI* and separated by electrophoresis on a 0.8% agarose-TAE gel. The gel was Southern blotted and hybridized with the oligonucleotide probe to characterize the toxin genes isolated from the lambda library. Two patterns were present, clones containing the 4.5 kb (17b) or the 2.7 kb (17a) *EcoRI* fragments. Preparative amounts of phage DNA were digested with *SaII* (to release the inserted DNA from lambda arms) and separated by electrophoresis on a 0.6% agarose-TAE gel. The large fragments, electroeluted and concentrated as described above, were ligated to *SaII*-digested and dephosphorylated pBClac, an *E. coli/B.t.* shuttle vector comprised of replication origins from pBC16 and pUC19. The ligation mix was introduced by transformation into NM522 competent *E. coli* cells and plated on LB agar containing ampicillin, isopropyl-(Beta)-D-thiogalactoside (IPTG) and 5-Bromo-4-Chloro-3-indolyl-(Beta)-D-galactoside (XGAL). White colonies, with putative insertions in the (Beta)-galactosidase gene of pBClac; were subjected to standard rapid

plasmid purification procedures to isolate the desired plasmids. The selected plasmid containing the 2.7 kb *EcoRI* fragment was named pMYC1627 and the plasmid containing the 4.5 kb *EcoRI* fragment was called pMYC1628.

5 The toxin genes were sequenced by the standard Sanger dideoxy chain termination method using the synthetic oligonucleotide probe, disclosed above, and by "walking" with primers made to the sequence of the new toxin genes.

10 The PS17 toxin genes were subcloned into the shuttle vector pHT3101 (Lereclus, D. *et al.* [1989] *FEMS Microbiol. Lett.* 60:211-218) using standard methods for expression in *B.t.* Briefly, *SalI* fragments containing the 17a and 17b toxin genes were isolated from pMYC1629 and pMYC1627, respectively, by preparative agarose gel electrophoresis, electroelution, and concentrated, as described above. These concentrated fragments were ligated into *SalI*-cleaved and dephosphorylated pHT3101. The ligation mixtures were used separately to transform frozen, competent *E. coli* NM522. Plasmids from each respective recombinant *E. coli* strain were prepared by alkaline lysis and analyzed by agarose gel electrophoresis. The resulting subclones, 15 pMYC2311 and pMYC2309, harbored the 17a and 17b toxin genes, respectively. These plasmids were transformed into the acrySTALLIFEROUS *B.t.* strain, HD-1 *cryB* (Aronson, A., Purdue University, West Lafayette, IN), by standard electroporation techniques (Instruction Manual, Biorad, Richmond, CA).

20 Recombinant *B.t.* strains HD-1 *cryB* [pMYC2311] and [pMYC2309] were grown to sporulation and the proteins purified by NaBr gradient centrifugation as described above for the wild-type *B.t.* proteins.

Example 4 — Molecular Cloning of a Gene Encoding a Novel Toxin from *Bacillus thuringiensis* Strain PS63B

25 Example 2 shows the aminoterminal and internal polypeptide sequences of the 63B toxin protein as determined by standard Edman protein sequencing. From these sequences, two oligonucleotide primers were designed using a codon frequency table assembled from *B.t.* genes encoding  $\delta$ -endotoxins. The sequence of the forward primer (63B-A) was complementary to the predicted DNA sequence at the 5' end of the gene:

30 63B-A - 5' CAA T/CTA CAA GCA/T CAA CC 3' (SEQ ID NO. 24)

The sequence of the reverse primer (63B-INT) was complementary to the inverse of the internal predicted DNA sequence:

63B-INT - 5' TTC ATC TAA AAT TCT TTG A/TAC 3' (SEQ ID NO. 25)

35 These primers were used in standard polymerase chain reactions (Cetus Corporation) to amplify an approximately 460 bp fragment of the 63B toxin gene for use as a DNA cloning probe. Standard Southern blots of total cellular DNA from 63B were hybridized with the radiolabeled PCR probe. Hybridizing bands included an approximately 4.4 kbp *XbaI* fragment, an approximately 2.0 kbp *HindIII* fragment, and an approximately 6.4 kbp *SpeI* fragment.

Total cellular DNA was prepared from *Bacillus thuringiensis* (*B.t.*) cells grown to an optical density of 1.0 at 600 nm. The cells were recovered by centrifugation and protoplasts were prepared in lysis mix (300 mM sucrose, 25 mM Tris-HCl, 25 mM EDTA, pH = 8.0) and lysozyme at a concentration of 20 mg/ml. The protoplasts were ruptured by addition of ten volumes of 0.1 M NaCl, 0.1 M Tris-HCl pH 8.0, and 0.1% SDS. The cellular material was quickly frozen at -70°C and thawed to 37°C twice. The supernatant was extracted twice with phenol/chloroform (1:1). The nucleic acids were precipitated with ethanol. To remove as much RNA as possible from the DNA preparation, RNase at final concentration of 200 µg/ml was added. After incubation at 37°C for 1 hour, the solution was extracted once with phenol/chloroform and precipitated with ethanol.

A gene library was constructed from 63B total cellular DNA partially digested with *Nde*II and size fractionated by gel electrophoresis. The 9-23 kb region of the gel was excised and the DNA was electroeluted and then concentrated using an Elutip-d ion exchange column (Schleicher and Schuel, Keene, NH). The isolated *Nde*II fragments were ligated into *Bam*HI-digested LambdaGEM-11 (PROMEGA). The packaged phage were plated on *E. coli* KW251 cells (PROMEGA) at a high titer and screened using the radiolabeled approximately 430 bp fragment probe amplified with the 63B-A and 63B internal primers (SEQ ID NOS. 27 and 28, respectively) by polymerase chain reaction. Hybridizing plaques were purified and rescreened at a lower plaque density. Single isolated, purified plaques that hybridized with the probe were used to infect KW251 cells in liquid culture for preparation of phage for DNA isolation. DNA was isolated by standard procedures (Maniatis, T., E.F. Fritsch, J. Sambrook [1982] *Molecular Cloning: A Laboratory Manual*, Cold Spring Harbor Laboratory, New York). Preparative amounts of DNA were digested with *Sal*I (to release the inserted DNA from lambda sequences) and separated by electrophoresis on a 0.6% agarose-TAE gel. The large fragments were purified by ion exchange chromatography as above and ligated to *Sal*I-digested, dephosphorylated pHTBlueII (an *E. coli*/*B.t.* shuttle vector comprised of pBlueScript S/K [Stratagene, San Diego, CA] and the replication origin from a resident *B.t.* plasmid [Lereclus, D. *et al.* (1989) *FEMS Microbiol. Lett.* 60:211-218]). The ligation mix was introduced by transformation into competent *E. coli* NM522 cells (ATCC 47000) and plated on LB agar containing ampicillin (100 µg/ml), IPTG (2%), and XGAL (2%). White colonies, with putative restriction fragment insertions in the (Beta)-galactosidase gene of pHTBlueII, were subjected to standard rapid plasmid purification procedures (Maniatis *et al.*, *supra*). Plasmids were analyzed by *Sal*I digestion and agarose gel electrophoresis. The desired plasmid construct, pMYC1641, contains an approximately 14 kb *Sal*I insert.

For subcloning, preparative amounts of DNA were digested with *Xba*I and electrophoresed on an agarose gel. The approximately 4.4 kbp band containing the toxin gene was excised from the gel, electroeluted from the gel slice, and purified by ion exchange chromatography as above. This fragment was ligated into *Xba*I cut pHTBlueII and the resultant plasmid was designated pMYC1642.

Example 5 — Cloning of a Novel Toxin Gene From *B.t.* PS33F2 and Transformation into *Escherichia coli*

Total cellular DNA was prepared from *B.t.* PS33F2 cells grown to an optical density, at 600 nm, of 1.0. Cells were pelleted by centrifugation and resuspended in protoplast buffer (20 mg/ml lysozyme in 0.3 M sucrose, 25 mM Tris-Cl [pH 8.0], 25 mM EDTA). After incubation at 37°C for 1 hour, protoplasts were lysed by the addition of nine volumes of a solution of 0.1 M NaCl, 0.1% SDS, 0.1 M Tris-Cl followed by two cycles of freezing and thawing. The cleared lysate was extracted twice with phenol:chloroform (1:1). Nucleic acids were precipitated with two volumes of ethanol and pelleted by centrifugation. The pellet was resuspended in 10 mM Tris-Cl, 1 mM EDTA (TE) and RNase was added to a final concentration of 50 µg/ml. After incubation at 37°C for 1 hour, the solution was extracted once each with phenol:chloroform (1:1) and TE-saturated chloroform. DNA was precipitated from the aqueous phase by the addition of one-tenth volume of 3 M NaOAc and two volumes of ethanol. DNA was pelleted by centrifugation, washed with 70% ethanol, dried, and resuspended in TE.

Plasmid DNA was extracted from protoplasts prepared as described above. Protoplasts were lysed by the addition of nine volumes of a solution of 10 mM Tris-Cl, 1 mM EDTA, 0.085 N NaOH, 0.1% SDS, pH=8.0. SDS was added to 1% final concentration to complete lysis. One-half volume of 3 M KOAc was then added and the cellular material was precipitated overnight at 4°C. After centrifugation, the DNA was precipitated with ethanol and plasmids were purified by isopycnic centrifugation on cesium chloride-ethidium bromide gradients.

Restriction Fragment Length Polymorphism (RFLP) analyses were performed by standard hybridization of Southern blots of PS33F2 plasmid and total cellular DNA with <sup>32</sup>P-labelled oligonucleotide probes designed to the N-terminal amino acid sequence disclosed in Example 2.

Probe 33F2A: 5' GCA/T ACA/T TTA AAT GAA GTA/T TAT 3' (SEQ ID NO. 26)

Probe 33F2B: 5' AAT GAA GTA/T TAT CCA/T GTA/T AAT 3' (SEQ ID NO. 27)

Hybridizing bands included an approximately 5.85 kbp *Eco*RI fragment. Probe 33F2A and a reverse PCR primer were used to amplify a DNA fragment of approximately 1.8 kbp for use as a hybridization probe for cloning the 33F2 toxin gene. The sequence of the reverse primer was: 5' GCAAGCGGCCGCTTATGGAATAAATTCAATT C/T T/G A/G TC T/A A 3' (SEQ ID NO. 28).

A gene library was constructed from 33F2 plasmid DNA digested with *Eco*RI. Restriction digests were fractionated by agarose gel electrophoresis. DNA fragments 4.3-6.6 kbp were excised from the gel, electroeluted from the gel slice, and recovered by ethanol precipitation after purification on an Elutip-D ion exchange column (Schleicher and Schuel, Keene NH). The *Eco*RI inserts were ligated into *Eco*RI-digested pHTBlueII (an *E. coli*/*B. thuringiensis* shuttle vector comprised of pBluescript S/K [Stratagene] and the replication origin from a resident *B.t.* plasmid [Lereclus, D. *et al.* [1989] *FEMS Microbial. Lett.* 60:211-218]). The ligation mixture was transformed into frozen, competent NM522 cells (ATCC 47000). Transformants were plated on LB agar containing ampicillin, isopropyl-(Beta)-D-thiogalactoside (IPTG), and 5-bromo-4-chloro-

3-indolyl-(Beta)-D-galactoside (XGAL). Colonies were screened by hybridization with the radiolabeled PCR amplified probe described above. Plasmids were purified from putative toxin gene clones by alkaline lysis and analyzed by agarose gel electrophoresis of restriction digests. The desired plasmid construct, pMYC2316, contains an approximately 5.85 kbp *Eco*4RI insert; the toxin gene residing on this DNA fragment (33F2a) is novel compared to the DNA sequences of other toxin genes encoding formicidal proteins.

Plasmid pMYC2316 was introduced into the acrySTALLIFEROUS (Cry-) *B.t.* host, HD-1 CryB (A. Aronson, Purdue University, West Lafayette, IN) by electroporation. Expression of an approximately 120-140 kDa crystal protein was verified by SDS-PAGE analysis. Crystals were purified on NaBr gradients (M.A. Pfannenstiel *et al.* [1984] *FEMS Microbiol. Lett.* 21:39) for determination of toxicity of the cloned gene product to *Pratylenchus* spp.

#### Example 6 – Cloning of a Novel Toxin Gene from *B.t.* Isolate PS86Q3

Total cellular DNA was prepared from *Bacillus thuringiensis* (*B.t.*) cells grown to an optical density of 1.0 at 600 nm. The cells were recovered by centrifugation and protoplasts were prepared in lysis mix (300 mM sucrose, 25 mM Tris-HCl, 25 mM EDTA, pH = 8.0) containing lysozyme at a concentration of 20 mg/ml. The protoplasts were ruptured by addition of ten volumes of 0.1 M NaCl, 0.1% SDS, 0.1 M Tris-Cl, pH = 8.0. The cleared lysate was quickly frozen at -70°C and thawed to 37°C twice. The supernate was extracted twice with phenol:chloroform (1:1). The pellet was resuspended in 10 mM Tris-Cl, 1 mM EDTA, pH = 8.0 (TE), and RNase was added to a final concentration of 50 µg/ml. After incubation at 37°C for one hour, the solution was extracted once with phenol:chloroform (1:1) and then with TE-saturated chloroform. DNA was precipitated from the aqueous phase by the addition of one-tenth volume of 3M NaOAc and two volumes of ethanol. DNA was pelleted by centrifugation, washed with 70% ethanol, dried, and resuspended in TE.

Total cellular DNA from isolate PS86Q3 was used as template for polymerase chain reaction (PCR) analysis according to protocols furnished by Perkin Elmer Cetus. An oligonucleotide derived from the N-terminal amino acid sequence of the toxin protein was used as a 5' primer. The sequence of this oligonucleotide is:

5'-AGACTGGATCCATGGC(A or T)AC(A or T)AT(A or T)AATGAATTATA (T or C)CC-3' (SEQ ID NO. 29).

An oligonucleotide coding for the amino acid sequence "ESKLKPNTRY" (SEQ ID NO. 30) can be used as the reverse 3' primer. The sequence of this oligonucleotide can be: "5'-TAACGTGTAT(A or T)CG(C or G)TTTAAATTT(T or A)GA(C or T)TC-3'" (SEQ ID NO. 31).

The reverse "YIDKIEFIP" (SEQ ID NO. 32) oligonucleotide was also used as a reverse 3' primer in conjunction with the above mentioned 5' primer. The sequence of the reverse primer can be: "5'-TGGAATAAATTCAATT(C or T)(T or G)(A or G)TC(T or A)A-3'" (SEQ ID NO. 33).

Amplification with the 5' primer and SEQ ID NO. 31 generates an approximately 2.3 kbp DNA fragment and an approximately 4.3 kbp DNA fragment. Amplification with the 5' primer and SEQ ID NO. 33 generates an approximate 1.8 kbp DNA fragment and an approximately 3.7 kbp DNA fragment. The approximately 2.3 kbp fragment was radiolabeled with  $^{32}\text{P}$  and used as a hybridization probe to generate restriction fragment polymorphism (RFLP) patterns and to screen recombinant phage libraries.

A Southern blot of total cellular DNA digested with *EcoRV* was probed with the radiolabeled 2.3 kbp probe described above. The resultant RFLP includes 9.5 kbp, 6.4 kbp, and 4.5 kbp hybridizing fragments.

A gene library was constructed from PS86Q3 total cellular DNA partially digested with *NdeII* and size fractionated by gel electrophoresis. The 9-23 kb region of the gel was excised and the DNA was electroeluted and then concentrated using an Elutip-d ion exchange column (Schleicher and Schuel, Keene, NH). The isolated *NdeII* fragments were ligated into *BamHI*-digested LambdaGEM-11 (PROMEGA). The packaged phage were plated on *E. coli* KW251 cells (PROMEGA) at a high titer and screened using the radiolabeled probe described above. Hybridizing plaques were purified and rescreened at a lower plaque density. Single isolated, purified plaques that hybridized with the probe were used to infect KW251 cells in liquid culture for preparation of phage for DNA isolation. DNA was isolated by standard procedures (Maniatis *et al.*, *supra*). Preparative amounts of DNA were digested with *SaII* (to release the inserted DNA from lambda sequences) and separated by electrophoresis on a 0.6% agarose-TAE gel. The large fragments were purified by ion exchange chromatography as above and ligated to *SaII*-digested, dephosphorylated pHTBlueII (an *E. coli/B.t.* shuttle vector comprised of pBluescript S/K [Stratagene, San Diego, CA]) and the replication origin from a resident *B.t.* plasmid (Lereclus *et al.* [1989], *supra*). The ligation mix was introduced by transformation into competent *E. coli* NM522 cells (ATCC 47000) and plated on LB agar containing ampicillin, IPTG, and XGAL. White colonies, with putative restriction fragment insertions in the (Beta)-galactosidase gene of pHTBlueII, were subjected to standard rapid plasmid purification procedures (Maniatis *et al.*, *supra*). Plasmid DNA was analyzed by *SaII* digestion and agarose gel electrophoresis. The desired plasmid construct, pMYC1647, contains an approximately 12 kb *SaII* insert.

Plasmid pMYC1647 was introduced by electroporation into an acrySTALLIFEROUS ( $\text{Cry}^-$ ) *B.t.*, HD-1 *CryB* (A.L. Aronson, Purdue University) host to yield MR515, a recombinant *B.t.* clone of 86Q3(a). Expression of an approximately 155 kDa protein was verified by SDS-PAGE. Spores and crystals were removed from broth cultures and were used for determination of toxicity to pharaoh ants.

#### Example 7 - Activity of the *B.t.* Toxin Protein and Gene Product Against Ants

Broths were tested for the presence of  $\beta$ -exotoxin by a larval house fly bioassay (Campbell, D.P., Dieball, D.E., Bracket, J.M. [1987] "Rapid HPLC assay for the  $\beta$ -exotoxin of

*Bacillus thuringiensis*," *J. Agric. Food Chem.* 35:156-158). Only isolates which tested free of  $\beta$ -exotoxin were used in the assays against ants.

A bait was made consisting of 10% *Bacillus thuringiensis* isolates of the invention and Crosse and Blackwell mint apple jelly. Approximately 100 ants were placed in each plastic test chamber replicate with the baits. Control experiments were performed with untreated mint apple jelly. Each test was replicated a minimum of 10 times. Mortality was assessed at 7, 14 and 21 days after introduction of the bait to the ants. Results are shown below:

Table 6. Toxicity of *B. thuringiensis* Isolates to the Pharaoh Ant (*Monomorium pharaonis*)

<i>B.t.</i> Isolate	Percent Mortality
PS140E2	91
PS 86Q3	84
Control	11
PS211B2	90.0
Control	3.8

#### Example 8 – Activity Against Pharaoh Ants

Mint apple jelly containing 10% *B.t.* (100,000 ppm) was fed to 5 replicates of approximately 100 worker ants for 21 days. Total mortality (in %) over the test period is compared to control.

Table 7. Three week mortality (%) on pharaoh ant workers.

Sample	Rate ppm	Percent Mortality
MR515	100000	40.1
86Q3	100000	29.2
211B2	100000	58.5
MAJ	Blank	25.0
Control	Blank	14.4

MR515 = a recombinant *B.t.* clone of 86Q3(a) gene, 10% in MAJ (Example 6)

86Q3 = spray dried powder of *B.t.* PS86Q3, 10% in MAJ

211B2 = spray dried power of *B.t.* PS211B2, 10% in MAJ

MAJ = Mint apple jelly, Crosse & Blackwell

Control = rearing diet of water, frozen flies, mealworms/honey agar

Table 8. Three week mortality (%) on pharaoh ant workers.		
Sample	Rate ppm	Percent Mortality
140E2	50000	100.0
86Q3	50000	99.6
211B2	50000	100.0
MAJ	Blank	75.3
Control	Blank	39.0

140E2 = 5% 140E2 purified protein in MAJ  
 86Q3 = 5% 86Q3 purified protein in MAJ  
 211B2 = 5% 211B2 purified protein in MAJ  
 MAJ = Mint apple jelly, Crosse & Blackwell  
 Control = rearing diet of water, frozen flies, mealworms/honey agar

#### Example 9 – Cloning of Novel Ant-Active Genes Using Generic Oligonucleotide Primers

The formicidal gene of a new formicidal *B.t.* can be obtained from DNA of the strain by performing the standard polymerase chain reaction procedure as in Example 6 using the oligonucleotides of SEQ ID NO. 33 or AGGAACAAAYTCAAKWCGRTCTA (SEQ ID NO. 34) as reverse primers and SEQ ID NO. 12, SEQ ID NO. 13, SEQ ID NO. 15, SEQ ID NO. 16, SEQ ID NO. 23, SEQ ID NO. 27, SEQ ID NO. 29, or SEQ ID NO. 24 as forward primers. The expected PCR fragments would be approximately 330 to 600 bp with either reverse primer and SEQ ID NO. 12 or SEQ ID NO. 13, 1000 to 1400 bp with either reverse primer and SEQ ID NO. 15 or SEQ ID NO. 16, and 1800 to 2100 bp with either reverse primer and any of the three N-terminal primers, SEQ ID NO. 27, SEQ ID NO. 23, SEQ ID NO. 29, and SEQ ID NO. 24. Alternatively, a complement from the primer family described by SEQ ID NO. 12 and SEQ ID NO. 13 can be used as reverse primer with SEQ ID NO. 15, SEQ ID NO. 16, SEQ ID NO. 23, SEQ ID NO. 27, SEQ ID NO. 29, or SEQ ID NO. 24 as forward primers. The expected PCR fragments would be approximately 650 to 1000 bp with SEQ ID NO. 15 or SEQ ID NO. 16, and 1400 to 1800 bp for the four N-terminal primers (SEQ ID NO. 27, SEQ ID NO. 23, SEQ ID NO. 29, and SEQ ID NO. 24).

As another alternative, the reverse primer SEQ ID NO. 31 can be used with any of the four N-terminal forward primers to yield fragments of approximately 2550-3100 bp; 1750-2150 bp with the forward primers SEQ ID NOS. 15 or 16; 850-1400 bp with SEQ ID NOS. 12 or 13; and 550-1050 bp with the forward primer TTAGATCGT(A or C)TTGA(G or A)TTT(A or G)T(A or T)CC (SEQ ID NO. 35).

As yet another alternative, the ITSED (SEQ ID NO 37) reverse primer (TCTCCATCTTCTGA(G or A)G(T or A)AAT) (SEQ ID NO. 37) can be used with the N-terminal forward primers (SEQ ID NO. 23, SEQ ID NO. 24, SEQ ID NO. 27, and SEQ ID NO.



ID NOS. 15 or 16; 1800-2400 bp with forward primers SEQ ID NOS. 12 or 13; and 1500-2050 bp with forward primer SEQ ID NO. 35.

Amplified DNA fragments of the indicated sizes can be radiolabeled and used as probes to clone the entire gene as in Example 6.

5

#### Example 10 – Insertion of Toxin Gene Into Plants

One aspect of the subject invention is the transformation of plants with genes coding for a formicidal toxin. The transformed plants are resistant to attack by ants.

10 Genes coding for formicidal toxins, as disclosed herein, can be inserted into plant cells using a variety of techniques which are well known in the art. For example, a large number of cloning vectors comprising a replication system in *E. coli* and a marker that permits selection of the transformed cells are available for preparation for the insertion of foreign genes into higher plants. The vectors comprise, for example, pBR322, pUC series, M13mp series, pACYC184, etc. Accordingly, the sequence coding for the *B.t.* toxin can be inserted into the vector at a suitable  
15 restriction site. The resulting plasmid is used for transformation into *E. coli*. The *E. coli* cells are cultivated in a suitable nutrient medium, then harvested and lysed. The plasmid is recovered. Sequence analysis, restriction analysis, electrophoresis, and other biochemical-molecular biological methods are generally carried out as methods of analysis. After each manipulation, the DNA sequence used can be cleaved and joined to the next DNA sequence. Each plasmid sequence can  
20 be cloned in the same or other plasmids. Depending on the method of inserting desired genes into the plant, other DNA sequences may be necessary. If, for example, the Ti or Ri plasmid is used for the transformation of the plant cell, then at least the right border, but often the right and the left border of the Ti or Ri plasmid T-DNA, has to be joined as the flanking region of the genes to be inserted.

25 The use of T-DNA for the transformation of plant cells has been intensively researched and sufficiently described in EP 120 516; Hoekema (1985) In: *The Binary Plant Vector System*, Offset-durkkerij Kanters B.V., Alblasserdam, Chapter 5; Fraley *et al.*, *Crit. Rev. Plant Sci.* 4:1-46; and An *et al.* (1985) *EMBO J.* 4:277-287.

30 Once the inserted DNA has been integrated in the genome, it is relatively stable there and, as a rule, does not come out again. It normally contains a selection marker that confers on the transformed plant cells resistance to a biocide or an antibiotic, such as kanamycin, G 418, bleomycin, hygromycin, or chloramphenicol, *inter alia*. The individually employed marker should accordingly permit the selection of transformed cells rather than cells that do not contain the inserted DNA.

35 A large number of techniques are available for inserting DNA into a plant host cell. Those techniques include transformation with T-DNA using *Agrobacterium tumefaciens* or *Agrobacterium rhizogenes* as transformation agent, fusion, injection, or electroporation as well as other possible methods. If agrobacteria are used for the transformation, the DNA to be inserted has to be cloned into special plasmids, namely either into an intermediate vector or into a binary

vector. The intermediate vectors can be integrated into the Ti or Ri plasmid by homologous recombination owing to sequences that are homologous to sequences in the T-DNA. The Ti or Ri plasmid also comprises the vir region necessary for the transfer of the T-DNA. Intermediate vectors cannot replicate themselves in agrobacteria. The intermediate vector can be transferred  
5 into *Agrobacterium tumefaciens* by means of a helper plasmid (conjugation). Binary vectors can replicate themselves both in *E. coli* and in agrobacteria. They comprise a selection marker gene and a linker or polylinker which are framed by the right and left T-DNA border regions. They can be transformed directly into agrobacteria (Holsters *et al.* [1978] *Mol. Gen. Genet.* 163:181-187). The agrobacterium used as host cell is to comprise a plasmid carrying a vir region. The vir region  
10 is necessary for the transfer of the T-DNA into the plant cell. Additional T-DNA may be contained. The bacterium so transformed is used for the transformation of plant cells. Plant explants can advantageously be cultivated with *Agrobacterium tumefaciens* or *Agrobacterium rhizogenes* for the transfer of the DNA into the plant cell. Whole plants can then be regenerated from the infected plant material (for example, pieces of leaf, segments of stalk, roots, but also  
15 protoplasts or suspension-cultivated cells) in a suitable medium, which may contain antibiotics or biocides for selection. The plants so obtained can then be tested for the presence of the inserted DNA. No special demands are made of the plasmids in the case of injection and electroporation. It is possible to use ordinary plasmids, such as, for example, pUC derivatives.

The transformed cells grow inside the plants in the usual manner. They can form germ  
20 cells and transmit the transformed trait(s) to progeny plants. Such plants can be grown in the normal manner and crossed with plants that have the same transformed hereditary factors or other hereditary factors. The resulting hybrid individuals have the corresponding phenotypic properties.

#### Example 11 – Cloning of Novel *B. thuringiensis* Genes Into Insect Viruses

25 A number of viruses are known to infect insects. These viruses include, for example, baculoviruses and entomopoxviruses. In one embodiment of the subject invention, ant-active genes, as described herein, can be placed with the genome of the insect virus, thus enhancing the pathogenicity of the virus. Methods for constructing insect viruses which comprise *B.t.* toxin genes are well known and readily practiced by those skilled in the art. These procedures are described,  
30 for example, in Merryweather *et al.* (Merryweather, A.T., U. Weyer, M.P.G. Harris, M. Hirst, T. Booth, R.D. Possee (1990) *J. Gen. Virol.* 71:1535-1544) and Martens *et al.* (Martens, J.W.M., G. Honee, D. Zuidema, J.W.M. van Lent, B. Visser, J.M. Vlak (1990) *Appl. Environmental Microbiol.* 56(9):2764-2770).

35 It should be understood that the examples and embodiments described herein are for illustrative purposes only and that various modifications or changes in light thereof will be suggested to persons skilled in the art and are to be included within the spirit and purview of this application and the scope of the appended claims.

32 - 1

**BUDAPEST TREATY ON THE INTERNATIONAL  
RECOGNITION OF THE DEPOSIT OF MICROORGANISMS  
FOR THE PURPOSES OF PATENT PROCEDURE**

**INTERNATIONAL FORM**

TO  
Dr. Jewel Payne  
Mycogen Corporation  
5451 Oberlin Drive  
San Diego, CA 92121

RECEIPT IN THE CASE OF AN ORIGINAL DEPOSIT  
issued pursuant to Rule 7.1 by the  
INTERNATIONAL DEPOSITARY AUTHORITY  
identified at the bottom of this page

NAME AND ADDRESS  
OF DEPOSITOR

<b>I. IDENTIFICATION OF THE MICROORGANISM</b>	
Identification reference given by the DEPOSITOR: <u>Bacillus thuringiensis PS86Q3</u>	Accession number given by the INTERNATIONAL DEPOSITARY AUTHORITY: NRRL B-18763
<b>II. SCIENTIFIC DESCRIPTION AND/OR PROPOSED TAXONOMIC DESIGNATION</b>	
The microorganism identified under I above was accompanied by:	
<input type="checkbox"/> a scientific description <input checked="" type="checkbox"/> a proposed taxonomic designation (Mark with a cross where applicable)	
<b>III. RECEIPT AND ACCEPTANCE</b>	
This International Depositary Authority accepts the microorganism identified under I above, which was received by it on Feb.6,1991 (date of the original deposit) <sup>1</sup>	
<b>IV. RECEIPT OF REQUEST FOR CONVERSION</b>	
The microorganism identified under I above was received by this International Depositary Authority on (date of the original deposit) and a request to convert the original deposit to a deposit under the Budapest Treaty was received by it on (date of receipt of request for conversion)	
<b>V. INTERNATIONAL DEPOSITARY AUTHORITY</b>	
Name: Agricultural Research Culture Collection (NRRL) International Depositary Authority Address: 1815 N. University Street Peoria, Illinois 61604 U.S.A.	Signature(s) of person(s) having the power to represent the International Depositary Authority or of authorized official(s): Date: <i>Alfred J. Zane</i> February 13, 1991

<sup>1</sup> Where Rule 6.4(d) applies, such date is the date on which the status of international depositary authority was acquired.

**SUBSTITUTE SHEET**


32-2  
BUDAPEST TREATY AND INTERNATIONAL  
RECOGNITION OF THE DEPOSIT OF MICROORGANISMS  
FOR THE PURPOSES OF PATENT PROCEDURE

## INTERNATIONAL FORM

TO  
Dr. Jewel Payne  
Mycogen Corporation  
5451 Oberlin Drive  
San Diego, CA 92121

RECEIPT IN THE CASE OF AN ORIGINAL DEPOSIT  
issued pursuant to Rule 7.1 by the  
INTERNATIONAL DEPOSITARY AUTHORITY  
identified at the bottom of this page

NAME AND ADDRESS  
OF DEPOSITOR

<b>I. IDENTIFICATION OF THE MICROORGANISM</b>	
Identification reference given by the DEPOSITOR:  <u>Bacillus thuringiensis</u> PS140E2	Accession number given by the INTERNATIONAL DEPOSITARY AUTHORITY:  NRRL B-18812
<b>II. SCIENTIFIC DESCRIPTION AND/OR PROPOSED TAXONOMIC DESIGNATION</b>	
The microorganism identified under I above was accompanied by: <div style="margin-top: 10px;"> <input type="checkbox"/> a scientific description  <input checked="" type="checkbox"/> a proposed taxonomic designation         </div> (Mark with a cross where applicable)	
<b>III. RECEIPT AND ACCEPTANCE</b>	
This International Depositary Authority accepts the microorganism identified under I above, which was received by it on Apr. 23, 1991 (date of the original deposit) <sup>1</sup>	
<b>IV. RECEIPT OF REQUEST FOR CONVERSION</b>	
The microorganism identified under I above was received by this International Depositary Authority on (date of the original deposit) and a request to convert the original deposit to a deposit under the Budapest Treaty was received by it on (date of receipt of request for conversion)	
<b>V. INTERNATIONAL DEPOSITARY AUTHORITY</b>	
Name: Agricultural Research Culture Collection (NRRL) International Depositary Authority Address: 1815 N. University Street Peoria, Illinois 61604 U.S.A.	Signature(s) of person(s) having the power to represent the International Depositary Authority or of authorized official(s): <div style="text-align: center; margin-top: 10px;">  </div> Date: 4-16-91

<sup>1</sup> Where Rule 6.4(d) applies, such date is the date on which the status of international depositary authority was acquired.

**SUBSTITUTE SHEET**

32 - 3

**BUDAPEST TREATY ON THE INTERNATIONAL  
RECOGNITION OF THE DEPOSIT OF MICROORGANISMS  
FOR THE PURPOSES OF PATENT PROCEDURE**

**INTERNATIONAL FORM**

To Dr. Jewel Payne  
Mycogen Corporation  
5451 Oberlin Drive  
San Diego, CA 92121

RECEIPT IN THE CASE OF AN ORIGINAL DEPOSIT  
issued pursuant to Rule 7.1 by the  
INTERNATIONAL DEPOSITARY AUTHORITY  
identified at the bottom of this page

NAME AND ADDRESS  
OF DEPOSITOR

<b>I. IDENTIFICATION OF THE MICROORGANISM</b>	
Identification reference given by the DEPOSITOR: <u>Bacillus thuringiensis</u> PS211B2	Accession number given by the INTERNATIONAL DEPOSITARY AUTHORITY: NRRL B-18921
<b>II. SCIENTIFIC DESCRIPTION AND/OR PROPOSED TAXONOMIC DESIGNATION</b>	
The microorganism identified under I above was accompanied by:	
<input type="checkbox"/> a scientific description <input checked="" type="checkbox"/> a proposed taxonomic designation (Mark with a cross where applicable)	
<b>III. RECEIPT AND ACCEPTANCE</b>	
This International Depositary Authority accepts the microorganism identified under I above, which was received by it on NOV. 15, 1991 (date of the original deposit) <sup>1</sup>	
<b>IV. RECEIPT OF REQUEST FOR CONVERSION</b>	
The microorganism identified under I above was received by this International Depositary Authority on (date of the original deposit) and a request to convert the original deposit to a deposit under the Budapest Treaty was received by it on (date of receipt of request for conversion)	
<b>V. INTERNATIONAL DEPOSITARY AUTHORITY</b>	
Name: Agricultural Research Culture Collection (NRRL) International Depositary Authority Address: 1815 N. University Street Peoria, Illinois 61604 U.S.A.	Signature(s) of person(s) having the power to represent the International Depositary Authority or of authorized official(s): Date: <i>[Signature]</i> 11-25-91

<sup>1</sup> Where Rule 6.4(d) applies, such date is the date on which the status of international depositary authority was acquired.

**SUBSTITUTE SHEET**

32 - 4

BP/A/II/12  
page 14BUDAPEST TREATY ON THE INTERNATIONAL  
RECOGNITION OF THE DEPOSIT OF MICROORGANISMS  
FOR THE PURPOSES OF PATENT PROCEDURE

## INTERNATIONAL FORM

TO  
Dr. Jewel Payne  
Entomology  
Mycogen Corporation  
5457 Oberlin Dr.  
San Diego, CA 92121  
NAME AND ADDRESS  
OF DEPOSITOR

RECEIPT IN THE CASE OF AN ORIGINAL DEPOSIT  
issued pursuant to Rule 7.1 by the  
INTERNATIONAL DEPOSITARY AUTHORITY  
identified at the bottom of this page

I. IDENTIFICATION OF THE MICROORGANISM	
Identification reference given by the DEPOSITOR: <u>Bacillus thuringiensis</u> PS17	Accession number given by the INTERNATIONAL DEPOSITARY AUTHORITY: NRRL B-18243
II. SCIENTIFIC DESCRIPTION AND/OR PROPOSED TAXONOMIC DESIGNATION	
The microorganism identified under I above was accompanied by:	
<input type="checkbox"/> a scientific description	
<input checked="" type="checkbox"/> a proposed taxonomic designation	
(Mark with a cross where applicable)	
III. RECEIPT AND ACCEPTANCE	
This International Depositary Authority accepts the microorganism identified under I above, which was received by it on July 28, 1987 (date of the original deposit) <sup>1</sup>	
IV. INTERNATIONAL DEPOSITARY AUTHORITY	
Name: Agricultural Research Culture Collection (NRRL) International Depositary Authority Address: 1815 N. University Street Peoria, Illinois 61604 U.S.A.	Signature(s) of person(s) having the power to represent the International Depositary Authority or of authorized official(s): Date: <i>Alfred J. Zorn</i> August 10, 1987

<sup>1</sup> Where Rule 6.4(d) applies, such date is the date on which the status of international depositary authority was acquired; where a deposit made outside the Budapest Treaty after the acquisition of the status of international depositary authority is converted into a deposit under the Budapest Treaty, such date is the date on which the microorganism was received by the international depositary authority.

32 - 5

BP/A/II/12  
page 14BUDAPEST TREATY ON THE INTERNATIONAL  
RECOGNITION OF THE DEPOSIT OF MICROORGANISMS  
FOR THE PURPOSES OF PATENT PROCEDURE

## INTERNATIONAL FORM

TO  
Dr. Jewel Payne  
Entomology  
Mycogen Corporation  
5457 Oberlin Dr.  
San Diego, CA 92121  
NAME AND ADDRESS  
OF DEPOSITOR

RECEIPT IN THE CASE OF AN ORIGINAL DEPOSIT  
issued pursuant to Rule 7.1 by the  
INTERNATIONAL DEPOSITARY AUTHORITY  
identified at the bottom of this page

I. IDENTIFICATION OF THE MICROORGANISM	
Identification reference given by the DEPOSITOR: <u>Bacillus thuringiensis</u> PS33F2	Accession number given by the INTERNATIONAL DEPOSITARY AUTHORITY: NRRL B-18244
II. SCIENTIFIC DESCRIPTION AND/OR PROPOSED TAXONOMIC DESIGNATION	
The microorganism identified under I above was accompanied by:  <input type="checkbox"/> a scientific description  <input checked="" type="checkbox"/> a proposed taxonomic designation  (Mark with a cross where applicable)	
III. RECEIPT AND ACCEPTANCE	
This International Depositary Authority accepts the microorganism identified under I above, which was received by it on July 28, 1987 (date of the original deposit): <sup>1</sup>	
IV. INTERNATIONAL DEPOSITARY AUTHORITY	
Name: Agricultural Research Culture Collection (NRRL) International Depositary Authority Address: 1815 N. University Street Peoria, Illinois 61604 U.S.A.	Signature(s) of person(s) having the power to represent the International Depositary Authority or of authorized official(s):  Date: <i>Albert J. Zane</i> August 10, 1987

<sup>1</sup> Where Rule 6.4(d) applies, such date is the date on which the status of international depositary authority was acquired; where a deposit made outside the Budapest Treaty after the acquisition of the status of international depositary authority is converted into a deposit under the Budapest Treaty, such date is the date on which the microorganism was received by the international depositary authority.

32 - 6

BP/A/II/12  
page 14BUDAPEST TREATY ON THE INTERNATIONAL  
RECOGNITION OF THE DEPOSIT OF MICROORGANISMS  
FOR THE PURPOSES OF PATENT PROCEDURE

## INTERNATIONAL FORM

TO  
Dr. Jewel Payne  
Entomology  
Mycogen Corporation  
5457 Oberlin Dr.  
San Diego, CA 92121  
NAME AND ADDRESS  
OF DEPOSITOR

RECEIPT IN THE CASE OF AN ORIGINAL DEPOSIT  
issued pursuant to Rule 7.1 by the  
INTERNATIONAL DEPOSITARY AUTHORITY  
identified at the bottom of this page

I. IDENTIFICATION OF THE MICROORGANISM	
Identification reference given by the DEPOSITOR: - <u>Bacillus thuringiensis</u> PS63B	Accession number given by the INTERNATIONAL DEPOSITARY AUTHORITY: NRRL B-18246
II. SCIENTIFIC DESCRIPTION AND/OR PROPOSED TAXONOMIC DESIGNATION	
The microorganism identified under I above was accompanied by:  <input type="checkbox"/> a scientific description  <input checked="" type="checkbox"/> a proposed taxonomic designation  (Mark with a cross where applicable)	
III. RECEIPT AND ACCEPTANCE	
This International Depositary Authority accepts the microorganism identified under I above, which was received by it on July 28, 1987 (date of the original deposit) <sup>1</sup>	
IV. INTERNATIONAL DEPOSITARY AUTHORITY	
Name: Agricultural Research Culture Collection (NRRL) International Depositary Authority Address: 1815 N. University Street Peoria, Illinois 61604 U.S.A.	Signature(s) of person(s) having the power to represent the International Depositary Authority or of authorized official(s):  Date: <i>Allette J. Zorn</i> <i>August 10, 1987</i>

<sup>1</sup> Where Rule 6.4(d) applies, such date is the date on which the status of international depositary authority was acquired; where a deposit made outside the Budapest Treaty after the acquisition of the status of international depositary authority is converted into a deposit under the Budapest Treaty, such date is the date on which the microorganism was received by the international depositary authority.



32 - 7

BUDAPEST TREATY ON THE INTERNATIONAL  
RECOGNITION OF THE DEPOSIT OF MICROORGANISMS  
FOR THE PURPOSES OF PATENT PROCEDURE

## INTERNATIONAL FORM

TO  
Ms. Lenore Linda R. Nygaard  
Mycogen Corporation  
5451 Oberlin Dr.  
San Diego, CA 92121

RECEIPT IN THE CASE OF AN ORIGINAL DEPOSIT  
issued pursuant to Rule 7.1 by the  
INTERNATIONAL DEPOSITARY AUTHORITY  
identified at the bottom of this page

NAME AND ADDRESS  
OF DEPOSITOR

<b>I. IDENTIFICATION OF THE MICROORGANISM</b>	
Identification reference given by the DEPOSITOR:  <u>Escherichia coli</u> NM522/pMYC2316 MR608	Accession number given by the INTERNATIONAL DEPOSITARY AUTHORITY:  NRRL B-18785
<b>II. SCIENTIFIC DESCRIPTION AND/OR PROPOSED TAXONOMIC DESIGNATION</b>	
The microorganism identified under I above was accompanied by:  <input type="checkbox"/> a scientific description  <input checked="" type="checkbox"/> a proposed taxonomic designation  (Mark with a cross where applicable)	
<b>III. RECEIPT AND ACCEPTANCE</b>	
This International Depositary Authority accepts the microorganism identified under I above, which was received by it on Mar. 15, 1991 (date of the original deposit) <sup>1</sup>	
<b>IV. RECEIPT OF REQUEST FOR CONVERSION</b>	
The microorganism identified under I above was received by this International Depositary Authority on (date of the original deposit) and a request to convert the original deposit to a deposit under the Budapest Treaty was received by it on (date of receipt of request for conversion)	
<b>V. INTERNATIONAL DEPOSITARY AUTHORITY</b>	
Name: Agricultural Research Culture Collection (NRRL) International Depositary Authority Address: 1815 N. University Street Peoria, Illinois 61604 U.S.A.	Signature(s) of person(s) having the power to represent the International Depositary Authority or of authorized official(s): Date: <i>Albert J. Jones</i> March 27, 1991

<sup>1</sup> Where Rule 6.4(d) applies, such date is the date on which the status of international depositary authority was acquired.

SUBSTITUTE SHEET

32 - 8

BUDAPEST TREATY ON THE INTERNATIONAL  
RECOGNITION OF THE DEPOSIT OF MICROORGANISMS  
FOR THE PURPOSES OF PATENT PROTECTION

## INTERNATIONAL FORM

To Ms. Lenore Linda R. Nygaard  
Mycogen Corporation  
5451 Oberlin Dr.  
San Diego, CA 92121

RECEIPT IN THE CASE OF AN ORIGINAL DEPOSIT  
issued pursuant to Rule 7.1 by the  
INTERNATIONAL DEPOSITARY AUTHORITY  
identified at the bottom of this page

NAME AND ADDRESS  
OF DEPOSITOR

I. IDENTIFICATION OF THE MICROORGANISM	
Identification reference given by the DEPOSITOR: <u>Escherichia coli</u> NM522/pMYC 2321 MR607	Accession number given by the INTERNATIONAL DEPOSITARY AUTHORITY: NRRL B-18770
II. SCIENTIFIC DESCRIPTION AND/OR PROPOSED TAXONOMIC DESIGNATION	
The microorganism identified under I above was accompanied by:  <input type="checkbox"/> a scientific description <input checked="" type="checkbox"/> a proposed taxonomic designation  (Mark with a cross where applicable)	
III. RECEIPT AND ACCEPTANCE	
This International Depositary Authority accepts the microorganism identified under I above, which was received by it on Feb.14,1991 (date of the original deposit) <sup>1</sup>	
IV. RECEIPT OF REQUEST FOR CONVERSION	
The microorganism identified under I above was received by this International Depositary Authority on (date of the original deposit) and a request to convert the original deposit to a deposit under the Budapest Treaty was received by it on (date of receipt of request for conversion)	
V. INTERNATIONAL DEPOSITARY AUTHORITY	
Name: Agricultural Research Culture Collection (NRRL) International Depositary Authority Address: 1815 N. University Street Peoria, Illinois 61604 U.S.A.	Signature(s) of person(s) having the power to represent the International Depositary Authority or of authorized official(s): Date: <i>Albert J. Jones</i> February 26, 1991

<sup>1</sup> Where Rule 6.4(d) applies, such date is the date on which the status of international depositary authority was acquired.

SUBSTITUTE SHEET

32 - 9

BUDAPEST TREATY ON THE INTERNATIONAL  
RECOGNITION OF THE DEPOSIT OF MICROORGANISMS  
FOR THE PURPOSES OF PATENT PROCEDURE

## INTERNATIONAL FORM

TO

Ms. Lenore Linda R. Nygaard  
Mycogen Corporation  
5451 Oberlin Dr.  
San Diego, CA 92121NAME AND ADDRESS  
OF DEPOSITORRECEIPT IN THE CASE OF AN ORIGINAL DEPOSIT  
issued pursuant to Rule 7.1 by the  
INTERNATIONAL DEPOSITARY AUTHORITY  
identified at the bottom of this page

<b>I. IDENTIFICATION OF THE MICROORGANISM</b>	
Identification reference given by the DEPOSITOR: <u>Escherichia coli</u> RI522/pMYC2317 MR609	Accession number given by the INTERNATIONAL DEPOSITARY AUTHORITY:  NRRL B-18816
<b>II. SCIENTIFIC DESCRIPTION AND/OR PROPOSED TAXONOMIC DESIGNATION</b>	
The microorganism identified under I above was accompanied by:  <input type="checkbox"/> a scientific description  <input checked="" type="checkbox"/> a proposed taxonomic designation  (Mark with a cross where applicable)	
<b>III. RECEIPT AND ACCEPTANCE</b>	
This International Depositary Authority accepts the microorganism identified under I above, which was received by it on Apr. 24, 1991 (date of the original deposit) <sup>1</sup>	
<b>IV. RECEIPT OF REQUEST FOR CONVERSION</b>	
The microorganism identified under I above was received by this International Depositary Authority on (date of the original deposit) and a request to convert the original deposit to a deposit under the Budapest Treaty was received by it on (date of receipt of request for conversion)	
<b>V. INTERNATIONAL DEPOSITARY AUTHORITY</b>	
Name: Agricultural Research Culture Collection (NRRL) International Depositary Authority Address: 1815 N. University Street Peoria, Illinois 61604 U.S.A.	Signature(s) of person(s) having the power to represent the International Depositary Authority or of authorized official(s):  Date: <i>James S. Searcy</i> 5-10-91

<sup>1</sup> Where Rule 6.4(d) applies, such date is the date on which the status of international depositary  
authority was acquired.

SUBSTITUTE SHEET

32 - 10

BP/A/II/12  
page 14BUDAPEST TREATY ON THE INTERNATIONAL  
RECOGNITION OF THE DEPOSIT OF MICROORGANISMS  
FOR THE PURPOSES OF PATENT PROCEDURE

## INTERNATIONAL FORM

Ms. <sup>TP</sup> Lenore Linda R. Nygaard  
Mycogen Corporation  
5451 Oberlin Dr.  
San Diego, CA 92121

RECEIPT IN THE CASE OF AN ORIGINAL DEPOSIT  
issued pursuant to Rule 7.1 by the  
INTERNATIONAL DEPOSITARY AUTHORITY  
identified at the bottom of this page.

NAME AND ADDRESS  
OF DEPOSITOR

<b>I. IDENTIFICATION OF THE MICROORGANISM</b>	
Identification reference given by the DEPOSITOR: <u>Escherichia coli</u> NM522/pMYC1627 MR398	Accession number given by the INTERNATIONAL DEPOSITARY AUTHORITY: NRRL B-18651
<b>II. SCIENTIFIC DESCRIPTION AND/OR PROPOSED TAXONOMIC DESIGNATION</b>	
The microorganism identified under I above was accompanied by:	
<input type="checkbox"/> a scientific description	
<input checked="" type="checkbox"/> a proposed taxonomic designation	
(Mark with a cross where applicable)	
<b>III. RECEIPT AND ACCEPTANCE</b>	
This International Depositary Authority accepts the microorganism identified under I above, which was received by it on May 11, 1990 (date of the original deposit) <sup>1</sup>	
<b>IV. INTERNATIONAL DEPOSITARY AUTHORITY</b>	
Name: Agricultural Research Culture Collection (NRRL) International Depositary Authority Address: 1815 N. University Street Peoria, Illinois 61604 U.S.A.	Signature(s) of person(s) having the power to represent the International Depositary Authority or of authorized official(s):  Date: <i>Albert J. Bern</i> May 17, 1990

<sup>1</sup> Where Rule 6.4(d) applies, such date is the date on which the status of international depositary authority was acquired; where a deposit made outside the Budapest Treaty after the acquisition of the status of international depositary authority is converted into a deposit under the Budapest Treaty, such date is the date on which the microorganism was received by the international depositary authority.

32 - 11

BP/A/II/12  
page 14BUDAPEST TREATY ON THE INTERNATIONAL  
RECOGNITION OF THE DEPOSIT OF MICROORGANISMS  
FOR THE PURPOSES OF PATENT PROCEDURE

## INTERNATIONAL FORM

TO  
Ms. Lenore Linda R. Nygaard  
Mycogen Corporation  
5451 Oberlin Dr.  
San Diego, CA 92121

RECEIPT IN THE CASE OF AN ORIGINAL DEPOSIT  
issued pursuant to Rule 7.1 by the  
INTERNATIONAL DEPOSITARY AUTHORITY  
identified at the bottom of this page.

NAME AND ADDRESS  
OF DEPOSITOR

<b>I. IDENTIFICATION OF THE MICROORGANISM</b>	
Identification reference given by the DEPOSITOR: <u>Escherichia coli</u> NM522/pMYC1628 MR399	Accession number given by the INTERNATIONAL DEPOSITARY AUTHORITY: NRRL B-18652
<b>II. SCIENTIFIC DESCRIPTION AND/OR PROPOSED TAXONOMIC DESIGNATION</b>	
The microorganism identified under I above was accompanied by:	
<input type="checkbox"/> a scientific description	
<input checked="" type="checkbox"/> a proposed taxonomic designation	
(Mark with a cross where applicable)	
<b>III. RECEIPT AND ACCEPTANCE</b>	
This International Depositary Authority accepts the microorganism identified under I above, which was received by it on May 11, 1990 (date of the original deposit) <sup>1</sup>	
<b>IV. INTERNATIONAL DEPOSITARY AUTHORITY</b>	
Name: Agricultural Research Culture Collection (NRRL) International Depositary Authority Address: 1815 N. University Street Peoria, Illinois 61604 U.S.A.	Signature(s) of person(s) having the power to represent the International Depositary Authority or of authorized official(s):  Date: <i>Ally J. Zimm</i> May 17, 1990

<sup>1</sup> Where Rule 6.4(d) applies, such date is the date on which the status of international depositary authority was acquired; where a deposit made outside the Budapest Treaty after the acquisition of the status of international depositary authority is converted into a deposit under the Budapest Treaty, such date is the date on which the microorganism was received by the international depositary authority.

32 - 12

BUDAPEST TREATY ON THE INTERNATIONAL  
RECOGNITION OF THE DEPOSIT OF MICROORGANISMS  
FOR THE PURPOSES OF PATENT PROCEDURE

## INTERNATIONAL FORM

TO  
Ms. Lenore Linda R. Nygaard  
Mycogen Corporation  
5451 Oberlin Drive  
San Diego, CA 92121

RECEIPT IN THE CASE OF AN ORIGINAL DEPOSIT  
issued pursuant to Rule 7.1 by the  
INTERNATIONAL DEPOSITARY AUTHORITY  
identified at the bottom of this page

NAME AND ADDRESS  
OF DEPOSITOR

I. IDENTIFICATION OF THE MICROORGANISM	
Identification reference given by the DEPOSITOR: <u>Escherichia coli</u> NM 522/pMYC 1642 MR626	Accession number given by the INTERNATIONAL DEPOSITARY AUTHORITY:  NRRL B-18961
II. SCIENTIFIC DESCRIPTION AND/OR PROPOSED TAXONOMIC DESIGNATION	
The microorganism identified under I above was accompanied by:  <input type="checkbox"/> a scientific description <input checked="" type="checkbox"/> a proposed taxonomic designation  (Mark with a cross where applicable)	
III. RECEIPT AND ACCEPTANCE	
This International Depositary Authority accepts the microorganism identified under I above, which was received by it on 4-10-92 (date of the original deposit) <sup>1</sup>	
IV. RECEIPT OF REQUEST FOR CONVERSION	
The microorganism identified under I above was received by this International Depositary Authority on (date of the original deposit) and a request to convert the original deposit to a deposit under the Budapest Treaty was received by it on (date of receipt of request for conversion)	
V. INTERNATIONAL DEPOSITARY AUTHORITY	
Name: Agricultural Research Culture Collection (NRRL) International Depositary Authority Address: 1815 N. University Street Peoria, Illinois 61604 U.S.A.	Signature(s) of person(s) having the power to represent the International Depositary Authority or of authorized official(s):  Date: J. L. Szegedy 4-16-92

<sup>1</sup> Where Rule 6.4(d) applies, such date is the date on which the status of international depositary authority was acquired.

SUBSTITUTE SHEET

## SEQUENCE LISTING

## (1) GENERAL INFORMATION:

- (i) APPLICANT: Payne, Jewel M.  
Kennedy, M. Keith  
Randall, John Brooks  
Meier, Henry  
Uick, Heidi Jane  
Foncerrada, Luis  
Schnepf, Harry E.  
Schwab, George E.
- (ii) TITLE OF INVENTION: Novel *Bacillus thuringiensis* Isolates  
Active Against Hymenopteran Pests and Genes Encoding  
Hymenopteran-Active Toxins
- (iii) NUMBER OF SEQUENCES: 38
- (iv) CORRESPONDENCE ADDRESS:  
(A) ADDRESSEE: David R. Saliwanchik  
(B) STREET: 2421 N.W. 41st Street, Suite A-1  
(C) CITY: Gainesville  
(D) STATE: FL  
(E) COUNTRY: USA  
(F) ZIP: 32606
- (v) COMPUTER READABLE FORM:  
(A) MEDIUM TYPE: Floppy disk  
(B) COMPUTER: IBM PC Compatible  
(C) OPERATING SYSTEM: PC-DOS/MS-DOS  
(D) SOFTWARE: PatentIn Release #1.0, Version #1.25
- (vi) CURRENT APPLICATION DATA:  
(A) APPLICATION NUMBER: US  
(B) FILING DATE:  
(C) CLASSIFICATION:
- (viii) ATTORNEY/AGENT INFORMATION:  
(A) NAME: Saliwanchik, David R.  
(B) REGISTRATION NUMBER: 31,794  
(C) REFERENCE/DOCKET NUMBER: M/SCJ 104
- (ix) TELECOMMUNICATION INFORMATION:  
(A) TELEPHONE: 904-375-8100  
(B) TELEFAX: 904-372-5800

## (2) INFORMATION FOR SEQ ID NO:1:

- (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 4155 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: double  
(D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: DNA (genomic)
- (iii) HYPOTHETICAL: NO
- (iv) ANTI-SENSE: NO
- (v) ORIGINAL SOURCE:  
(A) ORGANISM: *Bacillus thuringiensis*  
(B) STRAIN: PS17  
(C) INDIVIDUAL ISOLATE: PS17a
- (vii) IMMEDIATE SOURCE:  
(B) CLONE: E. coli NM522(pMYC1627) NRRL B-18651
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

ATGGCAATT TAAATGAATT ATATCCATCT GTACCTTATA ATGTATTGGC GTATACGCCA	60
CCCTCTTTT TACCTGATGC GGGTACACAA GCTACACCTG CTGACTTAAC AGCTTATGAA	120
CAATTGTTGA AAAATTTAGA AAAAGGGATA AATGCTGGAA CTTATTTCGAA AGCAATAGCT	180
GATGTACTTA AAGGTATTTT TATAGATGAT ACAATAAATT ATCAAACATA TGTAATATT	240
GGTTTAAAGT TAATTACATT AGCTGTACCG GAAATTGGTA TTTTACACC TTTCATCGGT	300
TTGTTTTTG CTGCATTGAA TAAACATGAT GCTCCACCTC CTCCTAATGC AAAAGATATA	360
TTTGAGGCTA TGAAACCAGC GATTCAAGAG ATGATTGATA GAACTTTAAC TGCGGATGAG	420
CAACATTTT TAAATGGGA AATAAGTGGT TTACAAAATT TAGCAGCAAG ATACCAGTCT	480

SUBSTITUTE SHEET

ACAATGGATG	ATATTCAAAG	CCATGGAGGA	TTTAATAAGG	TAGATTCTGG	ATTAATTAAA	540
AAGTTTACAG	ATGAGGTACT	ATCTTTAAAT	AGTTTTTATA	CAGATCGTTT	ACCTGTATTT	600
ATTACAGATA	ATACAGCGGA	TCGAACCTTG	TTAGGTCTTC	CTTATTATGC	TATACCTGCG	660
AGCATGCATC	TTATGTTATT	AAGAGATATC	ATTACTAAGG	GTCCGACATG	GGATTCTAAA	720
ATTAATTTCA	CACCAGATGC	AATTGATTCC	TTTAAAACCG	ATATTAAAAA	TAATATAAAG	780
CTTTACTCTA	AAACTATTTA	TGACGTATTT	CAGAAGGGAC	TTGCTTCATA	CGGAACGCCT	840
TCTGATTTAG	AGTCCTTTGC	AAAAAAACAA	AAATATATTG	AAATTATGAC	AACACATTGT	900
TTAGATTTTG	CAAGATTGTT	TCCTACTTTT	GATCCAGATC	TTTATCCAAC	AGGATCAGGT	960
GATATAAGTT	TACAAAAAAC	ACGTAGAATT	CTTTCTCCTT	TTATCCCTAT	ACGTACTGCA	1020
GATGGGTTAA	CATTAAATAA	TACTTCAATT	GATACTTCAA	ATTGGCCTAA	TTATGAAAAAT	1080
GGGAATGGCG	CGTTTCCAAA	CCCAAAGAA	AGAATATTAA	AACAATTCAA	ACTGTATCCT	1140
AGTTGGAGAG	CGGGACAGTA	CGGTGGGCTT	TTACRACCTT	ATTTATGGGC	AATAGAAGTC	1200
CAAGATTCTG	TAGAGACTCG	TTTGTATGGG	CAGCTTCCAG	CTGTAGATCC	ACAGGCAGGG	1260
CCTAATTATG	TTTCCATAGA	TTCTTCTAAT	CCAATCATAC	AAATAAATAT	GGATACTTGG	1320
AAAACACCAC	CACAAGGTGC	GAGTGGGTGG	AATACAAATT	TAATGAGAGG	AAGTGTAAGC	1380
GGGTAAAGTT	TTTTACAACG	AGATGGTACG	AGACTTAGTG	CTGGTATGGG	TGGTGGTTTT	1440
GCTGATACAA	TATATAGTCT	CCCTGCAACT	CATTATCTTT	CTTATCTCTA	TGGAACTCCT	1500
TATCAAACTT	CTGATAACTA	TTCTGGTCAC	GTTGGTGCAT	TGGTAGGTGT	GAGTACGCCT	1560
CAAGAGGCTA	CTCTTCCTAA	TATTATAGGT	CAACCAGATG	AACAGGGAAA	TGTATCTACA	1620
ATGGGATTTT	CGTTTGAAAA	AGCTTCTTAT	GGAGGTACAG	TTGTTAAAGA	ATGGTTAAAT	1680
GGTGCGAATG	CGATGAAGCT	TTCTCCTGGG	CAATCTATAG	GTATTCCTAT	TACAAATGTA	1740
ACAAGTGGAG	AATATCAAAAT	TCGTTGTCGT	TATGCAAGTA	ATGATAATAC	TAACGTTTTTC	1800
TTTAATGTAG	ATACTGGTGG	AGCAAATCCA	ATTTTCCAAC	AGATAAACTT	TGCATCTACT	1860
GTAGATAATA	ATACGGGAGT	ACAAGGAGCA	AATGGTGTCT	ATGTAGTCAA	ATCTATTGCT	1920
ACAACTGATA	ATTCTTTTAC	AGAAATTCCT	GCGAAGACGA	TTAATGTTCA	TTTAACCAAC	1980
CAAGGTTCTT	CTGATGTCTT	TTTAGACCGT	ATTGAATTTA	TACCTTTTTTC	TCTACCTCTT	2040
ATATATCATG	GAAGTTATAA	TACTTCATCA	GGTGCAGATG	ATGTTTTATG	GTCTTCTTCA	2100
AATATGAATT	ACTACGATAT	AATAGTAAAT	GGTCAGGCCA	ATAGTAGTAG	TATCGCTAGT	2160
TCTATGCATT	TGCTTAATAA	AGGAAAAGTG	ATAAAAACAA	TTGATATTCC	AGGGCATTTCG	2220
GAAACCTTCT	TTGCTACGTT	CCCAGTTCCA	GAAGGATTTA	ATGAAGTTAG	AATTCTTGCT	2280
GGCCTTCCAG	AAGTTAGTGG	AAATATTACC	GTACAATCTA	ATAATCCGCC	TCAACCTAGT	2340
AATAATGGTG	GTGGTGTATG	TGGTGGTAAT	GGTGGTGGTG	ATGGTGGTCA	ATACAATTTT	2400
TCTTTAAGCG	GATCTGATCA	TACGACTATT	TATCATGGAA	AACCTTGAAAC	TGGGATTTCAT	2460
GTACAAGGTA	ATTATACCTA	TACAGGTACT	CCCGTATTAA	TACTGAATGC	TTACAGAAAT	2520
AATACTGTAG	TATCAAGCAT	TCCAGTATAT	TCTCCTTTTG	ATATAACTAT	ACAGACAGAA	2580
GCTGATAGCC	TTGAGCTTGA	ACTACAACCT	AGATATGGTT	TTGCCACAGT	GAATGGTACT	2640
GCAACAGTAA	AAAGTCCTAA	TGTAAATTAC	GATAGATCAT	TTAAACTCCC	AATAGACTTA	2700
CAAAATATCA	CAACACBAGT	AAATGCATTA	TTGCGATCTG	GAACACAAAA	TATGCTTGCT	2760
CATAATGTAA	GTGATCATGA	TATTGAAGAA	GTTGTATTAA	AAGTGGATGC	CTTATCAGAT	2820
GAAGTATTTG	GAGATGAGAA	GAAGGCTTTA	CGTAAATTGG	TGAATCAAGC	AAAACGTTTG	2880
AGTAGAGCAA	GAAATCTTCT	GATAGGTGGG	AGTTTTGAAA	ATTGGGATGC	ATGGTATATA	2940
GGAAGAAATG	TAGTAACTGT	ATCTGATCAT	GAATATTTTA	AGAGTGATCA	TGTATTATTA	3000
CCACCACCAG	GATTGTCTCC	ATCTTATATT	TTCCAAAAGG	TGGAGGAATC	TAAATTAAAA	3060
CCAAATACAC	GTTATATTGT	TTCTGGATTG	ATCGCACATG	GAAAAGACCT	AGAAATTGTT	3120



```

GTTTCACGTT ATGGGCAAGA AGTGCAAAAG GTCGTGCAAG TTCCTTATGG AGAAGCATTC 3180
CCGTTAACAT CAAATGGACC AGTTTGTGTG CCCCCACGTT CTACAAGTAA TGGAACCTTA 3240
GGAGATCCAC ATTTCTTTAG TTACAGTATC GATGTAGGTG CACTAGATTT ACAAGCAAAC 3300
CCTGGTATTG AATTTGGTCT TCGTATTGTA AATCCAAC TG AATGGCACG CGTAAGCAAT 3360
TTGGAAATTC GTGAAGATCG TCCATTAGCA GCAAATGAAA TACGACAAGT ACAACGTGTC 3420
GCAAGAAATT GGAGAACCGA GTATGAGAAA GAACGTGCCG AAGTAACAAG TTTAATTCAA 3480
CCTGTTATCA ATCGAATCAA CGGATTGTAT GAAATGGAA ATTGGAACGG TTCTATTTCGT 3540
TCAGATATTT CGTATCAGAA TATAGACGCG ATTGTATTAC CAACGTTACC AAAGTTACGC 3600
CATTGGTTTA TGTCAGATAG ATTCAGTGAA CAAGGAGATA TAATGGCTAA ATTCCAAGGT 3660
GCATTAAATC GTGCGTATGC ACAACTGGAA CAAAGTACGC TTCTGCATAA TGGTCATTTT 3720
ACAAAAGATG CAGCTAATTG GACAATAGAA GGCGATGCAC ATCAGATAAC ACTAGAAGAT 3780
GGTAGACGTG TATTGCGACT TCCAGATTGG TCTTCGAGTG TATCTCAAAT GATTGAAATC 3840
GAGAATTTTA ATCCAGATAA AGAATACAAC TTAGTATTCC ATGGGCAAGG AGAAGGAACC 3900
GTTACGTTGG AGCATGGAGA AGAAACAAAA TATATAGAAA CGCATAACACA TCATTTTGCG 3960
AATTTTACAA CTTCTCAACG TCAAGGACTC ACGTTTGAAT CAAATAAAGT GACAGTGACC 4020
ATTTCTTCAG AAGATGGAGA ATTCCTTAGTG GATAATATTG CGCTTGTTGA AGCTCCTCTT 4080
CCTACAGATG ACCAAAATTC TGAGGGAAAT ACGGCTTCCA GTACGAATAG CGATACAAGT 4140
ATGAACAACA ATCAA 4155

```

## (2) INFORMATION FOR SEQ ID NO:2:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 1385 amino acids
  - (B) TYPE: amino acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: protein
- (iii) HYPOTHETICAL: YES
- (iv) ANTI-SENSE: NO
- (vi) ORIGINAL SOURCE:
  - (A) ORGANISM: BACILLUS THURINGIENSIS
  - (B) STRAIN: PS17
  - (C) INDIVIDUAL ISOLATE: PS17a
- (vii) IMMEDIATE SOURCE:
  - (B) CLONE: E. coli NM522(pMYC1627) NRRL B-18651
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:
 

Met	Ala	Ile	Leu	Asn	Glu	Leu	Tyr	Pro	Ser	Val	Pro	Tyr	Asn	Val	Leu
1				5						10				15	
Ala	Tyr	Thr	Pro	Pro	Ser	Phe	Leu	Pro	Asp	Ala	Gly	Thr	Gln	Ala	Thr
			20					25					30		
Pro	Ala	Asp	Leu	Thr	Ala	Tyr	Glu	Gln	Leu	Leu	Lys	Asn	Leu	Glu	Lys
			35				40					45			
Gly	Ile	Asn	Ala	Gly	Thr	Tyr	Ser	Lys	Ala	Ile	Ala	Asp	Val	Leu	Lys
	50					55				60					
Gly	Ile	Phe	Ile	Asp	Asp	Thr	Ile	Asn	Tyr	Gln	Thr	Tyr	Val	Asn	Ile
	65				70					75				80	
Gly	Leu	Ser	Leu	Ile	Thr	Leu	Ala	Val	Pro	Glu	Ile	Gly	Ile	Phe	Thr
			85					90						95	
Pro	Phe	Ile	Gly	Leu	Phe	Phe	Ala	Ala	Leu	Asn	Lys	His	Asp	Ala	Pro
			100				105						110		
Pro	Pro	Pro	Asn	Ala	Lys	Asp	Ile	Phe	Glu	Ala	Met	Lys	Pro	Ala	Ile
			115				120					125			
Gln	Glu	Met	Ile	Asp	Arg	Thr	Leu	Thr	Ala	Asp	Glu	Gln	Thr	Phe	Leu
	130					135					140				

Asn Gly Glu Ile Ser Gly Leu Gln Asn Leu Ala Ala Arg Tyr Gln Ser  
 145 150 155 160  
 Thr Met Asp Asp Ile Gln Ser His Gly Gly Phe Asn Lys Val Asp Ser  
 165 170 175  
 Gly Leu Ile Lys Lys Phe Thr Asp Glu Val Leu Ser Leu Asn Ser Phe  
 180 185 190  
 Tyr Thr Asp Arg Leu Pro Val Phe Ile Thr Asp Asn Thr Ala Asp Arg  
 195 200 205  
 Thr Leu Leu Gly Leu Pro Tyr Tyr Ala Ile Leu Ala Ser Met His Leu  
 210 215 220  
 Met Leu Leu Arg Asp Ile Ile Thr Lys Gly Pro Thr Trp Asp Ser Lys  
 225 230 235 240  
 Ile Asn Phe Thr Pro Asp Ala Ile Asp Ser Phe Lys Thr Asp Ile Lys  
 245 250 255  
 Asn Asn Ile Lys Leu Tyr Ser Lys Thr Ile Tyr Asp Val Phe Gln Lys  
 260 265 270  
 Gly Leu Ala Ser Tyr Gly Thr Pro Ser Asp Leu Glu Ser Phe Ala Lys  
 275 280 285  
 Lys Gln Lys Tyr Ile Glu Ile Met Thr Thr His Cys Leu Asp Phe Ala  
 290 295 300  
 Arg Leu Phe Pro Thr Phe Asp Pro Asp Leu Tyr Pro Thr Gly Ser Gly  
 305 310 315 320  
 Asp Ile Ser Leu Gln Lys Thr Arg Arg Ile Leu Ser Pro Phe Ile Pro  
 325 330 335  
 Ile Arg Thr Ala Asp Gly Leu Thr Leu Asn Asn Thr Ser Ile Asp Thr  
 340 345 350  
 Ser Asn Trp Pro Asn Tyr Glu Asn Gly Ala Phe Pro Asn Pro  
 355 360 365  
 Lys Glu Arg Ile Leu Lys Gln Phe Lys Leu Tyr Pro Ser Trp Arg Ala  
 370 375 380  
 Gly Gln Tyr Gly Gly Leu Leu Gln Pro Tyr Leu Trp Ala Ile Glu Val  
 385 390 395 400  
 Gln Asp Ser Val Glu Thr Arg Leu Tyr Gly Gln Leu Pro Ala Val Asp  
 405 410 415  
 Pro Gln Ala Gly Pro Asn Tyr Val Ser Ile Asp Ser Ser Asn Pro Ile  
 420 425 430  
 Ile Gln Ile Asn Met Asp Thr Trp Lys Thr Pro Pro Gln Gly Ala Ser  
 435 440 445  
 Gly Trp Asn Thr Asn Leu Met Arg Gly Ser Val Ser Gly Leu Ser Phe  
 450 455 460  
 Leu Gln Arg Asp Gly Thr Arg Leu Ser Ala Gly Met Gly Gly Gly Phe  
 465 470 475 480  
 Ala Asp Thr Ile Tyr Ser Leu Pro Ala Thr His Tyr Leu Ser Tyr Leu  
 485 490 495  
 Tyr Gly Thr Pro Tyr Gln Thr Ser Asp Asn Tyr Ser Gly His Val Gly  
 500 505 510  
 Ala Leu Val Gly Val Ser Thr Pro Gln Glu Ala Thr Leu Pro Asn Ile  
 515 520 525  
 Ile Gly Gln Pro Asp Glu Gln Gly Asn Val Ser Thr Met Gly Phe Pro  
 530 535 540  
 Phe Glu Lys Ala Ser Tyr Gly Gly Thr Val Val Lys Glu Trp Leu Asn  
 545 550 555 560  
 Gly Ala Asn Ala Met Lys Leu Ser Pro Gly Gln Ser Ile Gly Ile Pro  
 565 570 575  
 Ile Thr Asn Val Thr Ser Gly Glu Tyr Gln Ile Arg Cys Arg Tyr Ala  
 580 585 590  
 Ser Asn Asp Asn Thr Asn Val Phe Asn Val Asp Thr Gly Gly Ala  
 595 600 605

Asn Pro Ile Phe Gln Gln Ile Asn Phe Ala Ser Thr Val Asp Asn Asn  
 610 615 620 625 630 635 640 645 650 655 660 665 670 675 680 685 690 695 700 705 710 715 720 725 730 735 740 745 750 755 760 765 770 775 780 785 790 795 800 805 810 815 820 825 830 835 840 845 850 855 860 865 870 875 880 885 890 895 900 905 910 915 920 925 930 935 940 945 950 955 960 965 970 975 980 985 990 995 1000 1005 1010 1015 1020 1025 1030 1035 1040 1045 1050 1055 1060 1065 1070

Thr Gly Val Gln Gly Ala Asn Gly Val Tyr Val Val Lys Ser Ile Ala  
 Thr Thr Asp Asn Ser Phe Thr Glu Ile Pro Ala Lys Thr Ile Asn Val  
 His Leu Thr Asn Gln Gly Ser Ser Asp Val Phe Leu Asp Arg Ile Glu  
 Phe Ile Pro Phe Ser Leu Pro Leu Ile Tyr His Gly Ser Tyr Asn Thr  
 Ser Ser Gly Ala Asp Asp Val Leu Trp Ser Ser Ser Asn Met Asn Tyr  
 Tyr Asp Ile Ile Val Asn Gly Gln Ala Asn Ser Ser Ser Ile Ala Ser  
 Ser Met His Leu Asn Lys Gly Lys Val Ile Lys Thr Ile Asp Ile  
 Pro Gly His Ser Glu Thr Phe Phe Ala Thr Phe Pro Val Pro Glu Gly  
 Phe Asn Glu Val Arg Ile Leu Ala Gly Leu Pro Glu Val Ser Gly Asn  
 Ile Thr Val Gln Ser Asn Asn Pro Pro Gln Pro Ser Asn Asn Gly Gly  
 Gly Asp Gly Gly Gly Asn Gly Gly Gly Asp Gly Gly Gln Tyr Asn Phe  
 Ser Leu Ser Gly Ser Asp His Thr Thr Ile Tyr His Gly Lys Leu Glu  
 Thr Gly Ile His Val Gln Gly Asn Tyr Thr Tyr Thr Gly Thr Pro Val  
 Leu Ile Leu Asn Ala Tyr Arg Asn Asn Thr Val Val Ser Ser Ile Pro  
 Val Tyr Ser Pro Phe Asp Ile Thr Ile Gln Thr Glu Ala Asp Ser Leu  
 Glu Leu Glu Leu Gln Pro Arg Tyr Gly Phe Ala Thr Val Asn Gly Thr  
 Ala Thr Val Lys Ser Pro Asn Val Asn Tyr Asp Arg Ser Phe Lys Leu  
 Pro Ile Asp Leu Gln Asn Ile Thr Thr Gln Val Asn Ala Leu Phe Ala  
 Ser Gly Thr Gln Asn Met Leu Ala His Asn Val Ser Asp His Asp Ile  
 Glu Glu Val Val Leu Lys Val Asp Ala Leu Ser Asp Glu Val Phe Gly  
 Asp Glu Lys Lys Ala Leu Arg Lys Leu Val Asn Gln Ala Lys Arg Leu  
 Ser Arg Ala Arg Asn Leu Leu Ile Gly Gly Ser Phe Glu Asn Trp Asp  
 Ala Trp Tyr Lys Gly Arg Asn Val Val Thr Val Ser Asp His Glu Leu  
 Phe Lys Ser Asp His Val Leu Leu Pro Pro Pro Gly Leu Ser Pro Ser  
 Tyr Ile Phe Gln Lys Val Glu Glu Ser Lys Leu Lys Pro Asn Thr Arg  
 Tyr Ile Val Ser Gly Phe Ile Ala His Gly Lys Asp Leu Glu Ile Val  
 Val Ser Arg Tyr Gly Gln Glu Val Gln Lys Val Val Gln Val Pro Tyr  
 Gly Glu Ala Phe Pro Leu Thr Ser Asn Gly Pro Val Cys Cys Pro Pro

38

Arg Ser Thr Ser Asn Gly Thr Leu Gly Asp Pro His Phe Phe Ser Tyr  
 1075 1080 1085  
 Ser Ile Asp Val Gly Ala Leu Asp Leu Gln Ala Asn Pro Gly Ile Glu  
 1090 1095 1100  
 Phe Gly Leu Arg Ile Val Asn Pro Thr Gly Met Ala Arg Val Ser Asn  
 1105 1110 1115 1120  
 Leu Glu Ile Arg Glu Asp Arg Pro Leu Ala Ala Asn Glu Ile Arg Gln  
 1125 1130 1135  
 Val Gln Arg Val Ala Arg Asn Trp Arg Thr Glu Tyr Glu Lys Glu Arg  
 1140 1145 1150  
 Ala Glu Val Thr Ser Leu Ile Gln Pro Val Ile Asn Arg Ile Asn Gly  
 1155 1160 1165  
 Leu Tyr Glu Asn Gly Asn Trp Asn Gly Ser Ile Arg Ser Asp Ile Ser  
 1170 1175 1180  
 Tyr Gln Asn Ile Asp Ala Ile Val Leu Pro Thr Leu Pro Lys Leu Arg  
 1185 1190 1195 1200  
 His Trp Phe Met Ser Asp Arg Phe Ser Glu Gln Gly Asp Ile Met Ala  
 1205 1210 1215  
 Lys Phe Gln Gly Ala Leu Asn Arg Ala Tyr Ala Gln Leu Glu Gln Ser  
 1220 1225 1230  
 Thr Leu Leu His Asn Gly His Phe Thr Lys Asp Ala Ala Asn Trp Thr  
 1235 1240 1245  
 Ile Glu Gly Asp Ala His Gln Ile Thr Leu Glu Asp Gly Arg Arg Val  
 1250 1255 1260  
 Leu Arg Leu Pro Asp Trp Ser Ser Ser Val Ser Gln Met Ile Glu Ile  
 1265 1270 1275 1280  
 Glu Asn Phe Asn Pro Asp Lys Glu Tyr Asn Leu Val Phe His Gly Gln  
 1285 1290 1295  
 Gly Glu Gly Thr Val Thr Leu Glu His Gly Glu Glu Thr Lys Tyr Ile  
 1300 1305 1310  
 Glu Thr His Thr His His Phe Ala Asn Phe Thr Thr Ser Gln Arg Gln  
 1315 1320 1325  
 Gly Leu Thr Phe Glu Ser Asn Lys Val Thr Val Thr Ile Ser Ser Glu  
 1330 1335 1340  
 Asp Gly Glu Phe Leu Val Asp Asn Ile Ala Leu Val Glu Ala Pro Leu  
 1345 1350 1355 1360  
 Pro Thr Asp Asp Gln Asn Ser Glu Gly Asn Thr Ala Ser Ser Thr Asn  
 1365 1370 1375  
 Ser Asp Thr Ser Met Asn Asn Asn Gln  
 1380 1385

## (2) INFORMATION FOR SEQ ID NO:3:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 3867 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: double
  - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: DNA (genomic)
- (iii) HYPOTHETICAL: NO
- (iv) ANTI-SENSE: NO
- (vi) ORIGINAL SOURCE:
  - (A) ORGANISM: *Bacillus thuringiensis*
  - (B) STRAIN: PS17
  - (C) INDIVIDUAL ISOLATE: PS17b
- (vii) IMMEDIATE SOURCE:
  - (B) CLONE: E. coli NM522(pMYC1628) NRRL B-18652
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

ATGGCAATTT TAAATGAATT ATATCCATCT GTACCTTATA ATGTATTGGC GTATACGCCA

60

CCCTCTTTTT	TACCTGATGC	GGGTACACAA	GCTACACCTG	CTGACTTAAC	AGCTTATGAA	120
CARTTGTTGA	AAAATTTAGA	AAAAGGGATA	AATGCTGGAA	CTTATTCGAA	AGCAATAGCT	180
GATGTACTTA	AAGGTATTTT	TATAGATGAT	ACAATAAATT	ATCAAACATA	TGTAAATATT	240
GGTTTAAGTT	TAATTACATT	AGCTGTACCG	GAAATTGGTA	TTTTTACACC	TTTCATCGGT	300
TTGTTTTTTG	CTGCATTGAA	TAAACATGAT	GCTCCACCTC	CTCCTAATGC	AAAAGATATA	360
TTTGAGGCTA	TGAAACCAGC	GATTCAAGAG	ATGATTGATA	GAACTTTAAC	TGCGGATGAG	420
CAAAACATTTT	TAAATGGGGA	AATAAGTGGT	TTACAAAATT	TAGCAGCAAG	ATACCAGTCT	480
ACAATGGATG	ATATTCAAAG	CCATGGAGGA	TTTAATAAGG	TAGATTCTGG	ATTAATTAAA	540
AAGTTTACAG	ATGAGGTACT	ATCTTTAAAT	AGTTTTTATA	CAGATCGTTT	ACCTGTATTT	600
ATTACAGATA	ATACAGCGGA	TCGAACTTTG	TTAGGTCTTC	CTTATTATGC	TATACTTGCG	660
AGCATGCATC	TTATGTTATT	AAGAGATATC	ATTACTAAGG	GTCCGACATG	GGATTCTAAA	720
ATTAATTTCA	CACCAGATGC	AATTGATTCC	TTTAAAACCG	ATATTAAAAA	TAATATAAAG	780
CTTTACTCTA	AAACTATTTA	TGACGTATTT	CAGAAGGGAC	TTGCTTCATA	CGGAACGCCT	840
TCTGATTTAG	AGTCCTTTGC	AAAAAAACAA	AAATATATTG	AAATTATGAC	AACACATTGT	900
TTAGATTTTG	CAAGATTGTT	TCCTACTTTT	GATCCAGATC	TTTATCCAAC	AGGATCAGGT	960
GATATAAGTT	TACAAAAAAC	ACGTAGAATT	CTTTCTCCTT	TTATCCCTAT	ACGTACTGCA	1020
GATGGGTAA	CATTAAATAA	TACTTCAATT	GATACTTCAA	ATTGGCCTAA	TTATGAAAAT	1080
GGGAATGGCG	CGTTTCCAAA	CCCAAAAGAA	AGAATATTAA	AACAATTCAA	ACTGTATCCT	1140
AGTTGGAGAG	CGGCACAGTA	CGGTGGGCTT	TTACAACCTT	ATTTATGGGC	AATAGAAGTC	1200
CAAGATTCTG	TAGAGACTCG	TTTGTATGGG	CAGCTTCCAG	CTGTAGATCC	ACAGGCAGGG	1260
CCTAATTATG	TTTCCATAGA	TTCTTCTAAT	CCAATCATAC	AAATAAATAT	GGATACTTGG	1320
AAAACACCAC	CACAAGGTGC	GAGTGGGTGG	AATACAAATT	TAATGAGAGG	AAGTGTAAGC	1380
GGGTTAAGTT	TTTTACAACG	AGATGGTACG	AGACTTAGTG	CTGGTATGGG	TGGTGGTTTT	1440
GCTGATACAA	TATATAGTCT	CCCTGCAACT	CATTATCTTT	CTTATCTCTA	TGGAACCTCT	1500
TATCAAACCTT	CTGATAACTA	TTCTGGTCAC	GTTGGTGCAT	TGGTAGGTGT	GAGTACGCCCT	1560
CAAGAGGCTA	CTCTTCCTAA	TATTATAGGT	CAACCAGATG	AACAGGGAAA	TGTATCTACA	1620
ATGGGATTTT	CGTTTGAAAA	AGCTTCTTAT	GGAGGTACAG	TTGTTAAAGA	ATGGTTAAAT	1680
GGTGCGAATG	CGATGAAGCT	TTCTCCTGGG	CAATCTATAG	GTATTCCTAT	TACAAATGTA	1740
ACAAGTGGAG	AATATCAAAT	TCGTTGTCGT	TATGCAAGTA	ATGATAATAC	TAACGTTTTTC	1800
TTTAATGTAG	ATACTGGTGG	AGCAAATCCA	ATTTTCCAAC	AGATAAACTT	TGCATCTACT	1860
GTAGATAATA	ATACGGGAGT	ACAAGGAGCA	AATGGTGTCT	ATGTAGTCAA	ATCTATTGCT	1920
ACAACCTGATA	ATTCTTTTAC	AGTAAAAATT	CCTGCGAAGA	CGATTAAATGT	TCATTTAACC	1980
AACCAAGGTT	CTTCTGATGT	CTTTTLAGAT	CGTATTGAGT	TTGTTCCAAT	TCTAGAATCA	2040
AATACTGTAA	CTATATTCAA	CAATTCATAT	ACTACAGGTT	CAGCAAATCT	TATACCAGCA	2100
ATAGCTCCTC	TTTGGAGTAC	TAGTTCAGAT	AAAGCCCTTA	CAGGTCTCTAT	GTCAATAACA	2160
GGTCGAACTA	CCCCTAACAG	TGATGATGCT	TTGCTTCGAT	TTTTTAAAC	TAATTATGAT	2220
ACACAAACCA	TTCCTATTCC	GGGTTCGGGA	AAAGATTTTA	CAAATACTCT	AGAAATACAA	2280
GACATAGTTT	CTATTGATAT	TTTTGTGCGA	TCTGGTCTAC	ATGGATCCGA	TGGATCTATA	2340
AAATTAGATT	TTACCAATAA	TAATAGTGGT	AGTGGTGGCT	CTCCAAAGAG	TTTCACCGAG	2400
CAAAATGATT	TAGAGAATAT	CACAACACAA	GTGAATGCTC	TATTCACATC	TAATACACAA	2460
GATGCACTTG	CAACAGATGT	GAGTGATCAT	GATATTGAAG	AAGTGGTTCT	AAAAGTAGAT	2520
GCATTATCTG	ATGAAGTGTT	TGGAAAAGAG	AAAAAACAT	TGCGTAAATT	TGTAAATCAA	2580
GCGAAGCGCT	TAAGCAAGGC	GCGTAATCTC	CTGGTAGGAG	GCAATTTTGA	TAACCTGGAT	2640
GCTTGGTATA	GAGGAAGAAA	TGTAGTAAAC	GTATCTAATC	ACGAACGTGT	GAAGAGTGAT	2700

CATGTATTAT TACCACCACC AGGATTGTCT CCATCTTATA TTTTCCAAA AGTGGAGGAA	2760
TCTAAATTAA AACGAAATAC ACGTTATACG GTTCTCTGGAT TTATTGCGCA TGCAACAGAT	2820
TTAGAAATTG TGGTTTCTCG TTATGGGCAA GAAATAAAGA AAGTGGTGCA AGTTCCTTAT	2880
GGAGAAGCAT TCCCATTAAAC ATCAAGTGGG CCAGTTTGTT GTATCCCACA TTCTACAAGT	2940
AATGGAACCT TAGGCAATCC ACATTTCTTT AGTTACAGTA TTGATGTAGG TGCATTAGAT	3000
GTAGACACAA ACCCTGGTAT TGAATTCGGT CTTCTGATTG TAAATCCAAC TGGAAATGGCA	3060
CGCGTAAGCA ATTTGGAAAT TCGTGAAGAT CGTCCATTAG CAGCAAATGA AATACGACAA	3120
GTACAACGTG TCGCAAGAAA TTGGAGAACC GAGTATGAGA AAGAACGTGC GGAAGTAACA	3180
AGTTTAATTC AACCTGTTAT CAATCGAATC AATGGATTGT ATGACAATGG AAATTGGAAC	3240
GGTTCCTATTC GTTCAGATAT TTCGTATCAG AATATAGACG CGATTGTATT ACCAACGTTA	3300
CCAAAGTTAC GCCATTGGTT TATGTCAGAT AGATTTAGTG AACAAAGGAGA TATCATGGCT	3360
AAATTCCAAG GTGCATTAAA TCGTGCGTAT GCACAACCTGG AACAAAATAC GCTTCTGCAT	3420
AATGGTCATT TTACAAAAGA TGCAGCCAAT TGGACGGTAG AAGGCGATGC ACATCAGGTA	3480
GTATTAGAAG ATGGTAAACG TGTATTACGA TTGCCAGATT GGTCTTCGAG TGTGTCTCAA	3540
ACGATTGAAA TCGAGAATTT TGATCCAGAT AAAGAATATC AATTAGTATT TCATGGGCAA	3600
GGAGAAGGAA CGGTTACGTT GGAGCATGGA GAAGAAACAA AATATATAGA AACGCATACA	3660
CATCATTTTG CGAATTTTAC AACTTCTCAA CGTCAAGGAC TCACGTTTGA ATCAAATAAA	3720
GTGACAGTGA CCATTCTTTC AGAAGATGGA GAATTCTTAG TGGATAATAT TCGCCTTGTG	3780
GAAGCTCCTC TTCCTACAGA TGACCAAAAT TCTGAGGGAA ATACGGCTTC CAGTACGAAT	3840
AGCGATACAA GTATGAACAA CAATCAA	3867

## (2) INFORMATION FOR SEQ ID NO:4:

- (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 1289 amino acids  
 (B) TYPE: amino acid  
 (C) STRANDEDNESS: single  
 (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: protein
- (iii) HYPOTHETICAL: YES
- (iv) ANTI-SENSE: NO
- (vi) ORIGINAL SOURCE:  
 (A) ORGANISM: BACILLUS THURINGIENSIS  
 (B) STRAIN: PS17  
 (C) INDIVIDUAL ISOLATE: PS17b
- (vii) IMMEDIATE SOURCE:  
 (B) CLONE: E. coli NM522(pMYC1628) NRRL B-18652
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:
- |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Met | Ala | Ile | Leu | Asn | Glu | Leu | Tyr | Pro | Ser | Val | Pro | Tyr | Asn | Val | Leu |
| 1   |     |     |     | 5   |     |     |     |     | 10  |     |     |     | 15  |     |     |
| Ala | Tyr | Thr | Pro | Pro | Ser | Phe | Leu | Pro | Asp | Ala | Gly | Thr | Gln | Ala | Thr |
|     |     |     | 20  |     |     |     |     | 25  |     |     |     |     | 30  |     |     |
| Pro | Ala | Asp | Leu | Thr | Ala | Tyr | Glu | Gln | Leu | Leu | Lys | Asn | Leu | Glu | Lys |
|     |     | 35  |     |     |     | 40  |     |     |     |     | 45  |     |     |     |     |
| Gly | Ile | Asn | Ala | Gly | Thr | Tyr | Ser | Lys | Ala | Ile | Ala | Asp | Val | Leu | Lys |
| 50  |     |     |     | 55  |     |     |     |     | 60  |     |     |     |     |     |     |
| Gly | Ile | Phe | Ile | Asp | Asp | Thr | Ile | Asn | Tyr | Gln | Thr | Tyr | Val | Asn | Ile |
| 65  |     |     |     | 70  |     |     |     | 75  |     |     |     |     |     | 80  |     |
| Gly | Leu | Ser | Leu | Ile | Thr | Leu | Ala | Val | Pro | Glu | Ile | Gly | Ile | Phe | Thr |
|     |     |     | 85  |     |     |     |     | 90  |     |     |     |     | 95  |     |     |
| Pro | Phe | Ile | Gly | Leu | Phe | Phe | Ala | Ala | Leu | Asn | Lys | His | Asp | Ala | Pro |
|     |     |     | 100 |     |     |     | 105 |     |     |     |     |     | 110 |     |     |
| Pro | Pro | Pro | Asn | Ala | Lys | Asp | Ile | Phe | Glu | Ala | Met | Lys | Pro | Ala | Ile |
|     |     |     | 115 |     |     |     | 120 |     |     |     |     | 125 |     |     |     |

Gln Glu Met Ile Asp Arg Thr Leu Thr Ala Asp Glu Gln Thr Phe Leu  
 130 135 140  
 Asn Gly Glu Ile Ser Gly Leu Gln Asn Leu Ala Ala Arg Tyr Gln Ser  
 145 150 155  
 Thr Met Asp Asp Ile Gln Ser His Gly Gly Phe Asn Lys Val Asp Ser  
 165 170 175  
 Gly Leu Ile Lys Lys Phe Thr Asp Glu Val Leu Ser Leu Asn Ser Phe  
 180 185 190  
 Tyr Thr Asp Arg Leu Pro Val Phe Ile Thr Asp Asn Thr Ala Asp Arg  
 195 200 205  
 Thr Leu Leu Gly Leu Pro Tyr Tyr Ala Ile Leu Ala Ser Met His Leu  
 210 215 220  
 Met Leu Leu Arg Asp Ile Ile Thr Lys Gly Pro Thr Trp Asp Ser Lys  
 225 230 235 240  
 Ile Asn Phe Thr Pro Asp Ala Ile Asp Ser Phe Lys Thr Asp Ile Lys  
 245 250 255  
 Asn Asn Ile Lys Leu Tyr Ser Lys Thr Ile Tyr Asp Val Phe Gln Lys  
 260 265 270  
 Gly Leu Ala Ser Tyr Gly Thr Pro Ser Asp Leu Glu Ser Phe Ala Lys  
 275 280 285  
 Lys Gln Lys Tyr Ile Glu Ile Met Thr Thr His Cys Leu Asp Phe Ala  
 290 295 300  
 Arg Leu Phe Pro Thr Phe Asp Pro Asp Leu Tyr Pro Thr Gly Ser Gly  
 305 310 315 320  
 Asp Ile Ser Leu Gln Lys Thr Arg Arg Ile Leu Ser Pro Phe Ile Pro  
 325 330 335  
 Ile Arg Thr Ala Asp Gly Leu Thr Leu Asn Asn Thr Ser Ile Asp Thr  
 340 345 350  
 Ser Asn Trp Pro Asn Tyr Glu Asn Gly Asn Gly Ala Phe Pro Asn Pro  
 355 360 365  
 Lys Glu Arg Ile Leu Lys Gln Phe Lys Leu Tyr Pro Ser Trp Arg Ala  
 370 375 380  
 Ala Gln Tyr Gly Gly Leu Leu Gln Pro Tyr Leu Trp Ala Ile Glu Val  
 385 390 395 400  
 Gln Asp Ser Val Glu Thr Arg Leu Tyr Gly Gln Leu Pro Ala Val Asp  
 405 410 415  
 Pro Gln Ala Gly Pro Asn Tyr Val Ser Ile Asp Ser Ser Asn Pro Ile  
 420 425 430  
 Ile Gln Ile Asn Met Asp Thr Trp Lys Thr Pro Pro Gln Gly Ala Ser  
 435 440 445  
 Gly Trp Asn Thr Asn Leu Met Arg Gly Ser Val Ser Gly Leu Ser Phe  
 450 455 460  
 Leu Gln Arg Asp Gly Thr Arg Leu Ser Ala Gly Met Gly Gly Gly Phe  
 465 470 475 480  
 Ala Asp Thr Ile Tyr Ser Leu Pro Ala Thr His Tyr Leu Ser Tyr Leu  
 485 490 495  
 Tyr Gly Thr Pro Tyr Gln Thr Ser Asp Asn Tyr Ser Gly His Val Gly  
 500 505 510  
 Ala Leu Val Gly Val Ser Thr Pro Gln Glu Ala Thr Leu Pro Asn Ile  
 515 520 525  
 Ile Gly Gln Pro Asp Glu Gln Gly Asn Val Ser Thr Met Gly Phe Pro  
 530 535 540  
 Phe Glu Lys Ala Ser Tyr Gly Gly Thr Val Val Lys Glu Trp Leu Asn  
 545 550 555 560  
 Gly Ala Asn Ala Met Lys Leu Ser Pro Gly Gln Ser Ile Gly Ile Pro  
 565 570 575  
 Ile Thr Asn Val Thr Ser Gly Glu Tyr Gln Ile Arg Cys Arg Tyr Ala  
 580 585 590

Ser Asn Asp 595 Asn Thr Asn Val Phe 600 Phe Asn Val Asp 605 Thr Gly Gly Ala  
 Asn Pro 610 Ile Phe Gln Gln Ile 615 Asn Phe Ala Ser Thr 620 Val Asp Asn Asn  
 Thr Gly Val Gln Gly Ala 630 Asn Gly Val Tyr Val 635 Val Lys Ser Ile Ala 640  
 Thr Thr Asp Asn Ser 645 Phe Thr Val Lys Ile 650 Pro Ala Lys Thr Ile 655 Asn  
 Val His Leu Thr 660 Asn Gln Gly Ser Ser 665 Asp Val Phe Leu Asp 670 Arg Ile  
 Glu Phe Val 675 Pro Ile Leu Glu Ser 680 Asn Thr Val Thr Ile 685 Phe Asn Asn  
 Ser Tyr 690 Thr Thr Gly Ser Ala 695 Asn Leu Ile Pro Ala 700 Ile Ala Pro Leu  
 Trp 705 Ser Thr Ser Ser Asp 710 Lys Ala Leu Thr Gly 715 Ser Met Ser Ile Thr 720  
 Gly Arg Thr Thr Pro 725 Asn Ser Asp Asp Ala 730 Leu Leu Arg Phe Phe 735 Lys  
 Thr Asn Tyr Asp 740 Thr Gln Thr Ile Pro 745 Ile Pro Gly Ser Gly 750 Lys Asp  
 Phe Thr Asn 755 Thr Leu Glu Ile Gln 760 Asp Ile Val Ser Ile 765 Asp Ile Phe  
 Val Gly 770 Ser Gly Leu His Gly 775 Ser Asp Gly Ser Ile 780 Lys Leu Asp Phe  
 Thr 785 Asn Asn Asn Ser Gly 790 Ser Gly Gly Ser Pro 795 Lys Ser Phe Thr Glu 800  
 Gln Asn Asp Leu Glu 805 Asn Ile Thr Thr Gln Val Asn Ala Leu Phe Thr 815  
 Ser Asn Thr Gln 820 Asp Ala Leu Ala Thr 825 Asp Val Ser Asp His 830 Asp Ile  
 Glu Glu Val 835 Val Leu Lys Val Asp 840 Ala Leu Ser Asp Glu 845 Val Phe Gly  
 Lys Glu 850 Lys Lys Thr Leu Arg 855 Lys Phe Val Asn Gln 860 Ala Lys Arg Leu  
 Ser 865 Lys Ala Arg Asn Leu 870 Leu Val Gly Gly Asn 875 Phe Asp Asn Leu Asp 880  
 Ala Trp Tyr Arg Gly 885 Arg Asn Val Val Asn Val Ser Asn His Glu 895 Leu  
 Leu Lys Ser Asp 900 His Val Leu Leu Pro 905 Pro Pro Gly Leu Ser 910 Pro Ser  
 Tyr Ile Phe 915 Gln Lys Val Glu Glu 920 Ser Lys Leu Lys Arg 925 Asn Thr Arg  
 Tyr Thr 930 Val Ser Gly Phe Ile 935 Ala His Ala Thr Asp 940 Leu Glu Ile Val  
 Val Ser Arg Tyr Gly Gln 950 Glu Ile Lys Lys Val 955 Val Gln Val Pro Tyr 960  
 Gly Glu Ala Phe Pro 965 Leu Thr Ser Ser Gly 970 Pro Val Cys Cys Ile 975 Pro  
 His Ser Thr Ser 980 Asn Gly Thr Leu Gly 985 Asn Pro His Phe Phe 990 Ser Tyr  
 Ser Ile Asp 995 Val Gly Ala Leu Asp 1000 Val Asp Thr Asn Pro Gly 1005 Ile Glu  
 Phe Gly Leu Arg Ile Val Asn Pro Thr Gly Met Ala Arg Val Ser Asn 1020  
 Leu Glu Ile Arg Glu Asp Arg Pro Leu Ala 1035 Ala Asn Glu Ile Arg Gln 1040  
 Val Gln Arg Val Ala 1045 Arg Asn Trp Arg Thr Glu Tyr Glu Lys Glu Arg 1055



Ala Glu Val Thr Ser Leu Ile Gln Pro Val Ile Asn Arg Ile Asn Gly  
 1060 1065 1070  
 Leu Tyr Asp Asn Gly Asn Trp Asn Gly Ser Ile Arg Ser Asp Ile Ser  
 1075 1080 1085  
 Tyr Gln Asn Ile Asp Ala Ile Val Leu Pro Thr Leu Pro Lys Leu Arg  
 1090 1095 1100  
 His Trp Phe Met Ser Asp Arg Phe Ser Glu Gln Gly Asp Ile Met Ala  
 1105 1110 1115 1120  
 Lys Phe Gln Gly Ala Leu Asn Arg Ala Tyr Ala Gln Leu Glu Gln Asn  
 1125 1130 1135  
 Thr Leu Leu His Asn Gly His Phe Thr Lys Asp Ala Ala Asn Trp Thr  
 1140 1145 1150  
 Val Glu Gly Asp Ala His Gln Val Val Leu Glu Asp Gly Lys Arg Val  
 1155 1160 1165  
 Leu Arg Leu Pro Asp Trp Ser Ser Ser Val Ser Gln Thr Ile Glu Ile  
 1170 1175 1180  
 Glu Asn Phe Asp Pro Asp Lys Glu Tyr Gln Leu Val Phe His Gly Gln  
 1185 1190 1195 1200  
 Gly Glu Gly Thr Val Thr Leu Glu His Gly Glu Glu Thr Lys Tyr Ile  
 1205 1210 1215  
 Glu Thr His Thr His His Phe Ala Asn Phe Thr Thr Ser Gln Arg Gln  
 1220 1225 1230  
 Gly Leu Thr Phe Glu Ser Asn Lys Val Thr Val Thr Ile Ser Ser Glu  
 1235 1240 1245  
 Asp Gly Glu Phe Leu Val Asp Asn Ile Ala Leu Val Glu Ala Pro Leu  
 1250 1255 1260  
 Pro Thr Asp Asp Gln Asn Ser Glu Gly Asn Thr Ala Ser Ser Thr Asn  
 1265 1270 1275 1280  
 Ser Asp Thr Ser Met Asn Asn Asn Gln  
 1285

## (2) INFORMATION FOR SEQ ID NO:5:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 3771 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: double
  - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: DNA (genomic)
- (iii) HYPOTHETICAL: NO
- (iv) ANTI-SENSE: NO
- (vi) ORIGINAL SOURCE:
  - (A) ORGANISM: *Bacillus thuringiensis*
  - (C) INDIVIDUAL ISOLATE: 33F2
- (vii) IMMEDIATE SOURCE:
  - (B) CLONE: *E. coli* NM522(pMYC2316) B-18785
- (ix) FEATURE:
  - (A) NAME/KEY: misc feature
  - (B) LOCATION: 4..24
  - (D) OTHER INFORMATION: /function= "oligonucleotide hybridization probe"  
 /product= "GCA/T ACA/T TTA AAT GAA GTA/T TAT"  
 /standard name= "probe a"  
 /note= "Probe A"
- (ix) FEATURE:
  - (A) NAME/KEY: misc feature
  - (B) LOCATION: 13..33
  - (D) OTHER INFORMATION: /function= "oligonucleotide hybridization probe"  
 /product= "AAT GAA GTA/T TAT CCA/T GTA/T AAT"  
 /standard name= "Probe B"  
 /label= probe-b  
 /note= "probe b"
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

ATGGCTACAC	TTAATGAAGT	ATATCCTGTG	AATTATAATG	TATTATCTTC	TGATGCTTTT	60
CAACAATTAG	ATACAACAGG	TTTTAAAAAGT	AAATATGATG	AAATGATAAA	AGCATTGCGA	120
AAAAAATGGA	AAAAAGGGGC	AAAAGGAAAA	GACCTTTTAG	ATGTTGCATG	GACTTATATA	180
ACTACAGGAG	AAATTGACCC	TTTAAATGTA	ATTAAAGGTG	TTTATCTGTATTAACTTTA		240
ATTCCTGAAG	TTGGTACTGT	GGCCTCTGCA	GCAAGTACTA	TTGTAAGTTT	TATTTGGCCT	300
AAAAATTTTG	GAGATAAACC	AAATGC AAAA	AATATATTTG	AAGAGCTCAA	GCCTCAAATT	360
GAAGCATTAA	TTCAACAAGA	TATAACAAAC	TATCAAGATG	CAATTAATCA	AAAAAAATTT	420
GACAGTCTTC	AGAAAACAAT	TAATCTATAT	ACAGTAGCTA	TAGATAACAA	TGATTACGTA	480
ACAGCAAAAA	CGCAACTCGA	AAATCTAAAT	TCTATACTTA	CCTCAGATAT	CTCCATATTT	540
ATTCCAGAAG	GATATGAAAC	TGGAGGTTTA	CCTTATTATG	CTATGGTTGC	TAATGCTCAT	600
ATATTATTGT	TAAGAGACGC	TATAGTTAAT	GCAAGAAAT	TAGGCTTTAG	TGATAAAGAA	660
GTAGACACAC	ATAAAAAATA	TATCAAAATG	ACAATACACA	ATCATACTGA	AGCAGTAATA	720
AAAGCATTCT	TAAATGGACT	TGACAAATTT	AAGAGTTTAG	ATGTAAATAG	CTATAATAAA	780
AAAGCAAATT	ATATTAAAGG	TATGACAGAA	ATGGTTCTTG	ATCTAGTTGC	TCTATGGCCA	840
ACTTTCGATC	CAGATCATT	TCAAAAAGAA	GAGAAATTG	AATTTACAAG	AACTATTTCT	900
TCTCCAATTT	ACCAACCTGT	ACCTAAAAAC	ATGCAAAATA	CCTCTAGCTC	TATTGTACCT	960
AGCGATCTAT	TTCACTATCA	AGGAGATCTT	GTA AAATTAG	AATTTTCTAC	AAGAACGGAC	1020
AACGATGGTC	TTGCAAAAAT	TTTTACTGGT	ATTCGAAACA	CATTCTACAA	ATCGCCTAAT	1080
ACTCATGAAA	CATACCATGT	AGATTTTAGT	TATAATACCC	AATCTAGTGG	TAATATTTCA	1140
AGAGGCTCTT	CAAATCCGAT	TCCAATTGAT	CTTAATAATC	CCATTATTTT	AACTTGTATT	1200
AGAAATTCAT	TTTATAAGGC	AATAGCGGGA	TCTTCTGTTT	TAGTTAATTT	TAAAGATGGC	1260
ACTCAAGGGT	ATGCATTTGC	CCAAGCACCA	ACAGGAGGTG	CCTGGGACCA	TTCTTTTATT	1320
GAATCTGATG	GTGCCCCAGA	AGGGCATAAA	TTAAACTATA	TTTATACTTC	TCCAGGTGAT	1380
ACATTAAGAG	ATTTCAATCA	TGTATATACT	CTTATAAGTA	CTCCAATAT	AAATGAACATA	1440
TCAACAGAAA	AAATCAAAGG	CTTTCCTGCG	GAAAAAGGAT	ATATCAAAAA	TCAAGGGATC	1500
ATGAAATATT	ACGGTAAACC	AGAATATATT	AATGGAGCTC	AACCAGTTAA	TCTGGAAAAC	1560
CAGCAACAT	TAATATTCGA	ATTTCAATGCT	TCAAAAACAG	CTCAATATAC	CATTCGTATA	1620
CGTTATGCCA	GTACCCAAGG	AACAAAAGGT	TATTTTCGTT	TAGATAATCA	GGAAGTGC AA	1680
ACGCTTAATA	TACCTACTTC	ACACAACGGT	TATGTAACCG	GTAATATTGG	TGAAAATTAT	1740
GATTTATATA	CAATAGGTTT	ATATACAATT	ACAGAAGGTA	ACCATACTCT	TCAAATCCAA	1800
CATAATGATA	AAAATGGAAT	GGTTTTAGAT	CGTATTGAAT	TTGTTCCCTAA	AGATTCACCT	1860
CAAGATTCAC	CTCAAGATTC	ACCTCCAGAA	GTTACGAAT	CAACAATTAT	TTTTGATAAA	1920
TCATCTCCAA	CTATATGGTC	TTCTAACAAA	CATCATATA	GCCATATACA	TTTAGAAGGA	1980
TCATATACAA	GTCAGGGAAG	TTATCCACAC	AATTTATTAA	TTAATTTATT	TCATCCTACA	2040
GACCCTAACA	GAAATCATAC	TATTCATGTT	AACAATGGTG	ATATGAATGT	TGATTATGGA	2100
AAAGATTCTG	TAGCCGATGG	GTTAAATTTT	AATAAAATAA	CTGCTACGAT	ACCAAGTGAT	2160
GCTTGGTATA	GCGGTACTAT	TACTTCTATG	CATTTATTTA	ATGATAATAA	TTTTAAAACA	2220
ATAACTCCTA	AATTTGAACT	TTCTAATGAA	TTAGAAAACA	TCACAACTCA	AGTAAATGCT	2280
TTATTTCGCAT	CTAGTGCACA	AGATACTCTC	GCAAGTAATG	TAAGTGATTA	CTGGATTGAA	2340
CAGGTCGTTA	TGAAAAGTCGA	TGCCTTATCA	GATGAAGTAT	TTGGAAAAGA	GAAAAAAGCA	2400
TTACGTAAAT	TGGTAAATCA	AGCAAAACGT	CTCAGTAAAA	TACGAAATCT	TCTCATAGGT	2460
GGTAATTTTG	ACAATTTAGT	CGCTTGGTAT	ATGGGAAAAG	ATGTAGTAAA	AGAATCGGAT	2520
CATGAATTAT	TTAAAAGTGA	TCATGTCTTA	CTACCTCCCC	CAACATTCCA	TCCTTCTTAT	2580
ATTTTCCAAA	AGGTGGAAGA	ATCAAAACTA	AAACCAAATA	CACGTTATAC	TATTTCTGGT	2640

```

TTTATCGCAC ATGGAGAAGA TGTAGAGCTT GTTGTCTCTC GTTATGGGCA AGAAATACAA 2700
AAAGTGATGC AAGTGCCATA TGAAGAAGCA CTTCTCTTA CATCTGAATC TAATTCTAGT 2760
TGTGTGTTTC CAAATTTAAA TATAAATGAA ACAC TAGCTG ATCCACATTT CTTTAGTTAT 2820
AGCATCGATG TTGGTTCTCT GGAAATGGAA GCGAATCCTG GTATTGAATT TGGTCTCCGT 2880
ATTGTCAAAC CAACAGGTAT GGCACGTGTA AGTAATTTAG AAATTGAGAG AGACCGTCCA 2940
TTAACAGCAA AAGAAATTCG TCAAGTACAA CGTGCAGCAA GAGATTGGAA ACAAACACTAT 3000
GAACAAGAAC GAACAGAGAT CACAGCTATA ATTCAACCTG TTCTTAATCA AATTAATGCG 3060
TTATACGAAA ATGAAGATTG GAATGGTTCT ATTCGTTCAA ATGTTTCCTA TCATGATCTA 3120
GAGCAAATTA TGCTTCCTAC TTTATTAAAA ACTGAGGAAA TAAATTGTAA TTATGATCAT 3180
CCAGCTTTTT TATTAAAGT ATATCATTGG TTTATGACAG ATCGTATAGG AGAACATGGT 3240
ACTATTTTAG CACGTTTCCA AGAAGCATTG GATCGTGCAT ATACACAATT AGAAAGTCGT 3300
AATCTCCTGC ATAACGGTCA TTTTACAAC TATACAGCGA ATTGGACAAT AGAAGGAGAT 3360
GCCCATCATA CAATCTTAGA AGATGGTAGA CGTGTGTTAC GTTACCAGA TTGGTCTTCT 3420
AATGCAACTC AAACAATTGA AATTGAAGAT TTTGACTTAG ATCAAGAATA CCAATTGCTC 3480
ATTCATGCAA AAGGAAAAGG TTCCATTACT TTACAACATG GAGAAGAAAA CGAATATGTG 3540
GAAACACATA CTCATCATA AAATGATTTT ATAACATCCC AAAATATTCC TTTCACTTTT 3600
AAAGGAAATC AAATTGAAGT CCATATTACT TCAGAAGATG GAGAGTTTTT AATCGATCAC 3660
ATTACAGTAA TAGAAGTTTC TAAAACAGAC ACAAATACAA ATATTATTGA AAATTCACCA 3720
ATCAATACAA GTATGAATAG TAATGTAAGA GTAGATATAC CAAGAAGTCT C 3771

```

## (2) INFORMATION FOR SEQ ID NO:6:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 1257 amino acids
  - (B) TYPE: amino acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: protein
- (iii) HYPOTHETICAL: YES
- (iv) ANTI-SENSE: NO
- (vi) ORIGINAL SOURCE:
  - (A) ORGANISM: *Bacillus thuringiensis*
  - (C) INDIVIDUAL ISOLATE: PS33F2
- (vii) IMMEDIATE SOURCE:
  - (B) CLONE: E. coli NM522(pMYC2316) B-18785
- (ix) FEATURE:
  - (A) NAME/KEY: Protein
  - (B) LOCATION: 1..1257

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:

```

Met Ala Thr Leu Asn Glu Val Tyr Pro Val Asn Tyr Asn Val Leu Ser
 1           5           10           15
Ser Asp Ala Phe Gln Gln Leu Asp Thr Thr Gly Phe Lys Ser Lys Tyr
 20           25           30
Asp Glu Met Ile Lys Ala Phe Glu Lys Lys Trp Lys Lys Gly Ala Lys
 35           40           45
Gly Lys Asp Leu Leu Asp Val Ala Trp Thr Tyr Ile Thr Thr Gly Glu
 50           55           60
Ile Asp Pro Leu Asn Val Ile Lys Gly Val Leu Ser Val Leu Thr Leu
 65           70           75           80
Ile Pro Glu Val Gly Thr Val Ala Ser Ala Ala Ser Thr Ile Val Ser
 85           90           95
Phe Ile Trp Pro Lys Ile Phe Gly Asp Lys Pro Asn Ala Lys Asn Ile
100          105          110

```

Phe Glu Glu Leu Lys Pro Gln Ile Glu Ala Leu Ile Gln Gln Asp Ile  
 115 120 125  
 Thr Asn Tyr Gln Asp Ala Ile Asn Gln Lys Lys Phe Asp Ser Leu Gln  
 130 135 140  
 Lys Thr Ile Asn Leu Tyr Thr Val Ala Ile Asp Asn Asn Asp Tyr Val  
 145 150 155 160  
 Thr Ala Lys Thr Gln Leu Glu Asn Leu Asn Ser Ile Leu Thr Ser Asp  
 165 170 175  
 Ile Ser Ile Phe Ile Pro Glu Gly Tyr Glu Thr Gly Gly Leu Pro Tyr  
 180 185 190  
 Tyr Ala Met Val Ala Asn Ala His Ile Leu Leu Leu Arg Asp Ala Ile  
 195 200 205  
 Val Asn Ala Glu Lys Leu Gly Phe Ser Asp Lys Glu Val Asp Thr His  
 210 215 220  
 Lys Lys Tyr Ile Lys Met Thr Ile His Asn His Thr Glu Ala Val Ile  
 225 230 235 240  
 Lys Ala Phe Leu Asn Gly Leu Asp Lys Phe Lys Ser Leu Asp Val Asn  
 245 250 255  
 Ser Tyr Asn Lys Lys Ala Asn Tyr Ile Lys Gly Met Thr Glu Met Val  
 260 265 270  
 Leu Asp Leu Val Ala Leu Trp Pro Thr Phe Asp Pro Asp His Tyr Gln  
 275 280 285  
 Lys Glu Val Glu Ile Glu Phe Thr Arg Thr Ile Ser Ser Pro Ile Tyr  
 290 295 300  
 Gln Pro Val Pro Lys Asn Met Gln Asn Thr Ser Ser Ser Ile Val Pro  
 305 310 315 320  
 Ser Asp Leu Phe His Tyr Gln Gly Asp Leu Val Lys Leu Glu Phe Ser  
 325 330 335  
 Thr Arg Thr Asp Asn Asp Gly Leu Ala Lys Ile Phe Thr Gly Ile Arg  
 340 345 350  
 Asn Thr Phe Tyr Lys Ser Pro Asn Thr His Glu Thr Tyr His Val Asp  
 355 360 365  
 Phe Ser Tyr Asn Thr Gln Ser Ser Gly Asn Ile Ser Arg Gly Ser Ser  
 370 375 380  
 Asn Pro Ile Pro Ile Asp Leu Asn Asn Pro Ile Ile Ser Thr Cys Ile  
 385 390 395 400  
 Arg Asn Ser Phe Tyr Lys Ala Ile Ala Gly Ser Ser Val Leu Val Asn  
 405 410 415  
 Phe Lys Asp Gly Thr Gln Gly Tyr Ala Phe Ala Gln Ala Pro Thr Gly  
 420 425 430  
 Gly Ala Trp Asp His Ser Phe Ile Glu Ser Asp Gly Ala Pro Glu Gly  
 435 440 445  
 His Lys Leu Asn Tyr Ile Tyr Thr Ser Pro Gly Asp Thr Leu Arg Asp  
 450 455 460  
 Phe Ile Asn Val Tyr Thr Leu Ile Ser Thr Pro Thr Ile Asn Glu Leu  
 465 470 475 480  
 Ser Thr Glu Lys Ile Lys Gly Phe Pro Ala Glu Lys Gly Tyr Ile Lys  
 485 490 495  
 Asn Gln Gly Ile Met Lys Tyr Tyr Gly Lys Pro Glu Tyr Ile Asn Gly  
 500 505 510  
 Ala Gln Pro Val Asn Leu Glu Asn Gln Gln Thr Leu Ile Phe Glu Phe  
 515 520 525  
 His Ala Ser Lys Thr Ala Gln Tyr Thr Ile Arg Ile Arg Tyr Ala Ser  
 530 535 540  
 Thr Gln Gly Thr Lys Gly Tyr Phe Arg Leu Asp Asn Gln Glu Leu Gln  
 545 550 555 560  
 Thr Leu Asn Ile Pro Thr Ser His Asn Gly Tyr Val Thr Gly Asn Ile  
 565 570 575

Gly Glu Asn Tyr Asp Leu Tyr Thr Ile Gly Ser Tyr Thr Ile Thr Glu  
 580 585 590  
 Gly Asn His Thr Leu Gln Ile Gln His Asn Asp Lys Asn Gly Met Val  
 595 600 605  
 Leu Asp Arg Ile Glu Phe Val Pro Lys Asp Ser Leu Gln Asp Ser Pro  
 610 615 620  
 Gln Asp Ser Pro Pro Glu Val His Glu Ser Thr Ile Ile Phe Asp Lys  
 625 630 635 640  
 Ser Ser Pro Thr Ile Trp Ser Ser Asn Lys His Ser Tyr Ser His Ile  
 645 650 655  
 His Leu Glu Gly Ser Tyr Thr Ser Gln Gly Ser Tyr Pro His Asn Leu  
 660 665 670  
 Leu Ile Asn Leu Phe His Pro Thr Asp Pro Asn Arg Asn His Thr Ile  
 675 680 685  
 His Val Asn Asn Gly Asp Met Asn Val Asp Tyr Gly Lys Asp Ser Val  
 690 695 700  
 Ala Asp Gly Leu Asn Phe Asn Lys Ile Thr Ala Thr Ile Pro Ser Asp  
 705 710 715 720  
 Ala Trp Tyr Ser Gly Thr Ile Thr Ser Met His Leu Phe Asn Asp Asn  
 725 730 735  
 Asn Phe Lys Thr Ile Thr Pro Lys Phe Glu Leu Ser Asn Glu Leu Glu  
 740 745 750  
 Asn Ile Thr Thr Gln Val Asn Ala Leu Phe Ala Ser Ser Ala Gln Asp  
 755 760 765  
 Thr Leu Ala Ser Asn Val Ser Asp Tyr Trp Ile Glu Gln Val Val Met  
 770 775 780  
 Lys Val Asp Ala Leu Ser Asp Glu Val Phe Gly Lys Glu Lys Lys Ala  
 785 790 795 800  
 Leu Arg Lys Leu Val Asn Gln Ala Lys Arg Leu Ser Lys Ile Arg Asn  
 805 810 815  
 Leu Leu Ile Gly Glu Asn Phe Asp Asn Leu Val Ala Trp Tyr Met Gly  
 820 825 830  
 Lys Asp Val Val Lys Glu Ser Asp His Glu Leu Phe Lys Ser Asp His  
 835 840 845  
 Val Leu Leu Pro Pro Pro Thr Phe His Pro Ser Tyr Ile Phe Gln Lys  
 850 855 860  
 Val Glu Glu Ser Lys Leu Lys Pro Asn Thr Arg Tyr Thr Ile Ser Gly  
 865 870 875 880  
 Phe Ile Ala His Gly Glu Asp Val Glu Leu Val Val Ser Arg Tyr Gly  
 885 890 895  
 Gln Glu Ile Gln Lys Val Met Gln Val Pro Tyr Glu Glu Ala Leu Pro  
 900 905 910  
 Leu Thr Ser Glu Ser Asn Ser Ser Cys Cys Val Pro Asn Leu Asn Ile  
 915 920 925  
 Asn Glu Thr Leu Ala Asp Pro His Phe Phe Ser Tyr Ser Ile Asp Val  
 930 935 940  
 Gly Ser Leu Glu Met Glu Ala Asn Pro Gly Ile Glu Phe Gly Leu Arg  
 945 950 955 960  
 Ile Val Lys Pro Thr Gly Met Ala Arg Val Ser Asn Leu Glu Ile Arg  
 965 970 975  
 Glu Asp Arg Pro Leu Thr Ala Lys Glu Ile Arg Gln Val Gln Arg Ala  
 980 985 990  
 Ala Arg Asp Trp Lys Gln Asn Tyr Glu Gln Glu Arg Thr Glu Ile Thr  
 995 1000 1005  
 Ala Ile Ile Gln Pro Val Leu Asn Gln Ile Asn Ala Leu Tyr Glu Asn  
 1010 1015 1020  
 Glu Asp Trp Asn Gly Ser Ile Arg Ser Asn Val Ser Tyr His Asp Leu  
 1025 1030 1035 1040

Glu Gln Ile Met Leu Pro Thr Leu Leu Lys Thr Glu Glu Ile Asn Cys  
 1045 1050 1055  
 Asn Tyr Asp His Pro Ala Phe Leu Leu Lys Val Tyr His Trp Phe Met  
 1060 1065 1070  
 Thr Asp Arg Ile Gly Glu His Gly Thr Ile Leu Ala Arg Phe Gln Glu  
 1075 1080 1085  
 Ala Leu Asp Arg Ala Tyr Thr Gln Leu Glu Ser Arg Asn Leu Leu His  
 1090 1095 1100  
 Asn Gly His Phe Thr Thr Asp Thr Ala Asn Trp Thr Ile Glu Gly Asp  
 1105 1110 1115 1120  
 Ala His His Thr Ile Leu Glu Asp Gly Arg Arg Val Leu Arg Leu Pro  
 1125 1130 1135  
 Asp Trp Ser Ser Asn Ala Thr Gln Thr Ile Glu Ile Glu Asp Phe Asp  
 1140 1145 1150  
 Leu Asp Gln Glu Tyr Gln Leu Leu Ile His Ala Lys Gly Lys Gly Ser  
 1155 1160 1165  
 Ile Thr Leu Gln His Gly Glu Glu Asn Glu Tyr Val Glu Thr His Thr  
 1170 1175 1180  
 His His Thr Asn Asp Phe Ile Thr Ser Gln Asn Ile Pro Phe Thr Phe  
 1185 1190 1195 1200  
 Lys Gly Asn Gln Ile Glu Val His Ile Thr Ser Glu Asp Gly Glu Phe  
 1205 1210 1215  
 Leu Ile Asp His Ile Thr Val Ile Glu Val Ser Lys Thr Asp Thr Asn  
 1220 1225 1230  
 Thr Asn Ile Ile Glu Asn Ser Pro Ile Asn Thr Ser Met Asn Ser Asn  
 1235 1240 1245  
 Val Arg Val Asp Ile Pro Arg Ser Leu  
 1250 1255

## (2) INFORMATION FOR SEQ ID NO:7:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 3738 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: double
  - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: DNA (genomic)
- (iii) HYPOTHETICAL: NO
- (iv) ANTI-SENSE: NO
- (vi) ORIGINAL SOURCE:
  - (A) ORGANISM: *Bacillus thuringiensis*
  - (C) INDIVIDUAL ISOLATE: PS86Q3
- (vii) IMMEDIATE SOURCE:
  - (A) LIBRARY: Lambdagem (TM) - 11 LIBRARY
  - (B) CLONE: 86Q3a

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:

ATGGCAACAA TTAATGAGTT GTATCCAGTT CCTTATAATG TGCTAGCTCA TCCAATTAAA	60
GAAGTCGATG ATCCTTATTC TTGGTCAAAT TTATTAAAGG GTATACAAGA AGGTTGGGAA	120
GAATGGGGAA AACACAGGACA AAAAAAAGTT TTTGAAGACC ATCTTACGAT TGCATGGAAT	180
CTTTATAAAA CAGGAAAATT AGATTATTTT GCTTTGACAA AAGCATCAAT ATCATTGATT	240
GGATTATATC CAGGGGCAGA AGCAGCAGTT CCCTTTATTA ATATGTTTGT AGACTTTGTT	300
TGGCCTAAAT TATTTGGTGC GAATACAGAA GGAAGATC AACAGTTGTT TAATGCTATC	360
ATGGATGCAG TTAATAAAAT GGTAGATAAT AAGTCTCTAA GTTATAATCT TAGTACACTT	420
AATAAAACAA TTGAAGGACT TCAAGGTAAT TTAGGCCTAT TTCAAATGC TATACAAGTA	480
GCCATTTGTC AAGGCAGTAC ACCAGAAAGA GTAAATTTTG ATCAAAATTG TACACCATGT	540
AATCCAAATC AACCTTGTA AGATGATTTG GATAGAGTTG CTTACGTTT TGATACGGCT	600
AATCTCAAT TCACACAGCA TTTACCAGAA TTTAAAAATC CTTGGTCGGA TGAAAAGTCT	660

SUBSTITUTE SHEET

ACTCAGGAAT	TTAAAAGAAC	ATCTGTTGAA	TTAACTTTAC	CAATGTATAC	AACAGTAGCT	720
ACGTTACATC	TTTTATTATA	TGAAGGATAT	ATAGAATTTA	TGACAAAATG	GAATTTTCAC	780
AATGAACAAT	ATTTAAATAA	TTTAAAGGTA	GAATTACAAC	AATTGATACA	CTCATATTCA	840
GAAACTGTTT	GTACAAGTTT	CCTTCAATTT	TTACCTACCT	TGAATAATCG	TTCAAAATCA	900
TCCGTAAATG	CTTATAACCG	TTATGTCCGC	AATATGACTG	TTAACTGTTT	AGATATTGCT	960
GCTACATGGC	CTACATTTGA	TACACATAAT	TATCATCAAG	GTGGTAAATT	AGATTTAACT	1020
CGTATTATTC	TTTCAGATAC	AGCAGGACCA	ATAGAAGAAT	ATACTACTGG	CGACAAAAC	1080
TCAGGACCTG	AACATAGTAA	CATTACACCA	AATAATATTC	TAGATACACC	ATCTCCAACA	1140
TATCAGCACT	CATTTGTATC	TGTTGATTCT	ATTGTATATT	CTAGAAAAGA	ATTACAACAA	1200
TTAGACATAG	CTACTTATAG	TACAAATAAT	AGTAATAATT	GTCAACCTTA	TGGATTACGA	1260
CTTTCATATA	CAGATGGAAG	CAGATATGAT	TATGGAGATA	ATCAACCTGA	TTTTACTACT	1320
TCCAATAACA	ATTATTGTCA	TAATAGCTAT	ACTGCCCTTA	TTACACTTGT	GAATGCACGA	1380
CATTTATATA	ATGCAAAAGG	CTCTTTACAA	AATGTAGAAT	CTTAGTGGT	TAGTACTGTA	1440
AATGGTGGAA	GTGGTTCATG	CATTTGTGAT	GCATGGATTA	ATTATTTACG	TCCTCCTCAA	1500
ACAAGTAAAA	ATGAATCAGC	TCCTGATCAA	AAAATTAATG	TTTTGTATCC	AATAACAGAA	1560
ACTGTAAATA	AGGGGACTGG	AGGAAATTTA	GGAGTTATTT	CTGCCTATGT	TCCAATGGAA	1620
CTTGTACCAG	AAAACGTTAT	TGGAGATGTT	AATGCTGATA	CTAAATTGCC	ACTTACACAA	1680
TTAAAGGGCT	TTCCATTTGA	AAAATATGGT	TCTGAGTATA	ATAATCGGGG	TATCTCTCTT	1740
GTTGCGGAAT	GGATAAATGG	TAACAATGCA	GTTAAACTTT	CTAATAGTCA	ATCTGTTGGC	1800
ATACAAATTA	CGAATCAAAC	CAAAACAAAA	TATGAAATAC	GTTGCCGTTA	TGCGAGTAAA	1860
GGAGATAATA	ATGTTTATTT	TAATGTGGAT	TTAAGTGAAA	ATCCATTTAG	AAATTCCATT	1920
TCTTTTGGAT	CTACTGAAAG	TTCTGTTGTA	GGAGTACAAG	GTGAAAATGG	AAAGTATATA	1980
TTGAAATCAA	TCACAACGGT	AGAAATACCT	GCTGGAAGTT	TCTATGTTCA	TATAACAAAC	2040
CAAGGTTCTT	CAGATCTCTT	TTTAGATCGT	ATTGAGTTTG	TTCCAAAAAT	CCAATTCCAA	2100
TTCTGTGATA	ATAATAATCT	TCACTGTGAT	TGTAATAACC	CTGTTGACAC	CGATTGTACA	2160
TTTTGTTGCG	TTTGCACTAG	TCTTACTGAT	TGTGATTGTA	ATAACCCTCG	TGGCCTAGAT	2220
TGTACGCTAT	GTTGTCAGGT	AGAAAATCAG	CTACCTTCTT	TTGTGACACT	TACAGATTTA	2280
CAAAATATTA	CGACACAAGT	AAATGCATTA	GTTGCATCGA	GCGAACATGA	TACACTTGCA	2340
ACAGACGTGA	GTGATTATGA	GATTGAAGAA	GTTGTACTGA	AAGTAGATGC	ATTATCTGGT	2400
GAAGTGTTTG	GAAAAGAGAA	AAAAGCATTG	CGTAAATTGG	TAAATCACAC	AAAACGTTTA	2460
AGCAAAGCGC	GTAACCTCTT	GATAGGAGGA	AATTTTGATA	ACTTGGATGC	TTGGTACAGA	2520
GGCCGAAATG	TAGTAAACGT	ATCTGATCAT	GAAGTATTTA	AGAGTGATCA	TGTATTATTG	2580
CCACCACCAA	CACTGTACTC	ATCTTATATG	TTCCAAAAAG	TAGAGGAATC	GAAATTAAAA	2640
GCGAATACAC	GTTATACTGT	GTCTGGTTTT	ATTGCACATG	CAGAAGATTT	AGAAATTGTT	2700
GTGTCTCGTT	ATGGGCAAGA	AGTGAAGAAA	GTGGTTCAAG	TTCCATATGG	AGAAGCATTG	2760
CCATTGACAT	CGAGGGGAGC	GATTTGTTGC	CCTCCACGTT	CTACAAGTAA	TGGAAAACCT	2820
GCTGATCCAC	ATTTCTTTAG	TTACAGTATT	GATGTGGGAA	CATTAGATGT	AGAAGCAAAC	2880
CCTGGTATCG	AATTGGGTCT	TCGTATTGTA	GAACGAACTG	GAATGGCACG	TGTAAGTAAT	2940
TTAGAAATTC	GTGAAGATCG	TCCATTAAAG	AAAAATGAAC	TCCGCAATGT	ACAACGTGCA	3000
GCAAGAAATT	GGAGAACAGC	ATATGACCAA	GAACGTGCAG	AAGTAACGGC	CTTGATTCAA	3060
CCTGTATTAA	ATCAAAATCAA	TGCGTTGTAT	GAAAATGAAG	ATTGGAATGG	AGCAATTCGT	3120
TCTGGAGTTT	CTTATCATGA	CTTAGAAGCA	ATTGTTTTAC	CAACATTACC	AAAATTAAAT	3180
CATTGGTTTA	TGTCTGATAT	GTTAGGGGAA	CAAGGTTCCA	TTTTAGCTCA	ATTTCAAGAA	3240
GCATTAGATC	GTGCGTATAC	GCAACTCGAA	GAAAGTACAA	TTCTGCATAA	TGGTCATTTG	3300

ACAACAGATG CAGCAAATTG GACGATAGAA GGCGATGCAC ATCATGCGAT ATTAGAAGAT	3360
GGTAGACGCG TATTACGTCT TCCAGATTGG TCTTCTAGCG TTTCACAAAC CATTGAAATA	3420
GAAATTTTG ATCCAGATAA AGAATATCAG TTAGTTTTC ATGCACAAGG AGAAGGAACG	3480
GTCTCCCTTC AACATGGTGA AGAAGGAGAA TATGTGGAAA CACACCCGCA TAAGTCTGCG	3540
AATTTTACAA CTTACACCCG TCAAGGAGTC ACATTGAAA CAAATAAAGT AACAGTTGAA	3600
ATTACCTCAG AAGATGGAGA ATTCTAGTC GATCATATTG CTCTGTGGA AGCTCCTCTT	3660
CCTACAGATG ACCAAAGTTC AGATGGAAAT ACGACTTCCA ATACGAATAG CAATACAAGT	3720
ATGAATAATA ATCAATAA	3738

## (2) INFORMATION FOR SEQ ID NO:8:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 1245 amino acids
  - (B) TYPE: amino acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: protein
- (iii) HYPOTHETICAL: YES
- (iv) ANTI-SENSE: NO
- (vi) ORIGINAL SOURCE:
  - (A) ORGANISM: BACILLUS THURINGIENSIS
  - (C) INDIVIDUAL ISOLATE: PS86Q3
- (vii) IMMEDIATE SOURCE:
  - (A) LIBRARY: LAMBDA GEM (tm) - 11 library
  - (B) CLONE: 86Q3A

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:

Met	Ala	Thr	Ile	Asn	Glu	Leu	Tyr	Pro	Val	Pro	Tyr	Asn	Val	Leu	Ala
1				5					10					15	
His	Pro	Ile	Lys	Glu	Val	Asp	Asp	Pro	Tyr	Ser	Trp	Ser	Asn	Leu	Leu
			20					25					30		
Lys	Gly	Ile	Gln	Glu	Gly	Trp	Glu	Glu	Trp	Gly	Lys	Thr	Gly	Gln	Lys
		35				40						45			
Lys	Leu	Phe	Glu	Asp	His	Leu	Thr	Ile	Ala	Trp	Asn	Leu	Tyr	Lys	Thr
		50				55					60				
Gly	Lys	Leu	Asp	Tyr	Phe	Ala	Leu	Thr	Lys	Ala	Ser	Ile	Ser	Leu	Ile
		65			70				75					80	
Gly	Phe	Ile	Pro	Gly	Ala	Glu	Ala	Ala	Val	Pro	Phe	Ile	Asn	Met	Phe
			85						90					95	
Val	Asp	Phe	Val	Trp	Pro	Lys	Leu	Phe	Gly	Ala	Asn	Thr	Glu	Gly	Lys
			100				105						110		
Asp	Gln	Gln	Leu	Phe	Asn	Ala	Ile	Met	Asp	Ala	Val	Asn	Lys	Met	Val
		115					120					125			
Asp	Asn	Lys	Phe	Leu	Ser	Tyr	Asn	Leu	Ser	Thr	Leu	Asn	Lys	Thr	Ile
		130				135					140				
Glu	Gly	Leu	Gln	Gly	Asn	Leu	Gly	Leu	Phe	Gln	Asn	Ala	Ile	Gln	Val
		145			150				155					160	
Ala	Ile	Cys	Gln	Gly	Ser	Thr	Pro	Glu	Arg	Val	Asn	Phe	Asp	Gln	Asn
			165					170						175	
Cys	Thr	Pro	Cys	Asn	Pro	Asn	Gln	Pro	Cys	Lys	Asp	Asp	Leu	Asp	Arg
			180				185						190		
Val	Ala	Ser	Arg	Phe	Asp	Thr	Ala	Asn	Ser	Gln	Phe	Thr	Gln	His	Leu
			195				200					205			
Pro	Glu	Phe	Lys	Asn	Pro	Trp	Ser	Asp	Glu	Asn	Ser	Thr	Gln	Glu	Phe
		210				215					220				
Lys	Arg	Thr	Ser	Val	Glu	Leu	Thr	Leu	Pro	Met	Tyr	Thr	Thr	Val	Ala
		225			230					235				240	
Thr	Leu	His	Leu	Leu	Leu	Tyr	Glu	Gly	Tyr	Ile	Glu	Phe	Met	Thr	Lys
			245						250					255	



Trp Asn Phe His Asn Glu Gln Tyr Leu Asn Asn Leu Lys Val Glu Leu  
 260 265 270  
 Gln Gln Leu Ile His Ser Tyr Ser Glu Thr Val Arg Thr Ser Phe Leu  
 275 280 285  
 Gln Phe Leu Pro Thr Leu Asn Asn Arg Ser Lys Ser Ser Val Asn Ala  
 290 295 300  
 Tyr Asn Arg Tyr Val Arg Asn Met Thr Val Asn Cys Leu Asp Ile Ala  
 305 310 315 320  
 Ala Thr Trp Pro Thr Phe Asp Thr His Asn Tyr His Gln Gly Gly Lys  
 325 330 335  
 Leu Asp Leu Thr Arg Ile Ile Leu Ser Asp Thr Ala Gly Pro Ile Glu  
 340 345 350  
 Glu Tyr Thr Thr Gly Asp Lys Thr Ser Gly Pro Glu His Ser Asn Ile  
 355 360 365  
 Thr Pro Asn Asn Ile Leu Asp Thr Pro Ser Pro Thr Tyr Gln His Ser  
 370 375 380  
 Phe Val Ser Val Asp Ser Ile Val Tyr Ser Arg Lys Glu Leu Gln Gln  
 385 390 395 400  
 Leu Asp Ile Ala Thr Tyr Ser Thr Asn Asn Ser Asn Asn Cys His Pro  
 405 410 415  
 Tyr Gly Leu Arg Leu Ser Tyr Thr Asp Gly Ser Arg Tyr Asp Tyr Gly  
 420 425 430  
 Asp Asn Gln Pro Asp Phe Thr Thr Ser Asn Asn Asn Tyr Cys His Asn  
 435 440 445  
 Ser Tyr Thr Ala Pro Ile Thr Leu Val Asn Ala Arg His Leu Tyr Asn  
 450 455 460  
 Ala Lys Gly Ser Leu Gln Asn Val Glu Ser Leu Val Val Ser Thr Val  
 465 470 475 480  
 Asn Gly Gly Ser Gly Ser Cys Ile Cys Asp Ala Trp Ile Asn Tyr Leu  
 485 490 495  
 Arg Pro Pro Gln Thr Ser Lys Asn Glu Ser Arg Pro Asp Gln Lys Ile  
 500 505 510  
 Asn Val Leu Tyr Pro Ile Thr Glu Thr Val Asn Lys Gly Thr Gly Gly  
 515 520 525  
 Asn Leu Gly Val Ile Ser Ala Tyr Val Pro Met Glu Leu Val Pro Glu  
 530 535 540  
 Asn Val Ile Gly Asp Val Asn Ala Asp Thr Lys Leu Pro Leu Thr Gln  
 545 550 555 560  
 Leu Lys Gly Phe Pro Phe Glu Lys Tyr Gly Ser Glu Tyr Asn Asn Arg  
 565 570 575  
 Gly Ile Ser Leu Val Arg Glu Trp Ile Asn Gly Asn Asn Ala Val Lys  
 580 585 590  
 Leu Ser Asn Ser Gln Ser Val Gly Ile Gln Ile Thr Asn Gln Thr Lys  
 595 600 605  
 Gln Lys Tyr Glu Ile Arg Cys Arg Tyr Ala Ser Lys Gly Asp Asn Asn  
 610 615 620  
 Val Tyr Phe Asn Val Asp Leu Ser Glu Asn Pro Phe Arg Asn Ser Ile  
 625 630 635 640  
 Ser Phe Gly Ser Thr Glu Ser Ser Val Val Gly Val Gln Gly Glu Asn  
 645 650 655  
 Gly Lys Tyr Ile Leu Lys Ser Ile Thr Thr Val Glu Ile Pro Ala Gly  
 660 665 670  
 Ser Phe Tyr Val His Ile Thr Asn Gln Gly Ser Ser Asp Leu Phe Leu  
 675 680 685  
 Asp Arg Ile Glu Phe Val Pro Lys Ile Gln Phe Gln Phe Cys Asp Asn  
 690 695 700  
 Asn Asn Leu His Cys Asp Cys Asn Asn Pro Val Asp Thr Asp Cys Thr  
 705 710 715 720

Phe Cys Cys Val Cys Thr Ser Leu Thr Asp Cys Asp Cys Asn Asn Pro  
 725 730 735  
 Arg Gly Leu Asp Cys Thr Leu Cys Cys Gln Val Glu Asn Gln Leu Pro  
 740 745 750  
 Ser Phe Val Thr Leu Thr Asp Leu Gln Asn Ile Thr Thr Gln Val Asn  
 755 760 765  
 Ala Leu Val Ala Ser Ser Glu His Asp Thr Leu Ala Thr Asp Val Ser  
 770 775 780  
 Asp Tyr Glu Ile Glu Glu Val Val Leu Lys Val Asp Ala Leu Ser Gly  
 785 790 795 800  
 Glu Val Phe Gly Lys Glu Lys Lys Ala Leu Arg Lys Leu Val Asn His  
 805 810 815  
 Thr Lys Arg Leu Ser Lys Ala Arg Asn Leu Leu Ile Gly Gly Asn Phe  
 820 825 830  
 Asp Asn Leu Asp Ala Trp Tyr Arg Gly Arg Asn Val Val Asn Val Ser  
 835 840 845  
 Asp His Glu Leu Phe Lys Ser Asp His Val Leu Leu Pro Pro Pro Thr  
 850 855 860  
 Leu Tyr Ser Ser Tyr Met Phe Gln Lys Val Glu Glu Ser Lys Leu Lys  
 865 870 875 880  
 Ala Asn Thr Arg Tyr Thr Val Ser Gly Phe Ile Ala His Ala Glu Asp  
 885 890 895  
 Leu Glu Ile Val Val Ser Arg Tyr Gly Gln Glu Val Lys Lys Val Val  
 900 905 910  
 Gln Val Pro Tyr Gly Glu Ala Phe Pro Leu Thr Ser Arg Gly Ala Ile  
 915 920 925  
 Cys Cys Pro Pro Arg Ser Thr Ser Asn Gly Lys Pro Ala Asp Pro His  
 930 935 940  
 Phe Phe Ser Tyr Ser Ile Asp Val Gly Thr Leu Asp Val Glu Ala Asn  
 945 950 955 960  
 Pro Gly Ile Glu Leu Gly Leu Arg Ile Val Glu Arg Thr Gly Met Ala  
 965 970 975  
 Arg Val Ser Asn Leu Glu Ile Arg Glu Asp Arg Pro Leu Lys Lys Asn  
 980 985 990  
 Glu Leu Arg Asn Val Gln Arg Ala Ala Arg Asn Trp Arg Thr Ala Tyr  
 995 1000 1005  
 Asp Gln Glu Arg Ala Glu Val Thr Ala Leu Ile Gln Pro Val Leu Asn  
 1010 1015 1020  
 Gln Ile Asn Ala Leu Tyr Glu Asn Glu Asp Trp Asn Gly Ala Ile Arg  
 1025 1030 1035 1040  
 Ser Gly Val Ser Tyr His Asp Leu Glu Ala Ile Val Leu Pro Thr Leu  
 1045 1050 1055  
 Pro Lys Leu Asn His Trp Phe Met Ser Asp Met Leu Gly Glu Gln Gly  
 1060 1065 1070  
 Ser Ile Leu Ala Gln Phe Gln Glu Ala Leu Asp Arg Ala Tyr Thr Gln  
 1075 1080 1085  
 Leu Glu Glu Ser Thr Ile Leu His Asn Gly His Phe Thr Thr Asp Ala  
 1090 1095 1100  
 Ala Asn Trp Thr Ile Glu Gly Asp Ala His His Ala Ile Leu Glu Asp  
 1105 1110 1115 1120  
 Gly Arg Arg Val Leu Arg Leu Pro Asp Trp Ser Ser Ser Val Ser Gln  
 1125 1130 1135  
 Thr Ile Glu Ile Glu Asn Phe Asp Pro Asp Lys Glu Tyr Gln Leu Val  
 1140 1145 1150  
 Phe His Ala Gln Gly Glu Gly Thr Val Ser Leu Gln His Gly Glu Glu  
 1155 1160 1165  
 Gly Gln Tyr Val Glu Thr His Pro His Lys Ser Ala Asn Phe Thr Thr  
 1170 1175 1180

Ser His Arg Gln Gly Val Thr Phe Glu Thr Asn Lys Val Thr Val Glu  
 1185 1190 1195 1200  
 Ile Thr Ser Glu Asp Gly Glu Phe Leu Val Asp His Ile Ala Leu Val  
 1205 1210 1215  
 Glu Ala Pro Leu Pro Thr Asp Asp Gln Ser Ser Asp Gly Asn Thr Thr  
 1220 1225 1230  
 Ser Asn Thr Asn Ser Asn Thr Ser Met Asn Asn Asn Gln  
 1235 1240 1245

## (2) INFORMATION FOR SEQ ID NO:9:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 2412 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

## (vi) ORIGINAL SOURCE:

- (A) ORGANISM: *Bacillus thuringiensis*
- (C) INDIVIDUAL ISOLATE: PS63B

## (vii) IMMEDIATE SOURCE:

- (B) CLONE: E. coli NM522(pMYC1642) NRRL B-18961

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:

ATGACTTGTC AATTACAAGC GCAACCACTT ATTCCCTATA ACGTACTAGC AGGAGTTCCA	60
ACTAGTAATA CAGGTAGTCC AATCGGCAAT GCAGGTAATC AATTTGATCA GTTTGAGCAA	120
ACCGTTAAAG AGCTCAAGGA AGCATGGGAA GCGTTCCAAA AAAACGGAAG TTTCTCATT	180
GCAGCTCTTG AAAAGGGATT TGATGCAGCA ATCGGAGGAG GATCCTTTGA TTATTTAGGT	240
TTAGTTCAAG CCGGCCTAGG ATTAGTTGGT ACGCTAGGCG CCGCAATCCC TGGTGTTC	300
GTGGCAGTGC CTCTTATTAG CATGCTTGTT GGTGTTTTTT GGCCAAAGGG CACAAACAAC	360
CAAGAAAACC TTATTACAGT TATTGATAAG GAAGTTCAGA GAATACTAGA TGAAAAGCTA	420
TCTGATCAGT TAATAAAGAA ATTGAACGCA GATTTAAATG CTTTTACGGA CCTAGTAACT	480
CGTTTGGAAG AAGTAATAAT AGATGCAACT TTCGAGAATC ACAAGCCTGT ACTACAAGTA	540
AGTAAATCAA ATTATATGAA AGTGGATTCA GCATATTTCT CAACAGGAGG TATTCTTACT	600
CTTGGCATGA GTGATTTTCT TACTGATACC TATTCAAAGC TTACCTTCCC ATTATATGTA	660
CTAGGCGCAA CTATGAAACT TTCAGCATAT CATAGTTATA TACAATTCGG AAATACATGG	720
CTTAATAAAG TTTATGATTT ATCATCAGAT GAGGGAAAAA CAATGTCGCA GGCTTTAGCA	780
CGAGCTAAAC AGCATATGCG CCAAGACATA GCATTTTATA CAAGCCAAGC TTTAAACATG	840
TTTACTGGGA ATCTCCCTTC ATTATCATCT AATAAATATG CAATTAATGA CTATAATGTA	900
TACACTCGAG CAATGGTATT GAATGGCTTA GATATAGTAG CAACATGGCC TACCCTATAT	960
CCAGATGACT ATTCGTCTCA GATAAAACTG GAGAAAACAC GCGTGATCTT TTCAGATATG	1020
GTCGGGCAAA GTGAGAGTAG AGATGGCAGC GTAACGATTA AAAATATTTT TGACAATACA	1080
GATTCACATC AACATGGATC CATAGGTCTC AATTCATCT CTTATTTCCC AGATGAGTTA	1140
CAGAAAGCAC AACTTCGCAT GTATGATTAT AATCACAAC CTTATTGTAC GGACTGTTTC	1200
TGCTGGCCGT ATGGAGTGAT TTAAACTAT AACAGAATA CCTTTAGATA TGGCGATAAT	1260
GATCCAGGTC TTTCAGGAGA CGTTCAACTC CCAGCACCTA TGAGTGTAGT TAATGCCCAA	1320
ACTCAAACAG CCCAATATAC AGATGGAGAA AACATATGGA CAGATACTGG CCGCAGTTGG	1380
CTTTGTACTC TACGTGGCTA CTGTACTACA AACTGTTTTT CAGGAAGAGG TTGTTATAAT	1440
AATAGTACTG GATATGGAGA AAGTTGCAAT CAATCACTTC CAGGTCAAAA AATACATGCA	1500
CTATATCCTT TTACACAAAC AAATGTGCTG GGACAATCAG GCAAAC TAGG ATTGCTAGCA	1560
AGTCATATTC CATATGACCT AAGTCCGAAC AATACGATTG GTGACAAAGA TACAGATTCT	1620

```

ACGAATATTG TCGCAAAAGG AATTCCAGTG GAAAAAGGGT ATGCATCCAG TGGACAAAAA 1680
GTTGAAATTA TACGAGAGTG GATAAATGGT GCGAATGTAG TTCAATTATC TCCAGGCCAA 1740
TCTTGGGGAA TGGATTTTAC CAATAGCACA GGTGGTCAAT ATATGGTCCG CTGTTCGATAT 1800
GCAAGTACAA ACGATACTCC AATCTTTTTT AATTTAGTGT ATGACGGGGG ATCGAATCCT 1860
ATTTATAACC AGATGACATT CCCTGCTACA AAAGAGACTC CAGCTCACGA TTCAGTAGAT 1920
AACAGATAC TAGGCATAAA AGGAATAAAT GGAAATTATT CACTCATGAA TGTAAAGAT 1980
TCTGTCCAAC TTCCATCTGG GAAATTCAT GTTTTTTTCA CAAATAATGG ATCATCTGCT 2040
ATTTATTTAG ATCGACTTGA GTTTGTTCTT TTAGATCAAC CAGCAGCGCC AACACAGTCA 2100
ACACAACCAA TTAATTATCC TATCACAAGT AGGTTACCTC ATCGTTCCGG AGAACCACCT 2160
GCAATAATAT GGGAGAAATC AGGGAATGTT CGCGGGAATC AACTAACTAT ATCGGCACAA 2220
GGTGTTCAG AAAATTCCCA AATATATCTT TCGGTGGGTG GCGATCGCCA AATTTTAGAC 2280
CGTAGCAACG GATTAAATT AGTTAATTAC TCACCTACTT ATTCCTTCAC TAACATTCAG 2340
GCTAGCTCGT CAAATTTAGT AGATATTACA AGTGGTACCA TCACTGGCCA AGTACAAGTA 2400
TCTAATCTAT AA 2412

```

## (2) INFORMATION FOR SEQ ID NO:10:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 803 amino acids
  - (B) TYPE: amino acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: protein
- (iii) HYPOTHETICAL: YES
- (iv) ANTI-SENSE: NO
- (vi) ORIGINAL SOURCE:
  - (A) ORGANISM: *Bacillus thuringiensis*
  - (C) INDIVIDUAL ISOLATE: PS63B
- (vii) IMMEDIATE SOURCE:
  - (B) CLONE: E. coli NM522(pMYC1642) NRRL B-18961
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:
 

Met	Thr	Cys	Gln	Leu	Gln	Ala	Gln	Pro	Leu	Ile	Pro	Tyr	Asn	Val	Leu	
1				5					10					15		
Ala	Gly	Val	Pro	Thr	Ser	Asn	Thr	Gly	Ser	Pro	Ile	Gly	Asn	Ala	Gly	
			20					25					30			
Asn	Gln	Phe	Asp	Gln	Phe	Glu	Gln	Thr	Val	Lys	Glu	Leu	Lys	Glu	Ala	
		35				40						45				
Trp	Glu	Ala	Phe	Gln	Lys	Asn	Gly	Ser	Phe	Ser	Leu	Ala	Ala	Leu	Glu	
		50				55					60					
Lys	Gly	Phe	Asp	Ala	Ala	Ile	Gly	Gly	Gly	Ser	Phe	Asp	Tyr	Leu	Gly	
		65			70					75				80		
Leu	Val	Gln	Ala	Gly	Leu	Gly	Leu	Val	Gly	Thr	Leu	Gly	Ala	Ala	Ile	
				85				90						95		
Pro	Gly	Val	Ser	Val	Ala	Val	Pro	Leu	Ile	Ser	Met	Leu	Val	Gly	Val	
			100					105					110			
Phe	Trp	Pro	Lys	Gly	Thr	Asn	Asn	Gln	Glu	Asn	Leu	Ile	Thr	Val	Ile	
		115				120						125				
Asp	Lys	Glu	Val	Gln	Arg	Ile	Leu	Asp	Glu	Lys	Leu	Ser	Asp	Gln	Leu	
		130				135					140					
Ile	Lys	Lys	Leu	Asn	Ala	Asp	Leu	Asn	Ala	Phe	Thr	Asp	Leu	Val	Thr	
		145			150					155				160		
Arg	Leu	Glu	Glu	Val	Ile	Ile	Asp	Ala	Thr	Phe	Glu	Asn	His	Lys	Pro	
				165				170						175		
Val	Leu	Gln	Val	Ser	Lys	Ser	Asn	Tyr	Met	Lys	Val	Asp	Ser	Ala	Tyr	
			180					185					190			

55

Phe Ser Thr Gly Gly Ile Leu Thr Leu Gly Met Ser Asp Phe Leu Thr  
 195 200 205  
 Asp Thr Tyr Ser Lys Leu Thr Phe Pro Leu Tyr Val Leu Gly Ala Thr  
 210 215 220  
 Met Lys Leu Ser Ala Tyr His Ser Tyr Ile Gln Phe Gly Asn Thr Trp  
 225 230 235 240  
 Leu Asn Lys Val Tyr Asp Leu Ser Ser Asp Glu Gly Lys Thr Met Ser  
 245 250 255  
 Gln Ala Leu Ala Arg Ala Lys Gln His Met Arg Gln Asp Ile Ala Phe  
 260 265 270  
 Tyr Thr Ser Gln Ala Leu Asn Met Phe Thr Gly Asn Leu Pro Ser Leu  
 275 280 285  
 Ser Ser Asn Lys Tyr Ala Ile Asn Asp Tyr Asn Val Tyr Thr Arg Ala  
 290 295 300  
 Met Val Leu Asn Gly Leu Asp Ile Val Ala Thr Trp Pro Thr Leu Tyr  
 305 310 315 320  
 Pro Asp Asp Tyr Ser Ser Gln Ile Lys Leu Glu Lys Thr Arg Val Ile  
 325 330 335  
 Phe Ser Asp Met Val Gly Gln Ser Glu Ser Arg Asp Gly Ser Val Thr  
 340 345 350  
 Ile Lys Asn Ile Phe Asp Asn Thr Asp Ser His Gln His Gly Ser Ile  
 355 360 365  
 Gly Leu Asn Ser Ile Ser Tyr Phe Pro Asp Glu Leu Gln Lys Ala Gln  
 370 375 380  
 Leu Arg Met Tyr Asp Tyr Asn His Lys Pro Tyr Cys Thr Asp Cys Phe  
 385 390 395 400  
 Cys Trp Pro Tyr Gly Val Ile Leu Asn Tyr Asn Lys Asn Thr Phe Arg  
 405 410 415  
 Tyr Gly Asp Asn Asp Pro Gly Leu Ser Gly Asp Val Gln Leu Pro Ala  
 420 425 430  
 Pro Met Ser Val Val Asn Ala Gln Thr Gln Thr Ala Gln Tyr Thr Asp  
 435 440 445  
 Gly Glu Asn Ile Trp Thr Asp Thr Gly Arg Ser Trp Leu Cys Thr Leu  
 450 455 460  
 Arg Gly Tyr Cys Thr Thr Asn Cys Phe Pro Gly Arg Gly Cys Tyr Asn  
 465 470 475 480  
 Asn Ser Thr Gly Tyr Gly Glu Ser Cys Asn Gln Ser Leu Pro Gly Gln  
 485 490 495  
 Lys Ile His Ala Leu Tyr Pro Phe Thr Gln Thr Asn Val Leu Gly Gln  
 500 505 510  
 Ser Gly Lys Leu Gly Leu Leu Ala Ser His Ile Pro Tyr Asp Leu Ser  
 515 520 525  
 Pro Asn Asn Thr Ile Gly Asp Lys Asp Thr Asp Ser Thr Asn Ile Val  
 530 535 540  
 Ala Lys Gly Ile Pro Val Glu Lys Gly Tyr Ala Ser Ser Gly Gln Lys  
 545 550 555 560  
 Val Glu Ile Ile Arg Glu Trp Ile Asn Gly Ala Asn Val Val Gln Leu  
 565 570 575  
 Ser Pro Gly Gln Ser Trp Gly Met Asp Phe Thr Asn Ser Thr Gly Gly  
 580 585 590  
 Gln Tyr Met Val Arg Cys Arg Tyr Ala Ser Thr Asn Asp Thr Pro Ile  
 595 600 605  
 Phe Phe Asn Leu Val Tyr Asp Gly Gly Ser Asn Pro Ile Tyr Asn Gln  
 610 615 620  
 Met Thr Phe Pro Ala Thr Lys Glu Thr Pro Ala His Asp Ser Val Asp  
 625 630 635 640  
 Asn Lys Ile Leu Gly Ile Lys Gly Ile Asn Gly Asn Tyr Ser Leu Met  
 645 650 655

56

Asn Val Lys Asp Ser Val Glu Leu Pro Ser Gly Lys Phe His Val Phe  
                   660                  665                  670  
 Phe Thr Asn Asn Gly Ser Ser Ala Ile Tyr Leu Asp Arg Leu Glu Phe  
                   675                  680                  685  
 Val Pro Leu Asp Gln Pro Ala Ala Pro Thr Gln Ser Thr Gln Pro Ile  
                   690                  695                  700  
 Asn Tyr Pro Ile Thr Ser Arg Leu Pro His Arg Ser Gly Glu Pro Pro  
                   705                  710                  715                  720  
 Ala Ile Ile Trp Glu Lys Ser Gly Asn Val Arg Gly Asn Gln Leu Thr  
                   725                  730                  735  
 Ile Ser Ala Gln Gly Val Pro Glu Asn Ser Gln Ile Tyr Leu Ser Val  
                   740                  745                  750  
 Gly Gly Asp Arg Gln Ile Leu Asp Arg Ser Asn Gly Phe Lys Leu Val  
                   755                  760                  765  
 Asn Tyr Ser Pro Thr Tyr Ser Phe Thr Asn Ile Gln Ala Ser Ser Ser  
                   770                  775                  780  
 Asn Leu Val Asp Ile Thr Ser Gly Thr Ile Thr Gly Gln Val Gln Val  
                   785                  790                  795                  800  
 Ser Asn Leu

## (2) INFORMATION FOR SEQ ID NO:11:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 8 amino acids
  - (B) TYPE: amino acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:11:

Arg Glu Trp Ile Asn Gly Ala Asn  
 1                  5

## (2) INFORMATION FOR SEQ ID NO:12:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 21 bases
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (synthetic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:12:

AGATRKWTW AATGGWGCKM A

21

## (2) INFORMATION FOR SEQ ID NO:13:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 20 bases
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (synthetic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:13:

GARTGGWTAA ATGGTRMSAA

20

## (2) INFORMATION FOR SEQ ID NO:14:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 8 amino acids
  - (B) TYPE: amino acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:14:

Pro Thr Phe Asp Pro Asp Leu Tyr  
 1 5

## (2) INFORMATION FOR SEQ ID NO:15:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 24 bases
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (synthetic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:15:

CCNACYTTTK ATCCAGATSW YTAT

24

## (2) INFORMATION FOR SEQ ID NO:16:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 24 bases
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (synthetic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:16:

CCWACWTTYG ATMCASATMW TTAT

24

## (2) INFORMATION FOR SEQ ID NO:17:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 14 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:17:

Ala Ile Leu Asn Glu Leu Tyr Pro Ser Val Pro Tyr Asn Val  
 1 5 10

## (2) INFORMATION FOR SEQ ID NO:18:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 14 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:18:

Ala Ile Leu Asn Glu Leu Tyr Pro Ser Val Pro Tyr Asn Val  
 1 5 10

## (2) INFORMATION FOR SEQ ID NO:19:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 16 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:19:

Met Ala Thr Ile Asn Glu Leu Tyr Pro Asn Val Pro Tyr Asn Val Leu  
 1 5 10 15

## (2) INFORMATION FOR SEQ ID NO:20:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 14 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single

58

- (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: protein
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:20:
- Gln Leu Gln Ala Gln Pro Leu Ile Pro Tyr Asn Val Leu Ala  
1 5 10

(2) INFORMATION FOR SEQ ID NO:21:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 10 amino acids
  - (B) TYPE: amino acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: protein
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:21:
- Ala Thr Leu Asn Glu Val Tyr Pro Val Asn  
1 5 10

(2) INFORMATION FOR SEQ ID NO:22:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 15 amino acids
  - (B) TYPE: amino acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: protein
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:22:
- Val Gln Arg Ile Leu Asp Glu Lys Leu Ser Phe Gln Leu Ile Lys  
1 5 10 15

(2) INFORMATION FOR SEQ ID NO:23:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 23 bases
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: DNA (synthetic)
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:23:
- GCAATTTTAA ATGAATTATA TCC

23

(2) INFORMATION FOR SEQ ID NO:24:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 17 bases
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: DNA (synthetic)
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:24:
- CAAYTACAAG CWCAACC

17

(2) INFORMATION FOR SEQ ID NO:25:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 21 bases
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: DNA (synthetic)
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:25:
- TTCATCTAAA ATTCTTTGWA C

21



59

## (2) INFORMATION FOR SEQ ID NO:26:

- (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 21 bases  
 (B) TYPE: nucleic acid  
 (C) STRANDEDNESS: single  
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (synthetic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:26:

GCWACWTTAA ATGAAGTWTA T

21

## (2) INFORMATION FOR SEQ ID NO:27:

- (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 21 bases  
 (B) TYPE: nucleic acid  
 (C) STRANDEDNESS: single  
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (synthetic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:27:

AATGAAGTWT ATCCWGTWAA T

21

## (2) INFORMATION FOR SEQ ID NO:28:

- (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 38 bases  
 (B) TYPE: nucleic acid  
 (C) STRANDEDNESS: single  
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (synthetic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:28:

GCAAGCGGCC GCTTATGGAA TAAATTCAAT TYKRTCWA

38

## (2) INFORMATION FOR SEQ ID NO:29:

- (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 37 bases  
 (B) TYPE: nucleic acid  
 (C) STRANDEDNESS: single  
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (synthetic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:29:

AGACTGGATC CATGGCWACW ATWAATGAAT TATAYCC

37

## (2) INFORMATION FOR SEQ ID NO:30:

- (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 10 amino acids  
 (B) TYPE: amino acid  
 (C) STRANDEDNESS: single  
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:30:

Glu	Ser	Lys	Leu	Lys	Pro	Asn	Thr	Arg	Tyr
1				5					10

## (2) INFORMATION FOR SEQ ID NO:31:

- (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 29 bases  
 (B) TYPE: nucleic acid  
 (C) STRANDEDNESS: single  
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (synthetic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:31:  
TAACGTGTAT WCGSTTTTAA TTTWGAYTC

29

(2) INFORMATION FOR SEQ ID NO:32:

- (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 9 amino acids  
(B) TYPE: amino acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:32:

Tyr Ile Asp Lys Ile Glu Phe Ile Pro  
1 5

(2) INFORMATION FOR SEQ ID NO:33:

- (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 23 bases  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (synthetic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:33:

TGGAATAAAT TCAATTYKRT CWA

23

(2) INFORMATION FOR SEQ ID NO:34:

- (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 23 bases  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (synthetic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:34:

AGGAACAAAY TCAAKWCGRT CTA

23

(2) INFORMATION FOR SEQ ID NO:35:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:35:

TTAGATCGT MTTGARTTTR TWCC

24

(2) INFORMATION FOR SEQ ID NO:36:

- (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 5 amino acids  
(B) TYPE: amino acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:36:

Ile Thr Ser Glu Asp  
1 5

(2) INFORMATION FOR SEQ ID NO:37:

- (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 20 bases  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (synthetic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:37:

TCTCCATCTT CTGARGWAAT

20

## (2) INFORMATION FOR SEQ ID NO:38:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 8 amino acids
  - (B) TYPE: amino acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:38:

Leu Asp Arg Ile Glu Phe Val Pro  
1                    5

Claims

- 1           1. A substantially pure toxin protein which is toxic to ants and which has at least one  
2           characteristic selected from the group consisting of:
- 3           (a)     the amino acid sequence of said toxin conforms to the Generic Formula;  
4           (b)     the amino acid sequence of said toxin is at least 50% homologous with toxin  
5           86Q3(a);  
6           (c)     the amino acid sequence of said toxin has an alignment value of at least 100 with  
7           toxin 86Q3(a);  
8           (d)     the DNA which codes for said toxin hybridizes with DNA which codes for all or  
9           part of toxin 86Q3(a);  
10          (e)     the DNA which codes for said toxin hybridizes with a probe selected from the  
11          group consisting of SEQ ID NO. 12, SEQ ID NO. 13, SEQ ID NO. 15, SEQ ID  
12          NO. 16, SEQ ID NO. 34, SEQ ID NO. 33, SEQ ID NO. 31, SEQ ID NO. 27,  
13          SEQ ID NO. 23, SEQ ID NO. 24, SEQ ID NO. 29, and SEQ ID NO. 37;  
14          (f)     a portion of the nucleotide sequence coding for said toxin can be amplified from  
15          total cellular DNA from a *Bacillus thuringiensis* strain using polymerase chain  
16          reaction with a reverse primer selected from the group consisting of SEQ ID NO.  
17          34, SEQ ID NO. 33, SEQ ID NO. 31, SEQ ID NO. 37, and the complements of  
18          SEQ ID NO. 12 or SEQ ID NO. 13; and a forward primer selected from the  
19          group consisting of SEQ ID NO. 12, SEQ ID NO. 13, SEQ ID NO. 15, SEQ ID  
20          NO. 16, SEQ ID NO. 27, SEQ ID NO. 23, SEQ ID NO. 24, SEQ ID NO. 335,  
21          and SEQ ID NO. 29; and  
22          (g)     said toxin is immunoreactive with an antibody which immunoreacts with a toxin  
23          selected from the group consisting of toxins expressed by PS86Q3, toxins  
24          expressed by PS140E2, and toxins expressed by PS211B2.
- 1           2. The ant toxin, according to claim 1, wherein said toxin conforms to the Generic  
2           Formula.
- 1           3. The ant toxin, according to claim 1, wherein said toxin has an alignment value of at  
2           least 100 with toxin 86Q3(a).
- 1           4. The ant toxin, according to claim 1, wherein the DNA coding for said toxin hybridizes  
2           with DNA which codes for all or part of toxin 86Q3(a).
- 1           5. The ant toxin, according to claim 1, wherein the DNA coding for said toxin hybridizes  
2           with a probe selected from the group consisting of SEQ ID NO. 12, SEQ ID NO. 13, SEQ ID

3 NO. 15, SEQ ID NO. 16, SEQ ID NO. 34, SEQ ID NO. 33, SEQ ID NO. 31, SEQ ID NO. 27,  
4 SEQ ID NO. 23, SEQ ID NO. 24, SEQ ID NO. 29, and SEQ ID NO. 37.

1 6. The ant toxin, according to claim 1, wherein said toxin is immunoreactive with an  
2 antibody which immunoreacts with toxin 86Q3(a).

1 7. The ant toxin, according to claim 1, wherein a portion of the nucleotide sequence  
2 coding for said toxin can be amplified from total cellular DNA from a *Bacillus thuringiensis* strain  
3 using polymerase chain reaction with a reverse primer selected from the group consisting of SEQ  
4 ID NO. 34, SEQ ID NO. 33, SEQ ID NO. 37, SEQ ID NO. 31, and the complements of SEQ ID  
5 NO. 12 or SEQ ID NO. 13; and a forward primer selected from the group consisting of SEQ ID  
6 NO. 12, SEQ ID NO. 13, SEQ ID NO. 15, SEQ ID NO. 16, SEQ ID NO. 27, SEQ ID NO. 23,  
7 SEQ ID NO. 24, SEQ ID NO. 35, and SEQ ID NO. 29.

1 8. The ant toxin, according to claim 7, wherein said reverse primer is SEQ ID NO. 33  
2 or SEQ ID NO. 34 and

- 3 (a) the forward primer is SEQ ID NO. 12 or SEQ ID NO. 13, and the polymerase  
4 chain reaction fragment is approximately 330 to 600 bp;  
5 (b) the forward primer is SEQ ID NO. 15 or SEQ ID NO. 16, and the polymerase  
6 chain reaction fragment is approximately 1000 to 1400 bp; or  
7 (c) the forward primer is SEQ ID NO. 27, SEQ ID NO. 23, SEQ ID NO. 24, or  
8 SEQ ID NO. 29, and the polymerase chain reaction fragment is 1800 to 2100 bp.

1 9. The ant toxin, according to claim 7, wherein said reverse primer is a complement of  
2 SEQ ID NO. 12 or SEQ ID NO. 13 and

- 3 (a) the forward primer is SEQ ID NO. 15 or SEQ ID NO. 16, and the polymerase  
4 chain reaction fragment is approximately 650 to 1000 bp; or  
5 (b) the forward primer is SEQ ID NO. 27, SEQ ID NO. 23, SEQ ID NO. 24, or  
6 SEQ ID NO. 29, and the polymerase chain reaction fragment is approximately  
7 1000 to 1400 bp.

1 10. The ant toxin, according to claim 7, wherein said reverse primer is SEQ ID NO. 31  
2 and

- 3 (a) the forward primer is SEQ ID NO. 27, SEQ ID NO. 23, or SEQ ID NO. 29, and  
4 the polymerase chain reaction fragment is approximately 2550-3100 bp;  
5 (b) the forward primer is SEQ ID NO. 15 or SEQ ID NO. 16, and the resulting  
6 polymerase chain reaction fragment is 1750-2150 bp;  
7 (c) the forward primer is SEQ ID NO. 12 or SEQ ID NO. 13, and the polymerase  
8 chain reaction fragment is approximately 850-1400 bp;

- 9 (d) the forward primer is SEQ ID NO. 35, and the polymerase chain reaction  
10 fragments are approximately 550-1050 bp.
- 1 11. The ant toxin according to claim 7, wherein said reverse primer is SEQ ID NO. 37  
2 and  
3 (a) the forward primer is SEQ ID NO. 27, SEQ ID NO. 23, or SEQ ID NO. 29, and  
4 the polymerase chain reaction fragment is approximately 3550-4050 bp;  
5 (b) the forward primer is SEQ ID NO. 15 or SEQ ID NO. 16, and the resulting  
6 polymerase chain reaction fragment is 2600-3100 bp;  
7 (c) the forward primer is SEQ ID NO. 12 or SEQ ID NO. 13, and the polymerase  
8 chain reaction fragment is approximately 1800-2400 bp;  
9 (d) the forward primer is SEQ ID NO. 35, and the polymerase chain reaction  
10 fragment is approximately 1500-2050 bp.
- 1 12. The ant toxin, according to claim 1, wherein said toxin is 86Q3(a).
- 1 13. The toxin, according to claim 1, wherein said toxin is expressed by PS140E2.
- 1 14. The toxin, according to claim 1, wherein said toxin is expressed by PS211B2.
- 1 15. A nucleotide sequence encoding an ant toxin as defined in claim 1.
- 1 16. The nucleotide sequence, according to claim 15, which encodes 86Q3(a).
- 1 17. The nucleotide sequence, according to claim 15, which codes for a toxin expressed  
2 by PS140E2.
- 1 18. The nucleotide sequence, according to claim 15, which codes for a toxin expressed  
2 by PS211B2.
- 1 19. A host comprising a nucleotide sequence which codes for an ant toxin as defined in  
2 claim 1.
- 1 20. The host, according to claim 19, wherein said host expresses a toxin which  
2 immunoreacts with an antibody, which antibody immunoreacts with an ant-active toxin expressed  
3 by a microbe selected from the group consisting of PS86Q3, PS140E2, and PS211B2.
- 1 21. The host, according to claim 19, which is a *Bacillus thuringiensis*.

1           22. The host, according to claim 21, wherein said host has the characteristics of PS140E2.

1           23. The host, according to claim 21, wherein said host has the characteristics of PS211B2.

1           24. The host, according to claim 21, wherein said host has the characteristics of *Bacillus*  
2 *thuringiensis* PS86Q3.

1           25. The host, according to claim 19, wherein said nucleotide sequence is a heterologous  
2 sequence which has been transformed into said host and wherein said heterologous sequence is  
3 expressed at sufficient levels to result in the production of said ant toxin.

1           26. The host, according to claim 25, wherein said host is capable of inhabiting the  
2 phylloplane or rhizosphere of a plant or is capable of survival in a baited trap.

1           27. The host, according to claim 25, which is transformed with a nucleotide sequence  
2 which codes for 86Q3(a).

1           28. A process for controlling ants, wherein said process comprises contacting said ants  
2 with an ant-controlling effective amount of a toxin as defined in claim 1.


1           29. A formicidal composition comprising substantially intact cells which express a toxin  
2 as defined in claim 1.

1           30. The formicidal composition, according to claim 29, wherein said cells have been  
2 treated to prolong their formicidal activity.

1           31. A biologically pure culture of *Bacillus thuringiensis* PS140E2, having the identifying  
2 characteristic of activity against hymenopteran pests of NRRL B-18812, or mutants, thereof.

1           32. A biologically pure culture of *Bacillus thuringiensis* PS211B2, having the identifying  
2 characteristic of activity against hymenopteran pests of NRRL B-18921, or mutants, thereof.

1           33. A biologically pure culture of *Bacillus thuringiensis* PS86Q3, having the identifying  
2 characteristic of activity against hymenopteran pests of NRRL B-18765, or mutants, thereof.

FIGURE 1



2/5

FIGURE 2




FIGURE 3





FIGURE 4



FIGURE 5



**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☒ **BLACK BORDERS**
- ☒ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☒ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☒ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**